Appendix A: Search Methodology

Appendix A. Search Methodology:

BARIATRIC SURGERY & METABOLIC CONDITIONS – SEARCH METHODOLOGIES

Search performed 3/5/2010:

DATABASE SEARCHED & TIME PERIOD COVERED:
PubMed - All years

SEARCH STRATEGY:
diabetes OR diabetic* OR diabetes mellitus
AND
lifestyle* OR life style* OR life style OR exercis*[tiab] OR exercise therapy OR physical activity OR diet, reducing OR diet OR diets OR dieting OR nutrition
AND
obese OR obesity OR (weight AND reduce) OR (weight AND reducing) OR (weight AND reduction) OR weight-reducing OR (decreas* AND weight) OR "weight loss" OR (weight AND lost) OR overweight
AND
intervention OR patient education as topic OR "look ahead" OR prevent*[tiab] OR prevention[sh] OR psychology[sh]
AND
follow-up studies OR follow-up[tiab] OR followup[tiab] OR longitudinal studies OR longitudinal[tiab] OR outcome assessment (health care) OR treatment outcome OR randomi* OR randomized controlled trial[pt] OR double-blind OR double blind OR prospective studies

NUMBER OF RESULTS: 1413

Search performed 3/10/2010:

DATABASE SEARCHED & TIME PERIOD COVERED:
PubMed - All years

SEARCH STRATEGY:
[diabetes[tiab] OR diabetic* OR diabetes mellitus
AND
patient utilities OR "quality of life" OR "standard gamble" OR "time tradeoff" OR "time trade-off" OR cost-utilit* OR patient utilit* OR utility OR utilities]
AND
bariatric OR obesity/su OR (obesity AND (surgery OR surgical)]

NUMBER OF RESULTS: 161

Search performed 3/11/2010:

DATABASE SEARCHED & TIME PERIOD COVERED:
PubMed - All years

SEARCH STRATEGY:
diabetes[tiab] OR diabetic* OR diabetes mellitus
AND
cost-utilit* OR patient utilit* OR "standard gamble" OR "time tradeoff" OR "time trade-off" OR bariatric OR obesity/su OR (obesity AND (surgery OR surgical))

NUMBER OF RESULTS: 108

Search performed 3/25/2010:

DATABASE SEARCHED & TIME PERIOD COVERED:
PubMed - All years

SEARCH STRATEGY:
diabetes[tiab] OR diabetic* OR diabetes mellitus
AND
obese OR obesity OR (weight AND reduce) OR (weight AND reducing) OR (weight AND reduction) OR weight-reducing OR (decreas* AND weight) OR "weight loss" OR (weight AND lost) OR overweight
AND
lifestyle* OR life style* OR life style OR exercis*[tiab] OR exercise therapy OR physical activity OR diet, reducing OR diet OR diets OR dieting OR nutrition
AND
systematic[sb] OR systematic review* OR meta-analy* OR meta analy* OR metaanaly* OR meta-analysis[pt] OR randomized controlled trial* OR rct* OR randomized controlled trial[pt] OR controlled clinical trial* OR cct* OR controlled clinical trial[pt]

NUMBER OF RESULTS: 1766

Appendix B. Data Collection Forms

Appendix B. Data Collection Forms

Short Form Screener

EPC PROJECT: SCREENER FORM BARIATRIC SURGERY/METABOLIC CONDITIONS **FINAL 05-10-2010**

ID: _____

Reviewer: _____

Last name, first author: _____

Year of publication: _____

1. Does article report on cases with BMI between 30 and 35? **(Circle one)**

   Yes.....1
   Other weight determination.....2
   No/Unclear.....3 **(STOP)**

2. Does article include cases with type II diabetes or other metabolic conditions? **(Circle one)**

   Yes.....1
   No.....2 **(STOP)**

3. Does article report on any of these treatments? **(Check all that apply)**

   Non-surgical treatments of metabolic conditions .....☐

   Surgical treatments:
   Lap adjustable banding (LAGB) .....☐
   Roux-en-y gastric bypass.....☐
   Sleeve gastrectomy .....☐

   Other bariatric surgeries .....☐
   Biliopancreatic diversion (BPD/DS)....☐
   (if only BPD/DS, then STOP)

   None of the above.....☐ **(STOP)**
   (To flag an article for background go to Q4; to flag duplicate data go to Q9; to order a reference go to Q10.)

4. Study design: **(Circle one)**

   Background (historical, editorial etc.) .....1 **(STOP)**
   Non-systematic review .....2 **(STOP)**
   Systematic review / Meta-analysis.....3 **(STOP)**
   Case Report.....4 **(STOP)**

   Case series.....5
   Cohort.....6
   Case control.....7
   Controlled trial.....8
   Other.....9

5. Does the study focus on the following outcomes? **(Check all that apply)**

   Blood glucose/diabetes related..... ☐
   Blood pressure..... ☐
   Lipids/cholesterol ..... ☐
   Weight loss outcomes..... ☐

   Quality of life measures ..... ☐
   Removal rates..... ☐
   Band-to-RYGB conversion rates..... ☐
   Mortality ..... ☐

   Healthcare utilization/economics..... ☐
   Adverse events/complications..... ☐
   Other relevant outcomes..... ☐

6. Total sample size entering study. If entering sample not reported then enter total completing: **(Enter # or 999 if no sample reported)**

   _____

7. Total duration of follow up:

Duration #	Units Code
_____	_____

Unit Codes

01. Hour	03. Week	05. Year
02. Day	04. Month	99. NR

8. Language of article: **(Circle one)**

   English..... 1
   Other..... 2

   Language (specify): _____

9. Do you think that this article might be a duplicate or include the same data as another study? **(Circle one)**

   Yes 1
   No..... 2
   If YES, which one(s) :

   _____
   (Enter study ID #, author or 9999 if don't know.)

10. Is there a reference that needs to be checked? **(Circle one)**

    Yes 1
    No..... 2
    If YES, which one(s) :

    _____
    (Enter reference # and/or author or 9999 if don't know.)

Notes:

Detailed Abstraction Form

Submit Form and go to ☐ or Skip to Next

Participants

Country

- ☐ US
- ☐ Canada
- ☐ South/Central America
- ☐ UK
- ☐ Western Europe
- ☐ Eastern Europe
- ☐ Australia/NZ
- ☐ Japan
- ☐ Asia (not Japan)
- ☐ India
- ☐ Middle East
- ☐ Unclear
- ☐ Other

Race

% Caucasian % Black/African Ancestry % Asian % Hispanic % Middle-eastern % American Indian/Alaskan Native % other race

☐ Race not reported

Instructions: If study has only one arm, please put data into the "Arm 1" box, rather than the "Overall" box.

	Arm 1	Arm 2	Overall
Sample Size			
Intervention			
Sex - % female			
Ages - Min			
Max			
Mean			
Median			
Std Dev			

Baseline weight

	Min	Max	Mean	Median	Std Dev
BMI:					
Weight:					

Select an Answer

Diabetes

	Overall	Arm 1	Arm 2

% with Diabetes

Severity

- Years since dx
- Need for Meds (%)
- hgbA1c
- Pre-diabetes/IGT

- Years since dx
- Need for Meds (%)
- hgbA1c
- Pre-diabetes/IGT

- Years since dx
- Need for Meds (%)
- hgbA1c
- Pre-diabetes/IGT

Severity of Diabetes-Other

Label:	Data:	Label:	Data:	Label:	Data:

Comorbidities	% 0	% 1	% 2	Comorbidities	% 0	% 1	% 2	Comorbidities	% 0	% 1	% 2
Asthma				Hypertension				Sleep apnea			
Osteoarthritis				Depression				GERD			
Elevated lipids				Metabolic syndrome							
Oth											

Study Characteristics

Surgery type LABG RYGB Sleeve BPD Other Surgical Other non-Surgical

If RYGB, characterize the type:

- Lap
- Open
- Mixed
- Unknown
- Other

Duration

Study Select an Answer

Outcomes

Outcomes	Arm	Baseline t0	1st Follow-up t1	2nd Follow-up t2	3rd Follow-up t3	4th Follow-up t4	5th Follow-up t5	6th Follow-up t6	Units
N	Arm 1								Select an Answer
N	Arm 2								
BMI	Arm 1								
BMI	Arm 2								

Weight	Arm 1								Select an Answer
Weight	Arm 2								Select an Answer
HbA1c	Arm 1								
HbA1c	Arm 2								
Fasting Glucose	Arm 1								Select an Answer
Fasting Glucose	Arm 2								Select an Answer
% on Diabetes meds	Arm 1								
% on Diabetes meds	Arm 2								
Cholesterol	Arm 1								Select an Answer
Cholesterol	Arm 2								Select an Answer
Hypertension	Arm 1								Select an Answer
Hypertension	Arm 2								Select an Answer
	Select an Answer								Select an Answer
	Select an Answer								Select an Answer
	Select an Answer								Select an Answer
	Select an Answer								Select an Answer
	Select an Answer								Select an Answer
	Select an Answer								Select an Answer
	Select an Answer								Select an Answer
	Select an Answer								Select an Answer
	Select an Answer								Select an Answer
	Select an Answer								Select an Answer

Select an Answer | Select an Answer

And finally, please do not forget to answer these last questions:

Does this study report adverse events?

- ☐ Yes
- ☐ No

Is this article / abstract related to others? If so, please enter ID.

This form was filled out using...

- ☐ Abstract only
- ☐ Full text

Comments:

Submit Form and go to or Skip to Next

Bariatric surgery & metabolic conditions
Author, year _____
ID_____

AMSTAR Quality Assessment ANSWER EACH QUESTION

A/1 Was an 'a priori' design provided?
- Yes 1
- No 2
- Not reported 8
- Not applicable 9

A/2 Was there duplicate study selection and data extraction?
- Yes 1
- No 2
- Not reported 8
- Not applicable 9

A/3 Was a comprehensive literature search performed?
- Yes 1
- No 2
- Not reported 8
- Not applicable 9

A/4 Was the status of publication (i.e. grey literature) used as an inclusion criterion?
- Yes 1
- No 2
- Not reported 8
- Not applicable 9

A/5 Was a list of included studies provided?
- Yes 1
- No 2
- Not reported 8
- Not applicable 9

A/6 Were the characteristics of the included studies provided?
- Yes 1
- No 2
- Not reported 8
- Not applicable 9

A/7 Was the scientific quality of the included studies assessed and documented?
- Yes 1
- No 2
- Not reported 8
- Not applicable 9

A/8 Was the scientific quality of the included studies used appropriately in formulating conclusions?
- Yes 1
- No 2
- Not reported 8
- Not applicable 9

A/9 Were the methods used to combine the findings of studies appropriate?
- Yes 1
- No 2
- Not reported 8
- Not applicable 9

A/10 Was the likelihood of publication bias assessed?
- Yes 1
- No 2
- Not reported 8
- Not applicable 9

A/11 Was the conflict of interest stated?
- Yes 1
- No 2
- Not reported 8
- Not applicable 9

Appendix C. Evidence Tables

Appendix C Evidence Tables For Surgical Treatment v. Surgical Treatment Trials

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
Dixon 2008[49] Australia/New Zealand	RCT	30 T2DM patients with mean age 46.6 (SD=7.4), BMI 36.9 (SD NR)	LABG	**Mean Weight (kg)**: 24mths: 84.6 (SD=15.8) **Mean BMI**: 24mths: 29.4 (SD NR)	**Fasting blood glucose, mg/dL**: 24mths: 105.6 (SD=30.3) **HbA1c, %**: 24mths: 6.0 (SD=0.8) **HbA1c<6.2%**: 24mths: 80% **Taking DM meds, %**: Baseline: 28/30 (93.3%) 24mths: 4/30 (13.3%) **Metabolic Syndrome, %**: Baseline: 29/30 (96.7%) 24mths: 9/30 (30.0%)	Blood pressure, mm Hg: Systolic: 130.4 (SD=19.0) Diastolic: 85.4 (SD=7.0) Total Cholestrol, mg/dL:205.4 (SD=46.6) Triglycerides, mg/dL:118.9 (SD=79.7) HDL-C, mg/dL: 59.7 (SD=13.6)	**GI:** Feeding difficulties, 1/30 (3.3%) Other, 1/30 (3.3%) **Hepatobiliary:** Acute cholecystitis or CBD obstruction, 4/40 (10%) **Metabolic**: Hypoglycemia, 1/30 (3.3%) **Other:** Constitutional, 1/30 (3.3%) **Pouch/anastomosis**: Pouch dilation: 2/30 (6.7%) **Wound:** Infection: 1/30 (3.3%)
Dixon 2008[49] Australia/New Zealand	RCT	30 T2DM patients with mean age 47.1(SD=8.7), BMI 37.1 (SD NR)	Non-surgical treatment-Diet, pharmocotherapy & lifestyle change	**Mean Weight (kg)**: 24mths: 104.8 (SD=15.3) **Mean BMI**: 24mths: 36. (SD NR)	**Fasting blood glucose, mg/dL**: 24mths: 139.6 (SD=38.1) **HbA1c, %**: 24mths: 7.2 (SD=1.4) **HbA1c<6.2%**: 24mths: 20% **Taking DM meds, %**: Baseline: 26/30 (86.7%) 24mths: 22/30 (73.3%) **Metabolic Syndrome, %**: Baseline: 29/30 (96.7%) 24mths: 26/30 (86.7%)	Blood pressure, mm Hg: Systolic: 132.6 (SD=17.7) Diastolic: 83.1 (SD=8.5) Total Cholestrol, mg/dL:197.8 (SD=59.3) Triglycerides, mg/dL:186.7 (SD=127.2) HDL-C, mg/dL: 50.7 (SD=12.1)	**GI:** Diarrhea, 1/30 (3.3%) Feeding difficulties, 2/30 (6.7%) Other, 2/30 (6.7%) **Hepatobiliary:** Acute cholecystitis or CBD obstruction, 4/40 (10%) **Metabolic**: Hypoglycemia, 1/30 (3.3%) **Other:** Constitutional, 1/30 (3.3%) TIA, 1/30 (3.3%)

Appendix C Evidence Tables For Surgical Treatment v. Surgical Treatment Trials

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
O'Brien 2006[48] Australia/New Zealand	RCT	40 patients with mean age 41.8 (SD=6.4), BMI 33.7 (32.9-34.4) kg/m2	LABG	**Mean Weight (kg)**: 6mth: 81.6 (79.4-83.7) 12mths: 76.3 (74.1-78.5) 18mths: 75.2 (73.1-77.4) 24mths: 74.5 (72.4-76.7) **Mean BMI**: 1mth: 28.9 (28.1-29.7) 12mths: 27.0 (26.2-27.8) 18mths: 26.7 (25.9-27.5) 24mths: 26.4 (25.6-27.2) **Mean EWL, %:** 1mth: 57.2 (47.8-66.6) 12mths: 78.6 (69.2-88.1) 18mths: 83.6 (74.2-93.1) 24mths: 87.2 (77.7-96.6)	**Metabolic Syndrome, %**: Baseline: 15/40 (37.5%) 24mths: 1/39 (2.7%)	Percentage Change in: Systolic BP: -10.8 (SD=10.8) Diastolic BP: -10.9 (SD=12.5) Total cholesterol level: -0.4 (SD=18.1) Triglyceride level: -19.1 (SD=35.7) HDL cholesterol level: 30.0 (SD=28.9) LDL cholesterol level: -6.5 (19.0)	**Band related**: Band slippage, 4/40 (10%) Port infection, 1/40 (2.5%) **Hepatobiliary:** Acute cholecystitis or CBD obstruction, 1/40 (2.5%) **Major surgical complications**: NOS, 5/40 (12.5%)

Appendix C Evidence Tables For Surgical Treatment v. Surgical Treatment Trials

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
O'Brien 2006[48] Australia/New Zealand	RCT	40 patients with mean age 40.7 (SD=7.0), BMI 33.5(32.7-34.3) kg/m2	Non-surgical treatment-Diet, pharmocotherapy & lifestyle change	**Mean Weight (kg)**: 6mth: 81.6 (79.4-83.7) 12mths: 85.3 (83.0-87.5) 18mths: 87.7 (79.9-83.0) 24mths: 89.5 (80.5-83.6) **Mean BMI**: 1mth: 28.7 (27.9-29.6) 12mths: 29.9 (29.1-30.8) 18mths: 30.9 (30.0-31.8) 24mths: 31.5 (30.6-32.4) **Mean EWL, %:** 1mth: 57.4 (47.6-66.4) 12mths: 41.1 (31.1-50.9) 18mths: 29.0 (19.0-38.9) 24mths: 21.8 (11.9-31.6)	**Metabolic Syndrome, %**: Baseline: 15/40 (37.5%) 24mths: 8/33 (24.0%)	Percentage Change in: Systolic BP: -7.2 (SD=9.7) Diastolic BP: -1.6 (SD=11.2) Total cholesterol level: -3.0 (SD=17.0) Triglyceride level: -3.7 (SD=39.4) HDL cholesterol level: 6.9 (SD=18.9) LDL cholesterol level: -5.2 (21.6)	**GI:** Feeding difficulties, 1/40 (2.5%) Other, 8/40 (20.0%) **Hepatobiliary:** Acute cholecystitis or CBD obstruction, 4/40 (10%) **Major surgical complications**: NOS, 4/40 (10%)
Chiellini, 2009[45] Western Europe	Matched Cohort	5 T2DM patients with mean age 48 years (SE=3), BMI 30.9 (SE=1.1) kg/m^2	BPD	**Mean Weight (kg)**: 1mth: 92.6 (SE=6.4) 12mths: 77.8 (SE=3.5) 18mths: 76.8 (SE=3.0) **Mean BMI**: 1mth: 30.0(SE=0.8) 12mths: 25.4 (SE=0.01) 18mths: 25.1 (SE=0.01)	**2 hr Fasting Blood Glucose,mmol/L**: 1mth: 6.2 (SE=0.5) **HbA1c, %**: 1mth: 7.2 (SE=0.3) 12mth: 5.6 (SE=0.2) 18mth: 5.7 (SE=0.2)		No Mention of Adverse Events
Chiellini, 2009[45] Western Europe	Matched Cohort	7 T2DM patients with mean age 51 years (SE=3), BMI 30.0 (SE=1.7) kg/m2	Non-surgical treatment-Diet	**Mean Weight (kg):** 1mth: 83.7 (SE=5.5) **Mean BMI**: 1mth: 29.2 (SE=1.8)	**2 hr Fasting Blood Glucose, mmol/L**: 1mth: 15.2 TO 6.2 **HbA1c, %**: 1mth: 8.6 (SE=0.3)		No Mention of Adverse Events

Appendix C Evidence Tables For Surgical Treatment v. Surgical Treatment Trials

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
DeMaria, 2010[26] US	Cohort	109 T2DM patients with mean age 52.8 years (SD=9.5), BMI 33.7 (SE=1.1) kg/m^2	RYGB	**Mean BMI**: 0-3mths: 30.6(SD=3.0) 3-6mths: 27.2(SD=3.8) 6-12mths: 27.1(SD=4.5) 12-24mths: 23.0(SD=2.0) **% EBW**: 0-3mths: 41.7(SD=15.0) 3-6mths: 26.8(SD=17.4) 6-12mths: 26.9(SD=19.7) 12-24mths: 7.6(SD=7.6)	**Number of T2DM meds**: 0-3mths: 0.8(SD=1.0) 3-6mths: 0.4(SD=0.7) 6-12mths: 0.5(SD=0.7) 12-24mths: 0(SD=0) **% off T2DM meds**: 0-3mths: 37.5 3-6mths: 50.0 6-12mths: 55.2 12-24mths: 75.0	**Number of meds**: 0-3mths: 3.9(SD=3.2) 3-6mths: 3.5(SD=3.2) 6-12mths: 3.0(SD=2.5) 12-24mths: 1.5(SD=1.9)	**Bleeding/hematoma**: Band slippage, 1/109 (0.9%) **Cardiovascular/Respiratory:** Arrhythmia, 1/109 (0.9%) Atelectasis, 1/109 (0.9%) Pneumonia, 2/109 (1.8%) **Death:** NOS, 0/40 (0%) **GI**: Feeding difficulties, 1/109 (0.9%) Vomitting and/or nausea, 4/109 (3.7%) **Hepatobiliary:** Acute cholecystitis or CBD obstruction, 1/109 (0.9%) **Major Surgical Complications**: Internal hernia, 1/109 (0.9%) **Metabolic:** Vitamin def, 1/109 (0.9%) **Other:** NOS, 1/109 (0.9%) **Pouch/anastomosis**: Anastomotic leak, 1/109 (0.9%) Stricture, 4/109 (3.7%) **Wound:** Infection, 1/109 (0.9%)
DeMaria, 2010[26] US	Cohort	109 T2DM patients with mean age 52.0 years (SD=11.2), BMI 33.9 (SE=1.1) kg/m^2	LABG	**Mean BMI**: 0-3mths: 31.6(SD=2.5) 3-6mths: 31.0(SD=2.7) 6-12mths: 30.9(SD=2.9) 12-24mths: 29.9(SD=2.2) **% EBW**: 0-3mths: 40.6(SD=46.8) 3-6mths: 45.5(SD=12.9) 6-12mths: 45.4(SD=13.6) 12-24mths: 41.8(SD=10.2)	**Number of T2DM meds**: 0-3mths: 1.0(SD=1.1) 3-6mths: 0.8(SD=1.0) 6-12mths: 0.6(SD=0.8) 12-24mths: 0.8 (SD=1.1) **% off T2DM meds**: 0-3mths: 21.1 3-6mths: 31.8 6-12mths: 27.5 12-24mths: 36.4	**Number of meds**: 0-3mths: 4.2(SD=3.8) 3-6mths: 3.5(SD=3.7) 6-12mths: 3.1(SD=3.7) 12-24mths: 3.0(SD=3.3)	**Band related**: Band slippage, 1/109 (0.9%) **Death:** NOS, 0/40 (0%) **GI**: Ileus, 1/109 (0.9%) Vomitting and/or nausea, 1/109 (0.9%)

Appendix C Evidence Tables For Surgical Treatment v. Surgical Treatment Trials

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
Lee, 2011[27] Taiwan	RCT	30 T2DM patients with mean age 45 years (range 34-58), BMI 30.3 (range 25.0-34.0) kg/m^{2*}	RYGB	**Mean BMI**: 12mths: 22.8(SD=2.2) **Weight, kg**: 12mths: 60.7(SD=10.1) **% EWL**: 12mths: 94.4(SD=33.1)	**Remission of DM**: 12mths: 28/30 (93%) **Sucessful treatment of DM**: 12mths: 17/30 (57%) **Metabolic syndrome:** 12mths: 2/30 (7%)	C-peptides: 12 mths: 1.6(SD=1.1) Systolic BP: 12 mths: 119.6 (SD=17.3) Diastolic BP: 12 mths: 74.2(SD=12.3) Total cholesterol: 12 mths: 162.2(SD=26.6) Triglycerides: 12 mths: 104.9(SD=62.0) HDL-C: 12 mths: 49.3(SD=7.7) LDL-C: 12 mths: 96.9(SD=21.5)	**Death:** NOS, 0/30 (0%) **Major surgical complications:** NOS, 0/30 (0%) **Other:** Minor surigical complications 3/30 (10%) **Readmission:** Conservative treatment, 1/30 (3.3%)
Lee, 2011[27] Taiwan	RCT	30 T2DM patients with mean age 45 years (range 34-58), BMI 30.3 (range 25.0-34.0) kg/m^{2*}	Sleeve	**Mean BMI**: 12mths: 24.4(SD=2.4) **Weight, kg**: 12mths: 65.7(SD=7.9) **% EWL**: 12mths: 76.3(SD=38.9)	**Remission of DM**: 12mths: 14/30 (47%) **Sucessful treatment of DM**: 12mths: 0 (0%) **Metabolic syndrome:** 12mths: 18 (60%)	C-peptides: 12 mths: 1.6(SD=0.5) Systolic BP: 12 mths: 123.5(SD=9.8) Diastolic BP: 12 mths: 75.4(SD=8.5) Total cholesterol: 12 mths: 207.8(SD=67.0) Triglycerides: 12 mths: 144.2(SD=58.9) HDL-C: 12 mths: 45.4(SD=7.9) LDL-C: 12 mths: 136.6(SD=40.8)	**Death:** NOS, 0/30 (0%) **Major surgical complications:** NOS, 0/30 (0%) **Other:** Minor surigical complications 3/30 (10%) **Readmission:** Conservative treatment, 1/30 (3.3%)

Appendix C Evidence Tables For Observational Studies and Controlled Trials with 1 surgical arm**

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
Cohen, 2006[22] South America	Case Series	37 T2DM patients with mean age 34 years (range 28-45), BMI 32.5 (range 23.4-34.9) kg/m^{2*}	RYGB	**%EWL:** 6mths: 44 (SD NR) 12mths: 71.6 (SD NR) 18mths: 78.4 (SD NR) 36mths: 77 (SD NR) 48mths: 81 (SD NR)	**% off DM meds**: 20mths: 37/37 (100%) **% DM Remission**: 6mths: 36/37 (97.29%) **Mean Fasting Glucose, mg/dL**: 20mths: 88 (range 60-94)	Cholesterol,mg/dL: 20mths: 172 (range 161-190) Triglycerides,mg/dL: 20mths: 156 (range 172-163) LDL,mg/dL: 20mths: 115 (range 101-127) HDL men,mg/dL: 20mths: 41 (range 40-51) HDL women,mg/dL: 20mths: 50 (range 49-58)	**Death:** NOS,0/37 (0%) **GI:** GERD, 0/37 (0%)
Ferzli, 2009[24] South America	Case Series	7 T2DM patients with mean age 43.3 years (range 33-52), BMI 27.5 (range 21.7-33) kg/m^{2*}	RYGB	**Mean BMI:** 12mths: 27.3 (SD=3.1)	**Mean fasting glucose:** 12mths: 154.9 (SE=39.9) **Mean HbA1c:** 12mths: 8.5 (SE.07) **% off DM med**: 12mths: 1/7 (14%)	Triglyceride,mg/dl: 127.3 (SE=25.3) C-peptide,mmol/l: 1.2 (SE=0.3) Cholesterol,mg/dl: 186.0 (SE=19.9)	**Major surgical complications:** Liver abscess, 1/7 (14.3%)
Geloneze, 2009[25] South America	Controlled Trial	12 T2DM patients with mean age 50.0 (SD=5.3), BMI 26.1 (SD=1.7) kg/m^{2*}	RYGB	**Mean BMI:** 6mths: 25.6 (1.2) **Mean % Fat mass**: 6mths: 25 (SD=7)	**% off DM meds:** 3mths: 9/12 (75%) 6mths: 10/12 (83.3%) **Fasting plasma glucose,mmol/L** 3mths: 7.7 (SD=2.4) 6mths: 8.7 (SD=2.2) **HbA1c,%**: 3mths: 7.3 (SD=0.9) 6mths: 7.8 (SD=1.1)	Total cholesterol,mg/dL: 6mths: 173 (SD=40) HDL-C,mg/dL: 6mths: 36 (SD=6) LDL-C,mg/dL: 6mths: 91 (SD=33) Triglycerides,mg/dL: 6mths: 236 (SD=187) Systolic BP (mmHg): 6mths: 123 (SD=12) Diastolic BP, mmHg: 6mths: 78 (SD=8)	**Adverse events currently reported for 24 patients, 12 surgery and 12 controls:** **GI:** Feeding difficulties, 12/24 (50.0%) Vomitting and/or nausea, 6/24 (25.0)%) **Metabolic**: Hypoglycemia, 3/24 (12.5%) **Wound:** Mild wound infection, 2/24 (8.3%)

Appendix C Evidence Tables For Observational Studies and Controlled Trials with 1 surgical arm**

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
Lee, 2008[23] Asia	Cohort	44 T2DM patients with mean age 39.0 years (SD=8.9), BMI 31.7 (SD=2.7) kg/m^{2*}	RYGB	**Change in BMI:** 12mths: 8.5 (SD=2.2) **Change in Body Weight,kg**: 12mths: 23.1 (SD=6.7)	**% Metabolic Syndrome:** 12mths: 42.7% **Change in Glucose,mg/dl:** 12mths: 80.1 (SD=56.2) **Change in Insulin,pmol/l**: 20.6 (SD=27.1) **Change in HbA1c:** 1.7 (SD=2.3)	Change in HDL-C, mg/dl: 8.3 (SD=11.2) Change in LDL,mg/dl: 53.8 (SD=29) Triglyceride,mg/dl: 147.4 (SD=150.4) C-peptide,mmol/l: 2.6 (SD=2.3)	**Death:** NOS, 0/44, (0%) **Other:** Morbidity major, 2/44, (4.6%)
Shah, 2009[28] India	Case Series	15 T2DM patients with mean age 35 (SD=15), BMI 28 (SD=6) kg/m^{2*}	RYGB	**Mean BMI change**: 2 (SD=1.5)	**HbA1c,%:** 9mths: 5.9 (SD=1.5) **Off anti-diabetic meds**: 1mth: 12/15 (80%) 3mths: 15/15 (100%) 9mths: 15/15 (100%)		**Bleeding/hematoma:** Postop NOS, 1/27 (3.7%) **Major surgical complications** NOS 0/27 (0%) **Metabolic:** Hypoglycemia, 4mths, 2/27 (7.4%) Hypoglycemia, 8mths, 2/27 (7.4%)

Appendix C Evidence Tables For Observational Studies and Controlled Trials with 1 surgical arm**

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
Shah, 2010[29] India	Case Series	15 T2DM patients with mean age 45.6 years (SD=12), BMI 28.9 (SD=4.0) kg/m^{2*}	RYGB	**Mean BMI**: 9mths: 23.0 (SD=3.6) **Mean Body Weight,kg**: 62.7 (SD NR)	**% off DM meds:** 1mths: 12/15 (80%) 3mths: 15/15 (100%) 6mths: 15/15 (100%) 9mths: 15/15 (100%) **Fasting blood glucose,mg/dL:** 1mths: 106.7 (SD NR) 3mths: 112.3 (SD NR) 6mths: 100.2 (SD NR) 9mths: 89.2 (SD=12) **Mean HbA1c,%:** 1mths: 8.3 (SD NR) 3mths: 7.4 (SD NR) 6mths: 6.6 (SD NR) 9mths: 6.1 (SD=0.6)	Systolic blood pressure,mm Hg: 9mths: 116 (SD NR) Total cholesterol,mg/dL: 9mths: 135 (SD NR) High-density lipoprotein,mg/dL: 9mths: 50 (SD NR)	**Death:** NOS, 0/15 (0%) **Major surgical complications**: NOS, 0/15 (0%) **GI:** Anorexia/excessive weight loss, 0/15 (0%)
Angrisani, 2004[30] Western Europe	Cohort	210 patients (1.9% with DM) with mean age 38.2 years (range 17-66), BMI 33.9 (range 25.1-35.0) kg/m^{2*}	LABG	**Mean BMI**: 6mths: 31.1(SD=2.2) 12mths: 29.7(SD=2.2) 24mths: 28.7(SD=3.8) 36mths: 26.7(SD=4.3) 48mths: 27.9(SD=3.2) 60mths: 28.2(SD=0.9) **% EWL**: 6mths: 28.1(SD=20.7) 12mths: 52.5(SD=13.2) 24mths: 61.3(SD=14.7) 36mths: 64.7(SD=12.2) 48mths: 68.8(SD=15.3) 60mths: 71.9(SD=10.7)	**Resolution of DM**: 12mths: 210/210 (100%)	Hypertension: Baseline: 9/210 (4.3%) 12mth: 1/210 (0.5%) GERD: Baseline: 5/210 (2.4%) 12mth: 0/210 (0%)	**Band related:** Band slippage, 2/210 (1.0%) Port tube leak, 4/210 (1.9%) Removal, 7/210 (3.3%) **Death:** Band related - gastric perforation, 1/210 (0.5%) **Pouch/anastomosis:** Pouch dilation, 11/210 (5.2%)

Appendix C Evidence Tables For Observational Studies and Controlled Trials with 1 surgical arm**

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
Choi, 2010[33] US	Cohort	66 patients (6.5% with T2DM) with mean age 40.7 years (SD=11.0), BMI 36.1 (SD=2.6) kg/m^{2*}	LABG	**% EWL:** 3mths: 20.3 (SD=9.0) 6mths: 28.5 (SD=14.0) 12mths: 44.7 (SD=19.3) 18mths: 42.2 (33.7)	**DM improved/resolved:** 12mths: 22/66 (33.3%)	Hypertension Improved/resolved: 28.6% Hyperlipidemia inproved/resolved: 15.4% Apnea improved/resolved: 33.3% Arthritis improved/resolved: 36.7% GERD improved/resolved: 31.3% Stress incontinence improved/resolved: 46.6%	**Band related:** Band slippage, 2/66 (3.0%) Erosion, 1/66 (1.5%) Port site seroma, 1/66 (1.5%) **Death:** NOS, 0/66 (0%)
Parikh 2006[31] Australia/New Zealand	Case Series	93 patients (8.6% with T2DM) with mean age 44.6 years (range 16-76), BMI 32.7 (range 30-34) kg/m^{2*}	LABG	**Mean BMI:** 12mths: 27 (SD=2) 24mths: 27 (SD=3) 36mths: 27 (SD=3) **%EWL**: 12mths: 58 (SD=24) 24mths: 57 (SD=29) 36mths: 54 (SD=32)	**% off DM meds:** Pre-op 8/93 took DM meds, Post-op 0/93 needed meds (100%)	Asthma Meds: Pre-op 5/93, Post-op 1/93 Depression Meds: Pre-op 11/93, Post-op 7/93 no meds, 4/93 improved Hypertension Meds: Pre-op 8/93, Post-op 2/93 Sleep apnea Meds: Pre-op 7/93, Post-op 1/93 Arthritis Meds: Pre-op 9/93, Post-op 8/93 improved	**Band Related:** Band slippage, 3/93 (3.2%) Port leak, 1/93 (1.1%) **Death:** NOS, 0/93, (0%) **GI:** Hiatal hernia, 2/93, (2.2%)

Appendix C Evidence Tables For Observational Studies and Controlled Trials with 1 surgical arm**

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
Sultan, 2009[32] US	Case Series	53 patients (28.3% with T2DM) with mean age 46.9 years (range 16-68), BMI 33.1 (range 28.2-35) kg/m^{2*}	LABG	**Mean BMI:** 6mths: 28.1 (SD=2.4) 12mths: 25.8 (SD=2.9) 24mths: 25.8 (SD=3.1) **%EWL**: 6mths: 48.3 (SD=17.6) 12mths: 69.9 (SD=28.0) 24mths: 69.7 (SD=31.7)	**% off & improved DM meds:** Pre-op 15/53 took DM meds, Post-op 50% meds resolved & improved	Asthma Meds: Pre-op 8/53, Post-op 66.7% resolved, 0% improved Depression Meds: Pre-op 15/53, Post-op 25% resolved, 37.5% improved Hypercholesteremia Meds: Pre-op 25/53, Post-op 33.3% resolved, 0% improved Hypertension Meds: Pre-op 21/53, Post-op 45.5% resolved, 27.3% improved Hypertriglyceridemia Meds: Pre-op 11/53, Post-op 40% resolved, 20% improved Obstructive sleep apnea Meds: Pre-op 19/53, Post-op 50% resolved, 30% improved Osteoarthritis Meds: Pre-op 11/53, Post-op 100% resolved, 0% improved	**Band Related:** Band slippage, 1/53 (1.9%) Port leak, 2/53 (3.8%) **Death:** NOS, 0/53, (0%) **GI:** Esophagitis 2/53 (3.8%) Feeding difficulties 2/53 (3.8%)

Appendix C Evidence Tables For Observational Studies and Controlled Trials with 1 surgical arm**

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
DePaula, 2008[35] South America	Case Series	60 T2DM patients with mean age 51.7 years (range 27-66), BMI 30.7 (range 23.6-34.4) kg/m^{2*}	Sleeve	**Mean BMI:** 7.4mths: 23.8 (SD=4.1) **Mean % Weight Loss**: 7.4mths: 23 (SD=7)	**% off DM meds:** 7.4mths: 87% **DM Remission:** 7.4mths: 42/60 (69.7%) **Fasting plasma glucose,mg/dl**: 7.4mths:106.3 (SD=21.3) **Postprandial plasma glucose,mg/dl**: 7.4mths:140.7 (SD=59.6) **Fasting plasma insulin,mU/ml**: 7.4mths: 4.9 (SD=3.5) **Mean HbA1c:** 7.4mths: 5.8 (SD=0.8)	HDL, mg/dl: 51.3 (SD=8.6) LDL,mg/dl: 90.6 (SD=22.5) Triglyceride,mg/dl: 97.0 (SD=40.3) C-peptide,mmol/l: 2.5 (SD=0.9) Total cholesterol,mg/dl: 160.6 (SD=28.1)	**NEED THIS FOR DEPAULA ARTICLES**
DePaula, 2008[34] South America	Case Series	39 T2DM patients with mean age 50.3 years (range 36-66), BMI 30.1(range 23.4-34.9) kg/m^{2*}	Sleeve	**Mean BMI:** 7mths: 24.9 (SD=3.7) **Mean % Weight Loss**: 7mths: 22 (SD=6)	**% DM resolution:** 7mths: 18/39 (47.4%) **% DM control**: 7mths: 15/39 (39.5%) **% DM improvement**: 7mths: 5/39 (13.1%) **Mean HbA1c:** 7mths: 6.3 (SD=0.9) **Fasting glucose,mg/dl**: 7mths: 116.7 (SD=33.7) **Postprandial glucose,mg/dl:** 7mths: 141.7 (SD=56.6) **Insulin,mU/ml:** 7mths: 8.9 (SD=8.8)	Total cholesterol mg/dl: 7mths: 167.5 (SD=27.6) HDL, mg/dl: 7mths: 46.6 (SD=9.5) LDL, mg/dl: 7mths: 92.8 (SD=21.5) Triglycerides,mg/dl: 7mths: 131.3 (SD=80.2)	**NEED THIS FOR DEPAULA ARTICLES**

Appendix C Evidence Tables For Observational Studies and Controlled Trials with 1 surgical arm**

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
DePaula, 2009[36] South America	Case Series	69 T2DM patients with mean age 51 years (range 41-63), BMI 25.7 (range 21.8-29.2) kg/m^{2*}	Sleeve	**Mean BMI:** 21.7mths: 21.8 (SD=4.1) **Mean % Weight Loss**: 21.7mths: 17.7 (SD=6.2)	**% off DM meds:** 21.7mths: 95.7% **DM Remission:**21.7mths: 45/69 (65.2%) **Fasting plasma glucose,mg/dl**: 21.7mths:102.0 (SD=25.3) **Postprandial plasma glucose,mg/dl**: 21.7mths:141.5 (SD=49.9) **Fasting plasma insulin,mU/ml**: 21.7mths: 2.8 (SD=1.9) **Mean HbA1c:** 21.7mths: 5.9(SD=0.9)	HDL, mg/dl: 48.0 (SD=7.5) LDL,mg/dl: 82.4 (SD=22.4) Triglyceride,mg/dl: 105.8 (SD=43.63) C-peptide,mmol/l: 1.7 (SD=0.7) Microalbuminuria,mcg/min: 44.7 (SD=128.0)	**NEED THIS FOR DEPAULA ARTICLES**
DePaula, 2009[37] South America	Case Series	58 T2DM patients with mean age 51.4 years (range 40-66), BMI 28.2 (range 20.0-34.8) kg/m^{2*}	Sleeve		**% DM remission:** 28mths: 64.7% **% DM control**: 28mths: 26.5% **% DM improvement**: 28mths: 8.8% **Mean HbA1c:** 28mths: 6.3 (SD=0.9) **Fasting plasma glucose,mg/dl**: 28mths: 105.4 (SD=25.4) **Postprandial plasma glucose,mg/dl:**28mths: 133.6 (SD=51.6)	HDL, mg/dl: 28mths: 52.4 (SD=17.2) LDL, mg/dl: 28mths: 94.3 (SD=22.2) Triglycerides,mg/dl: 28mths: 111.1 (SD=45.3)	**NEED THIS FOR DEPAULA ARTICLES**

Appendix C Evidence Tables For Observational Studies and Controlled Trials with 1 surgical arm**

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
DePaula, 2010[40] South America	Controlled Trial	38 T2DM patients with mean age 53.3 years (range 27-66), BMI 28.9 (range 21.0-34.7) kg/m$^{2*;}$	Sleeve	**Mean BMI:** 24mths,II-SG: 22.1 (SD=3.1) 24mths,II-DSG: 22.7 (SD=1.8) **Mean Weight, kg**: 24mths,II-SG: 61.1 (SD=4.2) 24mths,II-DSG: 64.7 (SD=5.1)	**% DM remission:** 24mths: 57.6% **% DM control**: 24mths: 33.3% **% DM improvement**: 24mths: 9.1% **Mean HbA1c:** 24mths: 5.9 (SD=0.9) **Fasting plasma glucose,mg/dl**: 24mths: 114.6 (SD=33.8) **Postprandial plasma glucose,mg/dl:**24mths: 142.0 (SD=58.9) **Fasting plasma insulin,mU/mL**: 24mths: 4.6 (SD=2.5)	LDL, mg/dl: 24mths: 82.9 (SD=21.3) Total cholesterol, mg/dL: 24mths: 157.6 (SD=19.7) Triglycerides,mg/dL: 24mths: 116.4 (SD=53.5)	**NEED THIS FOR DEPAULA ARTICLES**

Appendix C Evidence Tables For Observational Studies and Controlled Trials with 1 surgical arm**

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
DePaula, 2010[38] South America	Case Series	72 T2DM patients with mean age 53.1 years (range 38-66), BMI 27 (range 21.8-29.4) kg/m^{2*}	Sleeve	**Mean BMI:** 24.5 mths: 21.3 (SD=2.3) **Mean % Weight Loss**: 24.5 mths: 22 (SD=3.6)	**% off DM meds:** 24.5mths: 86% **% DM remission**: 24.5mths: 50.0% **% DM control**: 24.5mths: 36.1% **% DM improvement**: 24.5mths: 13.9% **% HbA1c<7%:** 24.5mths: 86.1% **Mean HbA1c:** 24.5mths: 6.1 (SD=0.9) **Fasting plasma glucose,mg/dl**: 24.5mths: 105.1 (SD=23.1) **Fasting plasma insulin,mU/ml**: 24.5mths: 3.9 (SD=3.7	Total cholesterol mg/dl: 1mth: 153.8 (SD NR) 6mth: 154.4 (SD NR) 12mth: 161.1 (SD NR) 24mth: 150.8 (SD NR) 36mth: 172.2 (SD NR) HDL, mg/dl: 1mth: 45.5 (SD NR) 6mth: 47.8 (SD NR) 12mth: 46.8 (SD NR) 24mth: 47.6 (SD NR) 36mth: 47.3 (SD NR) LDL, mg/dl: 1mth: 83.5 (SD NR) 6mth: 79.2 (SD NR) 12mth: 86.5 (SD NR) 24mth: 82.16 (SD NR) 36mth: 93.3 (SD NR) Triglycerides, mg/dl: 1mth: 123 (SD NR) 6mth: 127 (SD NR) 12mth: 114 (SD NR) 24mth: 109 (SD NR) 36mth: 111 (SD NR)	**NEED THIS FOR DEPAULA ARTICLES**

Appendix C Evidence Tables For Observational Studies and Controlled Trials with 1 surgical arm**

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
DePaula, 2010[39] South America	Case Series	454 T2DM patients with mean age 53.6 years (range 27-75), BMI 29.7 (range 19-34.8) kg/m^{2*}	Sleeve	**Mean BMI:** 1mth: 25.8 (SD=3.5) **Mean % Weight Loss**: 1mth: 13 (SD=2.2)	**Fasting plasma glucose,mg/dl**: 1mth: 125.8 (SD=34.8) **Postprandial plasma glucose, mg/dl**: 1mth: 136.7 (SD=43.7)		**Bleeding/hematoma:** Abdominal wall hematoma, 4/454 (0.9%) GI bleed, 9/454 (2.0%) Intraabdominal, 1/454 (0.2%) Subcutaneous hematoma, 1/454 (0.2%) Trocar-related 2/454 (0.4%) **Cardiovascular/Respiratory:** Arrhythmia,4/454(0.9%),Asthma,1/454(0.2%), Hypertensive crisis 2/454 (0.4%), MI, 1/454 (0.2%), Pneumonia 9/454 (2.0%) **Death**: Infection/abscess-intraabdominal 1/454 (0.2%), Renal-ARF, 1/454 (0.2%) **GI:** Abdominal pain/discomfort 4/454 (0.9%), Anorexia/excessive weight loss, 96/454 (21.2%), Constipation 17/454 (3.7%), Diarrhea, 9/454 (2.0%), GERD, 50/454 (11.0%), Ileus, 11/454 (2.4%), Vomitting and/or nausea 33/454 (7.3%) **Major surgical complication**: Bladder perforation, 1/454 (0.2%) Gastric perforation, 3/454 (0.7%) Intraabdominal, 1/454 (0.2%) Ischemia, 9/454 (2.0%) **Metabolic:** Hyperuricemia/gout, 4/454 (0.9%) **Other:** Rhabdomyolisis, 1/454 (0.2%) **Pouch/anastomosis:** Gastric leak, 5/454 (1.1%) **Renal**:ARF,2/454(0.4%), UTI, 5/454 (1.1%) **Wound:** Abdominal wall infection, 8/454 (1.8%), Trocar-site infection, 1/454 (0.2%)

Appendix C Evidence Tables For Observational Studies and Controlled Trials with 1 surgical arm**

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
Kumar, 2009[41] India	Case Series	10 T2DM patients with mean age 48.2 years (range 34-62), BMI 33.8 kg/m^{2*}	Sleeve	**Mean BMI**: 4.6mths: 27.9 (SD=5.8) 13.6mths: 24.6 (SD=3.1) **Body Weight, kg**: 4.6mths: 83.6 (SD=13.9) 13.6mths: 61.4 (SD=8.0)	**Fasting blood glucose,mg/dL:** 4.6mths: 134.2 (SD=15.6) 13.6mths: 97.8 (SD=8.9) **Plasma blood sugar,mg/dL :** 4.6mths: 186.8 (SD=20) 13.6mths: 125(SD=27.5) **Mean HbA1c:** 4.6mths: 7.3 (SD=0.7) 13.6mths: 6.1 (SD=0.5)	HDL-C, mg/dl: 4.6mths: 37 (SD=5.6) 13.6mths: 41 (SD=7.8) LDL-C,mg/dl: 4.6mths: 93.4 (SD=17.2) 13.6mths: 94.2 (SD=37.2) Triglyceride,mg/dl: 4.6mths: 130.8 (SD=42.2) 13.6mths: 205.6 (SD=189) Microalbuminuria,mcg/min: 4.6mths: 24.9 (SD=10.1) 13.6mths: 53 (SD=59.7)	**GI:** Feeding difficulties, 2/10 (20%)
Cohen, 2007[43] South America	Case Series	2 T2DM patients with mean age 47 years (range 43-51), BMI 29.7 (range 29.0-30.3) kg/m^{2*}	BPD	**Mean BMI:** 1mth: 27.8 (SD=0.7) 2mths: 27.5 (SD=0.7) 3mths: 28.0 (SD=0.1) 4mths: 28.5 (SD=1.4) 5mths: 28.4 (SD=1.9) 6mths: 28.3 (SD=1.8) 7mths: 28.0 (SD=1.4) 8mths: 28.4 (SD=2.0) 9mths: 28.3 (SD=1.8)	**% off DM meds**: 5 weeks: 2/2 (100%) **Mean HbA1c, %**: 1mth: 8 (SD=0) 2mths: 7.5 (SD=0.4) 3mths: 6.0 (SD=0.7) 4mths: 6.8 (SD=0.2) 5mths: 6.2(SD=0.7) 6mths: 5.5 (SD=0.7) 7mths: 5.3 (SD=0.4) 8mths: 5.5 (SD=0) 9mths: 5.4 (SD=0.5)		No Mention of Adverse Events
Noya, 1998[42] Western Europe	Case Series	10 T2DM patients with mean age 52.1 years (range 40-62), BMI 33.2 (range 24-39) kg/m^{2*}	BPD	**Mean BMI:** 7mths: 27.2 (SD=3.6) **Mean Excess Weight,kg:** 7mths: 11.9 (SD=7.9)	**% off DM meds**: 8mths: 9/10 (90%)	Cholesterol: 7mths: 165.1 (sd=8.7)	**Cardiovascular:** PE,1/10 (10%0 **Major surgical complications** Reoperation NOS 1/10 (10%)

Appendix C Evidence Tables For Observational Studies and Controlled Trials with 1 surgical arm**

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
Ramos, 2009[46] South America	Case Series	20 T2DM patients with mean age 43 years (range 29-60), BMI 27.1 (range 25-30) kg/m^{2*}	BPD	**Mean BMI**: 3mths: 25 (range 22-29) 6mths: 24.4 (range 20.2-28.3)	**% off DM meds:** 6mths: 18/20 (90%) **Fasting glycemia level:** 3mths: 107.1(range 82-145) 6mths: 96.3 (range 78-118) **Mean HbA1c:** 3mths: 7.8 (range 6.7-9.6) 6mths: 6.8 (range 5.8-7.9)	C-peptide, ng/ml: 3mths: 2.1 (range 1.5-2.9) 6mths: 2.5 (range (1.7-3.2)	**Death:** NOS, 0/20 (0%) **Major surgical complications**: Abscess, 0/20 (0%) **Pouch/anastomosis:** Gastric fistula, 0/20 (0%)
Scopinaro, 2007[44] Western Europe	Case Series	7 T2DM patients with mean age 49 years (range 39-60), BMI 33.4 (range 32.0-34.6) kg/m^{2*}	BPD	**Mean Weight, kg:** 12mths: 71.2 (SD=9.5) 24mths: 74.7 (SD=9.8) **Mean BMI:** 12mths: 26.2 (SD=2.1) 24mths: 26.9 (SD=2.1)	**Mean serum glucose:** 12mths: 87.0 (SD=8.1) 24mths: 90.4 (SD=7.4) **% off DM meds**: 24mths: 7/7 (100%)	Triglycerides: 12mths: 156.5 (SD=67.5) 24mths: 144.1 (SD=62.2) Cholesterol: 12mths: 140.5 (SD=38.3) 24mths: 138.3 (SD=18.0)	No Mention of Adverse Events
Scopinaro, 2009[47] Western Europe	Case Series	27 T2DM patients with mean age 57 years (range 44-69), BMI 30.9 (range 25.3-34.9) kg/m^{2*}	BPD	**Mean BMI**: 1mth: 27.1(range 22.9-32.4) 4mths: 26.0(range 22.9-30.4) 8mths: 25.3(range 22.1-30.8) 12mths: 24.8(range 22.1-27.1)	**Mean fasting serum glucose, mg/dl:** 1mth: 179 (range 85-352) 4mths: 156(range 89-312) 8mths: 157(range 75-290) 12mths: 107(range 83-149) **HbA1c,%:** 1mth: 7.5 (range 5.7-9.8) 4mths: 7.1(range 5.3-10.4) 8mths: 25.3(range 22.1-		**Bleeding/hematoma:** Postop NOS, 1/27 (3.7%) **Major surgical complications** NOS 0/27 (0%) **Metabolic:** Hypoglycemia, 4mths, 2/27 (7.4%) Hypoglycemia, 8mths, 2/27 (7.4%)

Appendix C Evidence Tables For Observational Studies and Controlled Trials with 1 surgical arm**

Author, Year	Study Design	Patient Population	Procedures	Weight Loss Outcomes	Resolution or improvement in diabetes	Other Outcomes	Adverse Events
					30.8) 12mths: 24.8(range 22.1-27.1)		

Appendix D. Excluded Studies:

Appendix D. Excluded Studies:

Background:

1. Campos GM, Rabl C, Roll GR, Peeva S, Prado K, Smith J, et al. Better Weight Loss, Resolution of Diabetes, and Quality of Life for Laparoscopic Gastric Bypass vs Banding: Results of a 2-Cohort Pair-Matched Study. Arch Surg. 2011 Feb;146(2):149-55.
2. Cummings DEF, D. R. Gastrointestinal surgery as a treatment for diabetes. JAMA. 2008 Jan 23;299(3):341-3.
3. Deitel M. Surgery for diabetes at lower BMI: some caution. Obes Surg. 2008 Oct;18(10):1211-4.
4. Ferrannini EM, G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care. 2009 Mar;32(3):514-20.
5. Gary TLB-T, M. Bone, L. R. Yeh, H. C. Wang, N. Y. Hill-Briggs, F. Levine, D. M. Powe, N. R. Hill, M. N. Saudek, C. McGuire, M. Brancati, F. L. A randomized controlled trial of the effects of nurse case manager and community health worker team interventions in urban African-Americans with type 2 diabetes. Control Clin Trials. 2004 Feb;25(1):53-66.
6. Keating CLD, J. B. Moodie, M. L. Peeters, A. Playfair, J. O'Brien, P. E. Cost-efficacy of surgically induced weight loss for the management of type 2 diabetes: a randomized controlled trial. Diabetes Care. 2009 Apr;32(4):580-4.
7. Nathan DMB, M. Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes. Ann Intern Med. 2007 Mar 20;146(6):461-3.

Case Report:

1. Friedman MNS, A. J. Magovern, G. J. The amelioration of diabetes mellitus following subtotal gastrectomy. Surg Gynecol Obstet. 1955 Feb;100(2):201-4.

Wrong population – not diabetes:

1. Al-Sarraj TS, H. Calle, M. C. Volek, J. S. Fernandez, M. L. Carbohydrate restriction, as a first-line dietary intervention, effectively reduces biomarkers of metabolic syndrome in Emirati adults. J Nutr. 2009 Sep;139(9):1667-76.
2. Andersen TB, O. G. Stokholm, K. H. Quaade, F. Randomized trial of diet and gastroplasty compared with diet alone in morbid obesity. N Engl J Med. 1984 Feb 9;310(6):352-6.
3. Andersen TS, K. H. Backer, O. G. Quaade, F. Long-term (5-year) results after either horizontal gastroplasty or very-low-calorie diet for morbid obesity. Int J Obes. 1988;12(4):277-84.
4. Anderson AES, R. T. Scott, D. H. Gastric bypass for morbid obesity in children and adolescents. J Pediatr Surg. 1980 Dec;15(6):876-81.
5. Ashley SB, D. L. Sugden, G. Royston, C. M. Vertical banded gastroplasty for the treatment of morbid obesity. Br J Surg. 1993 Nov;80(11):1421-3.
6. Aude YWA, A. S. Lopez-Jimenez, F. Lieberman, E. H. Marie, Almon Hansen, M. Rojas, G. Lamas, G. A. Hennekens, C. H. The national cholesterol education program

diet vs a diet lower in carbohydrates and higher in protein and monounsaturated fat: a randomized trial. Arch Intern Med. 2004 Oct 25;164(19):2141-6.
7. Bacci VB, M. S. Greco, F. Lamberti, R. Elmore, U. Restuccia, A. Perrotta, N. Silecchia, G. Bucci, A. Modifications of metabolic and cardiovascular risk factors after weight loss induced by laparoscopic gastric banding. Obes Surg. 2002 Feb;12(1):77-82.
8. Benfield JRG, F. L. Bray, G. A. Barry, R. E. Lechago, J. Mena, I. Schedewie, H. Experience with jejunoileal bypass for obesity. Surg Gynecol Obstet. 1976 Sep;143(3):401-10.
9. Berrevoet FP, P. Cardon, A. de Ryck, F. Hesse, U. J. de Hemptinne, B. Retrospective analysis of laparoscopic gastric banding technique: short-term and mid-term follow-up. Obes Surg. 1999 Jun;9(3):272-5.
10. Bradley US, Michelle Courtney, C. Hamish McKinley, Michelle C. Ennis, Cieran N. McCance, David R. McEneny, Jane Bell, Patrick M. Young, Ian S. Hunter, Steven J. Low-Fat Versus Low-Carbohydrate Weight Reduction Diets. Diabetes. 2009 December 2009;58(12):2741-8.
11. Brekke HKJ, P. A. Lenner, R. A. Long-term (1- and 2-year) effects of lifestyle intervention in type 2 diabetes relatives. Diabetes Res Clin Pract. 2005 Dec;70(3):225-34.
12. Buckwalter JA. A prospective comparison of the jejunoileal and gastric bypass operations for morbid obesity. World J Surg. 1977 Nov;1(6):757-68.
13. Charles MAE, E. Grandmottet, P. Isnard, F. Cohen, J. M. Bensoussan, J. L. Berche, H. Chapiro, O. Andre, P. Vague, P. Juhan-Vague, I. Bard, J. M. Safar, M. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev. 2000 Jan-Feb;16(1):2-7.
14. Charuzi IL, P. Peiser, J. Peled, R. Bariatric surgery in morbidly obese sleep-apnea patients: short- and long-term follow-up. Am J Clin Nutr. 1992 Feb;55(2 Suppl):594S-6S.
15. Chua TYM, R. M. Laparoscopic Vertical Banded Gastroplasty: The Milwaukee Experience. Obes Surg. 1995 Feb;5(1):77-80.
16. Claessens MvB, M. A. Monsheimer, S. Saris, W. H. M. The effect of a low-fat, high-protein or high-carbohydrate ad libitum diet on weight loss maintenance and metabolic risk factors. Int J Obes. 2009;33(3):296-304.
17. Colles SLD, J. B. O'Brien, P. E. Hunger control and regular physical activity facilitate weight loss after laparoscopic adjustable gastric banding. Obes Surg. 2008 Jul;18(7):833-40.
18. Dastjerdi MSK, F. Najafian, A. Mohammady, M. Aminorroaya, A. Amini, M. An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. Int J Obes (Lond). 2007 Apr;31(4):713-7.
19. Davis JNV, E. E. Alexander, K. E. Salguero, L. E. Weigensberg, M. J. Crespo, N. C. Spruijt-Metz, D. Goran, M. I. Feasibility of a home-based versus classroom-based nutrition intervention to reduce obesity and type 2 diabetes in Latino youth. Int J Pediatr Obes. 2007;2(1):22-30.
20. de Rougemont AN, S. Nazare, J. A. Skilton, M. R. Sothier, M. Vinoy, S. Laville, M. Beneficial effects of a 5-week low-glycaemic index regimen on weight control and cardiovascular risk factors in overweight non-diabetic subjects. Br J Nutr. 2007 Dec;98(6):1288-98.

21. de Zwaan ML, K. L. Mitchell, J. E. Howell, L. M. Monson, N. Roerig, J. L. Crosby, R. D. Health-related quality of life in morbidly obese patients: effect of gastric bypass surgery. Obes Surg. 2002 Dec;12(6):773-80.
22. Derosa GC, A. F. Murdolo, G. Piccinni, M. N. Fogari, E. Bertone, G. Ciccarelli, L. Fogari, R. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab. 2005 Jan;7(1):47-55.
23. DeWind LTP, J. H. Intestinal bypass surgery for morbid obesity. Long-term results. JAMA. 1976 Nov 15;236(20):2298-301.
24. Dhabuwala AC, R. J. Stubbs, R. S. Improvement in co-morbidities following weight loss from gastric bypass surgery. Obes Surg. 2000 Oct;10(5):428-35.
25. Ditschuneit HHF-M, Marion Johnson, Timothy D Adler, Guido. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. Am J Clin Nutr. 1999 February 1, 1999;69(2):198-204.
26. Dolan KF, G. A comparison of laparoscopic adjustable gastric banding in adolescents and adults. Surg Endosc. 2004 Jan;18(1):45-7.
27. Due AL, T. M. Mu, H. Hermansen, K. Stender, S. Astrup, A. Comparison of 3 ad libitum diets for weight-loss maintenance, risk of cardiovascular disease, and diabetes: a 6-mo randomized, controlled trial. Am J Clin Nutr. 2008 Nov;88(5):1232-41.
28. Eckhout GVW, O. L. Moore, J. T. Vertical ring gastroplasty for morbid obesity. Five year experience with 1,463 patients. Am J Surg. 1986 Dec;152(6):713-6.
29. Farnsworth EL, N. D. Noakes, M. Wittert, G. Argyiou, E. Clifton, P. M. Effect of a high-protein, energy-restricted diet on body composition, glycemic control, and lipid concentrations in overweight and obese hyperinsulinemic men and women. Am J Clin Nutr. 2003 Jul;78(1):31-9.
30. Flechtner-Mors MD, Herwig H. Johnson, Timothy D. Suchard, Mark A. Adler, Guido. Metabolic and Weight Loss Effects of Long-Term Dietary Intervention in Obese Patients: Four-Year Results. Obesity. 2000;8(5):399-402.
31. Fobi ML, H. Igwe, D. Felahy, B. James, E. Stanczyk, M. Fobi, N. Gastric bypass in patients with BMI < 40 but > 32 without life-threatening co-morbidities: preliminary report. Obes Surg. 2002 Feb;12(1):52-6.
32. Foley EFB, P. N. Borlase, B. C. Hollingshead, J. Blackburn, G. L. Impact of gastric restrictive surgery on hypertension in the morbidly obese. Am J Surg. 1992 Mar;163(3):294-7.
33. Forsell PH, G. The Swedish Adjustable Gastric Banding (SAGB) for morbid obesity: 9 year experience and a 4-year follow-up of patients operated with a new adjustable band. Obes Surg. 1997 Aug;7(4):345-51.
34. Frank LLS, B. E. Yasui, Y. Tworoger, S. S. Schwartz, R. S. Ulrich, C. M. Irwin, M. L. Rudolph, R. E. Rajan, K. B. Stanczyk, F. Bowen, D. Weigle, D. S. Potter, J. D. McTiernan, A. Effects of exercise on metabolic risk variables in overweight postmenopausal women: a randomized clinical trial. Obes Res. 2005 Mar;13(3):615-25.
35. Fransis KD, F. Vanrykel, J. P. Aelvoet, C. Experience with laparoscopic adjustable gastric banding (la-band system) up to 8 years. Acta Chir Belg. 2005 Feb;105(1):69-73.
36. Freeman JBB, H. J. A comparison of gastric bypass and gastroplasty for morbid obesity. Surgery. 1980 Sep;88(3):433-44.

37. Frey H. [An investigation of the effect of biguanides on glucose tolerance and body weight in overweight individuals without diabetes mellitus]. Tidsskr Nor Laegeforen. 1972 May 30;92(15):1036-8.
38. Gleysteen JJ. Four-year weight loss Roux-Y gastric bypass: anastomotic reinforcement not additive. Gastroenterol Clin North Am. 1987 Sep;16(3):525-7.
39. Gomez CA. Gastroplasty in morbid obesity. Surg Clin North Am. 1979 Dec;59(6):1113-20.
40. Grey NK, D. M. Effect of diet composition on the hyperinsulinemia of obesity. N Engl J Med. 1971 Oct 7;285(15):827-31.
41. Hafner RJW, J. M. Rogers, J. Quality of life after gastric bypass for morbid obesity. Int J Obes. 1991 Aug;15(8):555-60.
42. Hajdukovic ZJ, A. Zivotic-Vanovic, M. Raden, S. [Influence of orlistat therapy on serum insulin level and morphological and functional parameters of peripheral arterial circulation in obese patients]. Vojnosanit Pregl. 2005 Nov;62(11):803-10.
43. Hall WDF, Z. George, V. A. Lewis, C. E. Oberman, A. Huber, M. Fouad, M. Cutler, J. A. Low-fat diet: effect on anthropometrics, blood pressure, glucose, and insulin in older women. Ethn Dis. 2003 Summer;13(3):337-43.
44. Harrison RAR, C. Elton, P. J. Does primary care referral to an exercise programme increase physical activity one year later? A randomized controlled trial. J Public Health (Oxf). 2005 Mar;27(1):25-32.
45. Herbst CA, Jr. Buckwalter, J. A. Weight loss and complications after four gastric operations for morbid obesity. South Med J. 1982 Nov;75(11):1324-8.
46. Kellum JMK, J. F. O'Dorisio, T. M. Rayford, P. Martin, D. Engle, K. Wolf, L. Sugerman, H. J. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg. 1990 Jun;211(6):763-70; discussion 70-1.
47. Kukkonen-Harjula KTB, P. T. Nenonen, A. M. Fogelholm, M. G. Effects of a weight maintenance program with or without exercise on the metabolic syndrome: a randomized trial in obese men. Prev Med. 2005 Sep-Oct;41(3-4):784-90.
48. Larsen JFK, J. P. [Laparoscopic adjustable gastric banding for the treatment of morbid obesity. Six years' experiences]. Ugeskr Laeger. 2005 May 2;167(18):1946-9.
49. Lee WJL, Y. C. Ser, K. H. Chen, J. C. Chen, S. C. Improvement of insulin resistance after obesity surgery: a comparison of gastric banding and bypass procedures. Obes Surg. 2008 Sep;18(9):1119-25.
50. Lee WJW, W. Yu, P. J. Wei, P. L. Huang, M. T. Gastrointestinal quality of life following laparoscopic adjustable gastric banding in Asia. Obes Surg. 2006 May;16(5):586-91.
51. Lucas CPB, M. N. Reaven, G. M. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol. 2003 Apr 15;91(8):961-4.
52. Martinez-Gonzalez MAdlF-A, C. Nunez-Cordoba, J. M. Basterra-Gortari, F. J. Beunza, J. J. Vazquez, Z. Benito, S. Tortosa, A. Bes-Rastrollo, M. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. BMJ. 2008 Jun 14;336(7657):1348-51.
53. McMahon FGF, K. Singh, B. N. Mendel, C. M. Rowe, E. Rolston, K. Johnson, F. Mooradian, A. D. Efficacy and safety of sibutramine in obese white and African

American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2000 Jul 24;160(14):2185-91.
54. Melchionda NB, L. Di Domizio, S. Pasqui, F. Nuccitelli, C. Migliorini, S. Baraldi, L. Natale, S. Manini, R. Bellini, M. Belsito, C. Forlani, G. Marchesini, G. Cognitive behavioural therapy for obesity: one-year follow-up in a clinical setting. Eat Weight Disord. 2003 Sep;8(3):188-93.
55. Moon Han SK, W. W. Oh, J. H. Results of laparoscopic sleeve gastrectomy (LSG) at 1 year in morbidly obese Korean patients. Obes Surg. 2005 Nov-Dec;15(10):1469-75.
56. Morino MT, M. Garrone, C. Disappointing long-term results of laparoscopic adjustable silicone gastric banding. Br J Surg. 1997 Jun;84(6):868-9.
57. Morino MT, M. Garrone, C. Morino, F. Laparoscopic adjustable silicone gastric banding for the treatment of morbid obesity. Br J Surg. 1994 Aug;81(8):1169-70.
58. Narayan KMH, M. Kozak, D. Kriska, A. M. Hanson, R. L. Pettitt, D. J. Nagi, D. K. Bennett, P. H. Knowler, W. C. Randomized clinical trial of lifestyle interventions in Pima Indians: a pilot study. Diabet Med. 1998 Jan;15(1):66-72.
59. Nedelnikova KS, S. Haas, T. Matoulek, M. Fried, M. Influence of metabolic state and diabetes on the outcome at the end of first year after gastric banding. Obes Surg. 2000 Aug;10(4):372-5.
60. Nicklas BJD, K. E. Berman, D. M. Sorkin, J. Ryan, A. S. Goldberg, A. P. Lifestyle intervention of hypocaloric dieting and walking reduces abdominal obesity and improves coronary heart disease risk factors in obese, postmenopausal, African-American and Caucasian women. J Gerontol A Biol Sci Med Sci. 2003 Feb;58(2):181-9.
61. Nilsson PML, L. H. Schersten, B. F. Life style changes improve insulin resistance in hyperinsulinaemic subjects: a one-year intervention study of hypertensives and normotensives in Dalby. J Hypertens. 1992 Sep;10(9):1071-8.
62. Olsson SAN-E, P. Pettersson, B. G. Sorbris, R. Gastroplasty as a treatment for massive obesity. A clinical and biochemical evaluation. Scand J Gastroenterol. 1985 Mar;20(2):215-21.
63. Olsson SAR, O. Danielsson, A. Nilsson-Ehle, P. Weight reduction after gastroplasty: the predictive value of surgical, metabolic, and psychological variables. Int J Obes. 1984;8(3):245-58.
64. Owen ERA, R. Kark, A. E. Gastroplasty for morbid obesity: technique, complications and results in 60 cases. Br J Surg. 1989 Feb;76(2):131-5.
65. Payne JHD, L. Schwab, C. E. Kern, W. H. Surgical treatment of morbid obesity. Sixteen years of experience. Arch Surg. 1973 Apr;106(4):432-7.
66. Peiser JL, P. Ovnat, A. Charuzi, I. Sleep apnea syndrome in the morbidly obese as an indication for weight reduction surgery. Ann Surg. 1984 Jan;199(1):112-5.
67. Pereira MAS, J. Goldfine, A. B. Rifai, N. Ludwig, D. S. Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. JAMA. 2004 Nov 24;292(20):2482-90.
68. Peterson CMJ-P, L. Randomized crossover study of 40% vs. 55% carbohydrate weight loss strategies in women with previous gestational diabetes mellitus and non-diabetic women of 130-200% ideal body weight. J Am Coll Nutr. 1995 Aug;14(4):369-75.

69. Pittas AGR, S. B. Das, S. K. Gilhooly, C. H. Saltzman, E. Golden, J. Stark, P. C. Greenberg, A. S. The effects of the dietary glycemic load on type 2 diabetes risk factors during weight loss. Obesity (Silver Spring). 2006 Dec;14(12):2200-9.
70. Rabast US, J. Kasper, H. Dietetic treatment of obesity with low and high-carbohydrate diets: comparative studies and clinical results. Int J Obes. 1979;3(3):201-11.
71. Ramsey-Stewart G. Vertical banded gastroplasty for morbid obesity: weight loss at short and long-term follow up. Aust N Z J Surg. 1995 Jan;65(1):4-7.
72. Reinhold RB. Critical analysis of long term weight loss following gastric bypass. Surg Gynecol Obstet. 1982 Sep;155(3):385-94.
73. Rokling-Andersen MHR, J. E. Veierod, M. B. Anderssen, S. A. Jacobs, D. R., Jr. Urdal, P. Jansson, J. O. Drevon, C. A. Effects of long-term exercise and diet intervention on plasma adipokine concentrations. Am J Clin Nutr. 2007 Nov;86(5):1293-301.
74. Ross RD, D. Jones, P. J. Smith, H. Paddags, A. Hudson, R. Janssen, I. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med. 2000 Jul 18;133(2):92-103.
75. Ross RJ, I. Physical activity, total and regional obesity: dose-response considerations. Med Sci Sports Exerc. 2001 Jun;33(6 Suppl):S521-7; discussion S8-9.
76. Rucker RD, Jr. Horstmann, J. Schneider, P. D. Varco, R. L. Buchwald, H. Comparisons between jejunoileal and gastric bypass operations for morbid obesity. Surgery. 1982 Aug;92(2):241-9.
77. Ryden OO, S. A. Danielsson, A. Nilsson-Ehle, P. Weight loss after gastroplasty: psychological sequelae in relation to clinical and metabolic observations. J Am Coll Nutr. 1989 Feb;8(1):15-23.
78. Schwarz AB, M. Usinger, K. Rieger, H. Glasbrenner, B. Friess, H. Kunz, R. Beger, H. G. Importance of the duodenal passage and pouch volume after total gastrectomy and reconstruction with the Ulm pouch: prospective randomized clinical study. World J Surg. 1996 Jan;20(1):60-6; discussion 6-7.
79. Shah MS, V. Garg, A. Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab. 2006 Nov;91(11):4223-31.
80. Toft UNK, L. H. Aadahl, M. von Huth Smith, L. Pisinger, C. Jorgensen, T. Diet and exercise intervention in a general population--mediators of participation and adherence: the Inter99 study. Eur J Public Health. 2007 Oct;17(5):455-63.
81. Tweddle EAW, S. Blamey, S. Laparoscopic gastric banding: safe and modestly successful. ANZ J Surg. 2004 Apr;74(4):191-4.
82. Vishne THR, E. Alper, D. Avraham, Z. Seror, D. Dreznik, Z. Long-term follow-up and factors influencing success of silastic ring vertical gastroplasty. Dig Surg. 2004;21(2):134-40; discussion 40-1.
83. Weissgerber TLW, L. A. Davies, G. A. Mottola, M. F. Exercise in the prevention and treatment of maternal-fetal disease: a review of the literature. Appl Physiol Nutr Metab. 2006 Dec;31(6):661-74.
84. Wickremesekera KM, G. Naotunne, T. D. Knowles, G. Stubbs, R. S. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg. 2005 Apr;15(4):474-81.

85. Wing RRJ, R. W. Effect of modest weight loss on changes in cardiovascular risk factors: are there differences between men and women or between weight loss and maintenance? Int J Obes Relat Metab Disord. 1995 Jan;19(1):67-73.
86. Yates BT. Survey comparison of success, morbidity, mortality, fees and psychological benefits and costs of 3,146 patients receiving jejunoileal or gastric bypass. Am J Clin Nutr. 1980 Feb;33(2 Suppl):518-22.

Wrong population: BMI > 35:

1. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002 May 15;287(19):2542-51.
2. U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study. Diabetes. 1985 Aug;34(8):793-8.
3. Adams TDG, R. E. Smith, S. C. Halverson, R. C. Simper, S. C. Rosamond, W. D. Lamonte, M. J. Stroup, A. M. Hunt, S. C. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007 Aug 23;357(8):753-61.
4. Agren GN, I. A prospective randomized comparison of vertical banded gastroplasty (VBG), loop gastric bypass (GBY) and gastric banding (GB). Int J Obes 1989;13:595.
5. Anderson JWC, S. B. Nicholas, A. S. One hundred pound weight losses with an intensive behavioral program: changes in risk factors in 118 patients with long-term follow-up. Am J Clin Nutr. 2007 Aug;86(2):301-7.
6. Aronne LF, K. Aroda, V. Chen, K. Halseth, A. Kesty, N. C. Burns, C. Lush, C. W. Weyer, C. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007 Aug;92(8):2977-83.
7. Avenell AB, J. Brown, T. J. Poobalan, A. Aucott, L. Stearns, S. C. Smith, W. C. Jung, R. T. Campbell, M. K. Grant, A. M. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004 May;8(21):iii-iv, 1-182.
8. Babio NB, M. Salas-Salvado, J. Mediterranean diet and metabolic syndrome: the evidence. Public Health Nutr. 2009 Sep;12(9A):1607-17.
9. Balducci SZ, S. Fernando, F. Fallucca, S. Fallucca, F. Pugliese, G. Physical activity/exercise training in type 2 diabetes. The role of the Italian Diabetes and Exercise Study. Diabetes Metab Res Rev. 2009 Sep;25 Suppl 1:S29-33.
10. Baltasar AB, R. Miro, J. Et al. Roux-en-Y laparoscopic gastric bypass in patients with morbid obesity. Revista Espanola de Enfermedades Digestivas. 2000;92:661-8.
11. Basdevant AP, M. Rodde-Dunet, M. H. Marty, M. Nogues, F. Slim, K. Chevallier, J. M. A nationwide survey on bariatric surgery in France: two years prospective follow-up. Obes Surg. 2007 Jan;17(1):39-44.
12. Beaser SBH, F. M. Partial remission of diabetes mellitus after oral antidiabetic therapy. Postgrad Med. 1971 Mar;49(3):101-5.
13. Belachew MJ, P. Lardinois, F. Karler, C. Vertical Banded Gastroplasty vs Adjustable Silicone Gastric Banding in the Treatment of Morbid Obesity: a Preliminary Report. Obes Surg. 1993 Aug;3(3):275-8.

14. Best JHB, K. S. Rubin, R. R. Cao, D. Kim, T. H. Peyrot, M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med. 2009 Jul;26(7):722-8.
15. Bray GA. Lifestyle and pharmacological approaches to weight loss: efficacy and safety. J Clin Endocrinol Metab. 2008 Nov;93(11 Suppl 1):S81-8.
16. Breum LB, U. Bak, J. F. Jacobsen, S. Astrup, A. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism. 1995 Dec;44(12):1570-6.
17. Brolin REK, H. A. Wilson, A. C. Kuo, P. T. Cody, R. P. Serum lipids after gastric bypass surgery for morbid obesity. Int J Obes. 1990 Nov;14(11):939-50.
18. Buchwald HV, R. L. A bypass operation for obese hyperlipidemic patients. Surgery. 1971 Jul;70(1):62-70.
19. Buchwald HV, R. L. Matts, J. P. Long, J. M. Fitch, L. L. Campbell, G. S. Pearce, M. B. Yellin, A. E. Edmiston, W. A. Smink, R. D., Jr. et al.,. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990 Oct 4;323(14):946-55.
20. Buffington CKC, G. S., Jr. Smith, H. Significant Changes in the Lipid-Lipoprotein Status of Premenopausal Morbidly Obese Females following Gastric Bypass Surgery. Obes Surg. 1994 Nov;4(4):328-35.
21. Buffington CKM, R. T. Ethnic differences in obesity and surgical weight loss between African-American and Caucasian females. Obes Surg. 2006 Feb;16(2):159-65.
22. Busetto LP, C. Rinaldi, D. Longhin, P. L. Segato, G. De Marchi, F. Foletto, M. Favretti, F. Lise, M. Enzi, G. Variation in lipid levels in morbidly obese patients operated with the LAP-BAND adjustable gastric banding system: effects of different levels of weight loss. Obes Surg. 2000 Dec;10(6):569-77.
23. Carey DGP, G. J. Raymond, R. L. Body composition and metabolic changes following bariatric surgery: effects on fat mass, lean mass and basal metabolic rate: six months to one-year follow-up. Obes Surg. 2006 Dec;16(12):1602-8.
24. Case CCJ, P. H. Nelson, K. O'Brian Smith, E. Ballantyne, C. M. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab. 2002 Nov;4(6):407-14.
25. Champagne CM. The usefulness of a Mediterranean-based diet in individuals with type 2 diabetes. Curr Diab Rep. 2009 Oct;9(5):389-95.
26. Chau WYS, H. J. Kouli, W. Davis, D. Wasielewski, A. Ballantyne, G. H. Patient characteristics impacting excess weight loss following laparoscopic adjustable gastric banding. Obes Surg. 2005 Mar;15(3):346-50.
27. Chen KML, W. J. Lai, H. S. Chen, W. J. Fifteen years' experience with gastric partitioning for obesity treatment. J Formos Med Assoc. 1998 Jun;97(6):381-6.
28. Clegg AS, M. Colquitt, J. Et al. Clinical and cost effectiveness of surgery for people with morbid obesity. Southhampton: Wessex Institute for Health and Research and Development; 2001 Contract No.: Document Number|.
29. Colle BB, S. [Cardiovascular risk reduction: impact of an international project]. Ann Ig. 2008 May-Jun;20(3 Suppl 1):43-8.

30. Collet DR, A. Sa Cunha, A. Larroude, D. Masson, B. Laparoscopic adjustable gastric banding results after 2 years with two different band types. Obes Surg. 2005 Jun-Jul;15(6):853-7.
31. Cowan GS, Jr. Buffington, C. K. Significant changes in blood pressure, glucose, and lipids with gastric bypass surgery. World J Surg. 1998 Sep;22(9):987-92.
32. Crampton NAI, V. Stubbs, R. S. Silastic ring gastric bypass: a comparison of two ring sizes: a preliminary report. Obes Surg. 1997 Dec;7(6):495-9.
33. Cranor CWB, B. A. Christensen, D. B. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003 Mar-Apr;43(2):173-84.
34. Cummings DEW, D. S. Frayo, R. S. Breen, P. A. Ma, M. K. Dellinger, E. P. Purnell, J. Q. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002 May 23;346(21):1623-30.
35. Cunneen SA. Review of meta-analytic comparisons of bariatric surgery with a focus on laparoscopic adjustable gastric banding. Surg Obes Relat Dis. 2008 May-Jun;4(3 Suppl):S47-55.
36. de Paula ALM, A. L. Prudente, A. S. Queiroz, L. Schraibman, V. Pinus, J. Laparoscopic sleeve gastrectomy with ileal interposition ("neuroendocrine brake")--pilot study of a new operation. Surg Obes Relat Dis. 2006 Jul-Aug;2(4):464-7.
37. DeMaria EJS, H. J. A critical look at laparoscopic adjustable silicone gastric banding for surgical treatment of morbid obesity: does it measure up? Surg Endosc. 2000 Aug;14(8):697-9.
38. Desaive C. A critical review of a personal series of 1000 gastroplasties. Int J Obes Relat Metab Disord. 1995 Sep;19 Suppl 3:S56-60.
39. Dixon JBD, M. E. O'Brien, P. E. Quality of life after lap-band placement: influence of time, weight loss, and comorbidities. Obes Res. 2001 Nov;9(11):713-21.
40. Dixon JBOB, P. E. Lipid profile in the severely obese: changes with weight loss after lap-band surgery. Obes Res. 2002 Sep;10(9):903-10.
41. Dixon JBP, W. J. O'Brien, P. E. Schauer, P. R. Zimmet, P. Surgery as an effective early intervention for diabesity: why the reluctance? Diabetes Care. 2005 Feb;28(2):472-4.
42. Elmore UR, A. Perrotta, N. Et al. Laparoscopic adjustable silicone gastric banding (LASGB) - analysis of 64 consecutive patients. Obes Surg. 1998;8:399 (abstract).
43. Favretti FS, G. Ashton, D. Busetto, L. De Luca, M. Mazza, M. Ceoloni, A. Banzato, O. Calo, E. Enzi, G. Laparoscopic adjustable gastric banding in 1,791 consecutive obese patients: 12-year results. Obes Surg. 2007 Feb;17(2):168-75.
44. Fera TB, B. M. Ellis, W. M. Schaller, C. W. Garrett, D. G. The Diabetes Ten City Challenge: interim clinical and humanistic outcomes of a multisite community pharmacy diabetes care program. J Am Pharm Assoc (2003). 2008 Mar-Apr;48(2):181-90.
45. Finer NR, D. H. Renz, C. L. Hewkin, A. C. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab. 2006 Mar;8(2):206-13.
46. Fleischman AS, S. E. Bernier, R. Goldfine, A. B. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008 Feb;31(2):289-94.

47. Flum DRS, L. Elrod, J. A. Dellinger, E. P. Cheadle, A. Chan, L. Early mortality among Medicare beneficiaries undergoing bariatric surgical procedures. JAMA. 2005 Oct 19;294(15):1903-8.
48. Fobi MAL, H. SILASTIC ring vertical banded gastric bypass for the treatment of obesity: two years of follow-up in 84 patients [corrected]. J Natl Med Assoc. 1994 Feb;86(2):125-8.
49. Foster GDB, K. E. Vander Veur, S. S. Leh Shantz, K. Dilks, R. J. Goldbacher, E. M. Oliver, T. L. Lagrotte, C. A. Homko, C. Satz, W. The effects of a commercially available weight loss program among obese patients with type 2 diabetes: a randomized study. Postgrad Med. 2009 Sep;121(5):113-8.
50. Foster GDB, Kelley E. Sanders, Mark H. Millman, Richard Zammit, Gary Newman, Anne B. Wadden, Thomas A. Kelley, David Wing, Rena R. Pi-Sunyer, F. Xavier Reboussin, David Kuna, Samuel T. for the Sleep AHEAD Research Group of the Look AHEAD Research Group,. A Randomized Study on the Effect of Weight Loss on Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes: The Sleep AHEAD Study. Arch Intern Med. 2009 September 28, 2009;169(17):1619-26.
51. Gannon MCN, F. Q. Saeed, A. Jordan, K. Hoover, H. An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes. Am J Clin Nutr. 2003 Oct;78(4):734-41.
52. Garcia-Fuentes EG-A, J. M. Garcia-Arnes, J. Rivas-Marin, J. Gallego-Perales, J. L. Gonzalez-Jimenez, B. Cardona, I. Garcia-Serrano, S. Garriga, M. J. Gonzalo, M. de Adana, M. S. Soriguer, F. Morbidly obese individuals with impaired fasting glucose have a specific pattern of insulin secretion and sensitivity: effect of weight loss after bariatric surgery. Obes Surg. 2006 Sep;16(9):1179-88.
53. Garrett DGB, B. M. Patient self-management program for diabetes: first-year clinical, humanistic, and economic outcomes. J Am Pharm Assoc (2003). 2005 Mar-Apr;45(2):130-7.
54. Glasgow REN, C. C. Kearney, K. A. Reid, R. Ritzwoller, D. P. Strecher, V. J. Couper, M. P. Green, B. Wildenhaus, K. Reach, engagement, and retention in an Internet-based weight loss program in a multi-site randomized controlled trial. J Med Internet Res. 2007;9(2):e11.
55. Gleysteen JJB, J. J. Sasse, E. A. Sustained coronary-risk-factor reduction after gastric bypass for morbid obesity. Am J Clin Nutr. 1990 May;51(5):774-8.
56. Gorin AAN, H. M. Hogan, P. Coday, M. Davis, C. DiLillo, V. G. Gluck, M. E. Wadden, T. A. West, D. S. Williamson, D. Yanovski, S. Z. Binge eating and weight loss outcomes in overweight and obese individuals with type 2 diabetes: results from the Look AHEAD trial. Arch Gen Psychiatry. 2008 Dec;65(12):1447-55.
57. Gray AR, M. McGuire, A. Fenn, P. Stevens, R. Cull, C. Stratton, I. Adler, A. Holman, R. Turner, R. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ. 2000 May 20;320(7246):1373-8.
58. Gray DSF, K. Devine, W. Bray, G. A. A randomized double-blind clinical trial of fluoxetine in obese diabetics. Int J Obes Relat Metab Disord. 1992 Dec;16 Suppl 4:S67-72.

59. Hartweg JP, R. Montori, V. Dinneen, S. Neil, H. A. Farmer, A. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008(1):CD003205.
60. Havas S. The ACCORD Trial and control of blood glucose level in type 2 diabetes mellitus: time to challenge conventional wisdom. Arch Intern Med. 2009 Jan 26;169(2):150-4.
61. Henness S. Pharmacological interventions in the prevention of type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2007 Apr;14(2):166-9.
62. Heymsfield SBS, K. R. Hauptman, J. Lucas, C. P. Boldrin, M. N. Rissanen, A. Wilding, J. P. Sjostrom, L. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000 May 8;160(9):1321-6.
63. Karastergiou KK, J. C. Medical management of the diabetic patient with coronary artery disease. Curr Pharm Des. 2008;14(25):2527-36.
64. Karlsson JS, L. Sullivan, M. Swedish obese subjects (SOS)--an intervention study of obesity. Two-year follow-up of health-related quality of life (HRQL) and eating behavior after gastric surgery for severe obesity. Int J Obes Relat Metab Disord. 1998 Feb;22(2):113-26.
65. Kelley DEB, G. A. Pi-Sunyer, F. X. Klein, S. Hill, J. Miles, J. Hollander, P. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care. 2002 Jun;25(6):1033-41.
66. Keyserling TCA, A. S. Samuel-Hodge, C. D. Ingram, A. F. Skelly, A. H. Elasy, T. A. Johnston, L. F. Cole, A. S. Henriquez-Roldan, C. F. A diabetes management program for African American women with type 2 diabetes. Diabetes Educ. 2000 Sep-Oct;26(5):796-805.
67. Kriska AMB, S. N. Pereira, M. A. The potential role of physical activity in the prevention of non-insulin-dependent diabetes mellitus: the epidemiological evidence. Exerc Sport Sci Rev. 1994;22:121-43.
68. La Londe MAG, C. L. Falko, J. M. Snow, R. J. Spencer, K. Caulin-Glaser, T. Effect of a weight management program on the determinants and prevalence of metabolic syndrome. Obesity (Silver Spring). 2008 Mar;16(3):637-42.
69. Laferrere BT, J. McGinty, J. Tran, H. Egger, J. R. Colarusso, A. Kovack, B. Bawa, B. Koshy, N. Lee, H. Yapp, K. Olivan, B. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008 Jul;93(7):2479-85.
70. Lancaster RTH, M. M. Bands and bypasses: 30-day morbidity and mortality of bariatric surgical procedures as assessed by prospective, multi-center, risk-adjusted ACS-NSQIP data. Surg Endosc. 2008 Dec;22(12):2554-63.
71. Lee HJP, K. Y. [Body weight, cardiovascular risk factors, and self-efficacy of diabetic control among obese type II diabetic patients]. Taehan Kanho Hakhoe Chi. 2005 Aug;35(5):787-97.
72. Lee WJH, M. T. Wang, W. Lin, C. M. Chen, T. C. Lai, I. R. Effects of obesity surgery on the metabolic syndrome. Arch Surg. 2004 Oct;139(10):1088-92.
73. Leichman JGA, D. King, T. M. Mehta, S. Majka, C. Scarborough, T. Wilson, E. B. Taegtmeyer, H. Improvements in systemic metabolism, anthropometrics, and left

ventricular geometry 3 months after bariatric surgery. Surg Obes Relat Dis. 2006 Nov-Dec;2(6):592-9.
74. Levy PF, M. Santini, F. Finer, N. The comparative effects of bariatric surgery on weight and type 2 diabetes. Obes Surg. 2007 Sep;17(9):1248-56.
75. Lim PK, O. T. Metformin compared with tolbutamide in the treatment of maturity-onset diabetes mellitus. Med J Aust. 1970 Feb 7;1(6):271-3.
76. Lujan JAF, M. D. Hernandez, Q. Liron, R. Cuenca, J. R. Valero, G. Parrilla, P. Laparoscopic versus open gastric bypass in the treatment of morbid obesity: a randomized prospective study. Ann Surg. 2004 Apr;239(4):433-7.
77. Ma YO, B. C. Merriam, P. A. Chiriboga, D. E. Culver, A. L. Li, W. Hebert, J. R. Ockene, I. S. Griffith, J. A. Pagoto, S. L. A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 diabetes. Nutrition. 2008 Jan;24(1):45-56.
78. MacDonald KG, Jr. Long, S. D. Swanson, M. S. Brown, B. M. Morris, P. Dohm, G. L. Pories, W. J. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg. 1997 May-Jun;1(3):213-20; discussion 20.
79. Madan AKO, W. Ternovits, C. A. Tichansky, D. S. Metabolic syndrome: yet another co-morbidity gastric bypass helps cure. Surg Obes Relat Dis. 2006 Jan-Feb;2(1):48-51; discussion
80. Mattar SGV, L. M. Rabinovitz, M. Demetris, A. J. Krasinskas, A. M. Barinas-Mitchell, E. Eid, G. M. Ramanathan, R. Taylor, D. S. Schauer, P. R. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg. 2005 Oct;242(4):610-7; discussion 8-20.
81. Mayer-Davis EJDA, A. Martin, M. Wandersman, A. Parra-Medina, D. Schulz, R. Pilot study of strategies for effective weight management in type 2 diabetes: Pounds Off with Empowerment (POWER). Fam Community Health. 2001 Jul;24(2):27-35.
82. McAuley KAH, C. M. Smith, K. J. McLay, R. T. Williams, S. M. Taylor, R. W. Mann, J. I. Comparison of high-fat and high-protein diets with a high-carbohydrate diet in insulin-resistant obese women. Diabetologia. 2005 Jan;48(1):8-16.
83. McNabb WLQ, M. T. Rosing, L. Weight loss program for inner-city black women with non-insulin-dependent diabetes mellitus: PATHWAYS. J Am Diet Assoc. 1993 Jan;93(1):75-7.
84. McTigue KMH, R. Ziouras, J. Obesity in older adults: a systematic review of the evidence for diagnosis and treatment. Obesity (Silver Spring). 2006 Sep;14(9):1485-97.
85. Meshcheriakova VAP, O. A. Sharafetdinov, KhKh Iatsyshina, T. A. [The use of the combined food products with soy protein in diet therapy for patients with diabetes mellitus type 2]. Vopr Pitan. 2002;71(5):19-24.
86. Meyer LR, S. Becker, J. Pradignac, A. Meyer, C. Schlienger, J. L. Simon, C. Retrospective study of laparoscopic adjustable silicone gastric banding for the treatment of morbid obesity: results and complications in 127 patients. Diabetes Metab. 2004 Feb;30(1):53-60.
87. Miller YDD, D. W. The effectiveness of physical activity interventions for the treatment of overweight and obesity and type 2 diabetes. J Sci Med Sport. 2004 Apr;7(1 Suppl):52-9.

88. Morino MT, M. Forestieri, P. Angrisani, L. Allaix, M. E. Scopinaro, N. Mortality after bariatric surgery: analysis of 13,871 morbidly obese patients from a national registry. Ann Surg. 2007 Dec;246(6):1002-7; discussion 7-9.
89. Nehoda HH, K. Sauper, T. Mittermair, R. Lanthaler, M. Aigner, F. Weiss, H. Laparoscopic gastric banding in older patients. Arch Surg. 2001 Oct;136(10):1171-6.
90. Nielsen JVJ, E. A. Low-carbohydrate diet in type 2 diabetes: stable improvement of bodyweight and glycemic control during 44 months follow-up. Nutr Metab (Lond). 2008;5:14.
91. Nightengale MLS, M. G. Kelly, K. A. Jensen, M. D. Zinsmeister, A. R. Palumbo, P. J. Prospective evaluation of vertical banded gastroplasty as the primary operation for morbid obesity. Mayo Clin Proc. 1991 Aug;66(8):773-82.
92. O'Brien PED, J. B. Laparoscopic adjustable gastric banding in the treatment of morbid obesity. Arch Surg. 2003 Apr;138(4):376-82.
93. O'Kane MW, P. G. Wales, J. K. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med. 1994 Jan-Feb;11(1):105-10.
94. Olivan BMDT, Julio M. D. Bose, Mousumi PhD Bawa, Baani B. A. Chang, Tangel M. S. Summe, Heather M. S. Lee, Hongchan M. D. Laferrere, Blandine M. D. Effect of Weight Loss by Diet or Gastric Bypass Surgery on Peptide YY3-36 Levels. Ann Surg. 2009;249(6):948-53.
95. Paisey RBF, J. Harvey, P. Paisey, A. Bower, L. Paisey, R. M. Taylor, P. Belka, I. Five year results of a prospective very low calorie diet or conventional weight loss programme in type 2 diabetes. J Hum Nutr Diet. 2002 Apr;15(2):121-7.
96. Paxton JHM, J. B. The cost effectiveness of laparoscopic versus open gastric bypass surgery. Obes Surg. 2005 Jan;15(1):24-34.
97. Pinkney JHS, C. D. Gale, E. A. Should surgeons treat diabetes in severely obese people? Lancet. 2001 Apr 28;357(9265):1357-9.
98. Podnos YDJ, J. C. Wilson, S. E. Stevens, C. M. Nguyen, N. T. Complications after laparoscopic gastric bypass: a review of 3464 cases. Arch Surg. 2003 Sep;138(9):957-61.
99. Ponce JH, B. Paynter, S. Fromm, R. Lindsey, B. Shafer, A. Manahan, E. Sutterfield, C. Effect of Lap-Band-induced weight loss on type 2 diabetes mellitus and hypertension. Obes Surg. 2004 Nov-Dec;14(10):1335-42.
100. Puzziferri NA-S, I. T. Wolfe, B. M. Wilson, S. E. Nguyen, N. T. Three-year follow-up of a prospective randomized trial comparing laparoscopic versus open gastric bypass. Ann Surg. 2006 Feb;243(2):181-8.
101. Raz IH, M. Xu, L. Caria, C. Williams-Herman, D. Khatami, H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006 Nov;49(11):2564-71.
102. Riddle MF, J. Zhang, B. Maier, H. Brown, C. Lutz, K. Kolterman, O. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007 Nov;30(11):2794-9.
103. Robinson JCF, A. R. Nabulsi, A. A. Watson, R. Brancati, F. L. Cai, J. Can postmenopausal hormone replacement improve plasma lipids in women with diabetes? The Atherosclerosis Risk in Communities Study Investigators. Diabetes Care. 1996 May;19(5):480-5.

104. Rodriguez LR, Eliana Fagalde, Pilar Oltra, Maria Soledad Saba, Jorge Aylwin, Carmen Gloria Prieto, Carolina Ramos, Almino Galvao, Manoel Gersin, Keith S. Sorli, Christopher. Pilot Clinical Study of an Endoscopic, Removable Duodenal-Jejunal Bypass Liner for the Treatment of Type 2 Diabetes. Diabetes Technology & Therapeutics. 2009;11(11):725-32.
105. Roslin MSO, Jonathan H. Yatco, Edward Shah, Paresh C. PL-205: Abnormal glucose tolerance testing following gastric bypass. Surgery for Obesity and Related Diseases. [doi: DOI: 10.1016/j.soard.2009.03.033]. 2009;5(3, Supplement 1):S10-S.
106. Ross RF, J. A. Janssen, I. Exercise alone is an effective strategy for reducing obesity and related comorbidities. Exerc Sport Sci Rev. 2000 Oct;28(4):165-70.
107. Ryan DHE, M. A. Foster, G. D. Haffner, S. M. Hubbard, V. S. Johnson, K. C. Kahn, S. E. Knowler, W. C. Yanovski, S. Z. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003 Oct;24(5):610-28.
108. Salas MW, A. Caro, J. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. Clin Ther. 2002 Oct;24(10):1690-705.
109. Sartorelli DSS, E. C. Franco, L. J. Cardoso, M. A. Beneficial effects of short-term nutritional counselling at the primary health-care level among Brazilian adults. Public Health Nutr. 2005 Oct;8(7):820-5.
110. Schachter M. Metabolic effects of moxonidine and other centrally acting antihypertensives. Diabetes Obes Metab. 1999 Nov;1(6):317-22.
111. Schauer PRI, S. Gourash, W. Ramanathan, R. Luketich, J. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg. 2000 Oct;232(4):515-29.
112. Scheen AJE, P. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes Metab. 2002 Dec;28(6 Pt 1):437-45.
113. Schok MG, R. van Antwerpen, T. de Wit, P. Brand, N. van Ramshorst, B. Quality of life after laparoscopic adjustable gastric banding for severe obesity: postoperative and retrospective preoperative evaluations. Obes Surg. 2000 Dec;10(6):502-8.
114. Schouten RMDR, Carianne S. M. D. Bouvy, Nicole D. M. D. PhD Hameeteman, Wim M. D. PhD Koek, Ger H. M. D. PhD Janssen, Ignace M. C. M. D. Greve, Jan-Willem M. M. D. PhD. A Multicenter, Randomized Efficacy Study of the EndoBarrier Gastrointestinal Liner for Presurgical Weight Loss Prior to Bariatric Surgery. [Miscellaneous Article]. Ann Surg. 2010;251(2):236-43.
115. Schouten RvD, F. M. Greve, J. W. Re-operation after laparoscopic adjustable gastric banding leads to a further decrease in BMI and obesity-related co-morbidities: results in 33 patients. Obes Surg. 2006 Jul;16(7):821-8.
116. Scopinaro NM, G. M. Camerini, G. B. Papadia, F. S. Adami, G. F. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care. 2005 Oct;28(10):2406-11.
117. Shah PST, Jayashree S. Shah, Shashank S. PL-214: Behavior of type 2 diabetes mellitus in obese Indian patients submitted to sleeve gastrectomy. Surgery for Obesity and Related Diseases. [doi: DOI: 10.1016/j.soard.2009.03.042]. 2009;5(3, Supplement 1):S13-S4.

118. Sjostrom L. Analysis of the XENDOS study (Xenical in the Prevention of Diabetes in Obese Subjects). Endocr Pract. 2006 Jan-Feb;12 Suppl 1:31-3.
119. Smith DEW, R. R. Diminished weight loss and behavioral compliance during repeated diets in obese patients with type II diabetes. Health Psychol. 1991;10(6):378-83.
120. Sosa JLP, H. Pallavicini, H. Ruiz-Rodriguez, M. Laparoscopic gastric bypass beyond age 60. Obes Surg. 2004 Nov-Dec;14(10):1398-401.
121. Sugerman HJW, L. G. Sica, D. A. Clore, J. N. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg. 2003 Jun;237(6):751-6; discussion 7-8.
122. Suter MG, V. Worreth, M. Heraief, E. Calmes, J. M. Laparoscopic gastric banding: a prospective, randomized study comparing the Lapband and the SAGB: early results. Ann Surg. 2005 Jan;241(1):55-62.
123. Tarnoff MR, L. Escalona, A. Ramos, A. Neto, M. Alamo, M. Reyes, E. Pimentel, F. Ibanez, L. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surgical Endoscopy. [10.1007/s00464-008-0125-4]. 2009;23(3):650-6.
124. Turnin MCB, O. Cathelineau, G. Leguerrier, A. M. Halimi, S. Sandre-Banon, D. Coliche, V. Breux, M. Verlet, E. Labrousse, F. Bensoussan, D. Grenier, J. L. Poncet, M. F. Tordjmann, F. Brun, J. M. Blickle, J. F. Mattei, C. Bolzonella, C. Buisson, J. C. Fabre, D. Tauber, J. P. Hanaire-Broutin, H. Multicenter randomized evaluation of a nutritional education software in obese patients. Diabetes Metab. 2001 Apr;27(2 Pt 1):139-47.
125. Tuthill AQ, A. McColgan, D. McKenna, M. O'Shea, D. McKenna, T. J. A prospective randomized controlled trial of lifestyle intervention on quality of life and cardiovascular risk score in patients with obesity and type 2 diabetes. Diabetes Obes Metab. 2007 Nov;9(6):917-9.
126. Valera-Mora MES, B. Gagliardi, L. Scarfone, A. Nanni, G. Castagneto, M. Manco, M. Mingrone, G. Ferrannini, E. Predictors of weight loss and reversal of comorbidities in malabsorptive bariatric surgery. Am J Clin Nutr. 2005 Jun;81(6):1292-7.
127. van Dam HAvdH, F. G. Knoops, L. Ryckman, R. M. Crebolder, H. F. van den Borne, B. H. Social support in diabetes: a systematic review of controlled intervention studies. Patient Educ Couns. 2005 Oct;59(1):1-12.
128. van Dielen FMS, P. B. de Brauw, L. M. Greve, J. W. Laparoscopic adjustable gastric banding versus open vertical banded gastroplasty: a prospective randomized trial. Obes Surg. 2005 Oct;15(9):1292-8.
129. Vidal JI, A. Nicolau, J. Vidov, M. Delgado, S. Martinez, G. Balust, J. Morinigo, R. Lacy, A. Short-term effects of sleeve gastrectomy on type 2 diabetes mellitus in severely obese subjects. Obes Surg. 2007 Aug;17(8):1069-74.
130. Vogel JAF, B. A. Zalesin, K. C. Trivax, J. E. Krause, K. R. Chengelis, D. L. McCullough, P. A. Reduction in predicted coronary heart disease risk after substantial weight reduction after bariatric surgery. Am J Cardiol. 2007 Jan 15;99(2):222-6.
131. Wilding JVG, L. Rissanen, A. Vercruysse, F. Fitchet, M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord. 2004 Nov;28(11):1399-410.
132. Williamson DAR, Jack Lang, Wei Van Dorsten, Brent Fabricatore, Anthony N. Toledo, Katie for the Look AHEAD Research Group,. Impact of a Weight Management

Program on Health-Related Quality of Life in Overweight Adults With Type 2 Diabetes. Arch Intern Med. 2009 January 26, 2009;169(2):163-71.
133. Wing RRB, E. Marcus, M. Epstein, L. H. Harvey, J. Year-long weight loss treatment for obese patients with type II diabetes: does including an intermittent very-low-calorie diet improve outcome? Am J Med. 1994 Oct;97(4):354-62.
134. Wing RRM, M. D. Epstein, L. H. Jawad, A. A "family-based" approach to the treatment of obese type II diabetic patients. J Consult Clin Psychol. 1991 Feb;59(1):156-62.
135. Wing RRS, M. Marcus, M. D. McDermott, M. Gooding, W. Variables associated with weight loss and improvements in glycemic control in type II diabetic patients in behavioral weight control programs. Int J Obes. 1990 Jun;14(6):495-503.
136. Wittgrove ACC, G. W. Laparoscopic gastric bypass, Roux-en-Y- 500 patients: technique and results, with 3-60 month follow-up. Obes Surg. 2000 Jun;10(3):233-9.
137. Wolf AMC, M. R. Crowther, J. Q. Hazen, K. Y. L. Nadler J Oneida, B. Bovbjerg, V. E. Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. Diabetes Care. 2004 Jul;27(7):1570-6.
138. Wolf AMK, H. W. Reoperation Due to Complications after Gastric Restriction Operation. Obes Surg. 1995 May;5(2):171-8.
139. Zehetner JH, F. Triaca, H. Klaiber, Ch. A 6-year experience with the Swedish adjustable gastric band Prospective long-term audit of laparoscopic gastric banding. Surg Endosc. 2005 Jan;19(1):21-8.
140. Zlabek JAG, M. S. Larson, C. J. Mathiason, M. A. Lambert, P. J. Kothari, S. N. The effect of laparoscopic gastric bypass surgery on dyslipidemia in severely obese patients. Surg Obes Relat Dis. 2005 Nov-Dec;1(6):537-42.
141. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999 Apr;22(4):623-34.
142. Angrisani LA, M. Basso, N. Belvederesi, N. Campanile, F. Capizzi, F. D. D'Atri, C. Di Cosmo, L. Doldi, S. B. Favretti, F. Forestieri, P. Furbetta, F. Giacomelli, F. Giardiello, C. Iuppa, A. Lesti, G. Lucchese, M. Puglisi, F. Scipioni, L. Toppino, M. Turicchia, G. U. Veneziani, A. Docimo, C. Borrelli, V. Lorenzo, M. Laparoscopic Italian experience with the Lap-Band. Obes Surg. 2001 Jun;11(3):307-10.
143. Angrisani LDL, N. Favretti, F. Furbetta, F. Iuppa, A. Doldi, S. B. Paganelli, M. Basso, N. Lucchese, M. Zappa, M. Lesti, G. Capizzi, F. D. Giardiello, C. Paganini, A. Di Cosmo, L. Veneziani, A. Lacitignola, S. Silecchia, G. Alkilani, M. Forestieri, P. Puglisi, F. Gardinazzi, A. Toppino, M. Campanile, F. Marzano, B. Bernante, P. Perrotta, G. Borrelli, V. Lorenzo, M. The Italian Group for LAP-BAND: predictive value of initial body mass index for weight loss after 5 years of follow-up. Surg Endosc. 2004 Oct;18(10):1524-7.
144. Angrisani LL, M. Borrelli, V. Laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass: 5-year results of a prospective randomized trial. Surg Obes Relat Dis. 2007 Mar-Apr;3(2):127-32; discussion 32-3.
145. Boule NGH, E. Kenny, G. P. Wells, G. A. Sigal, R. J. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001 Sep 12;286(10):1218-27.

146. Brolin RE. Bariatric surgery and long-term control of morbid obesity. JAMA. 2002 Dec 11;288(22):2793-6.
147. Caro JJK, W. S. Raggio, G. Kavanagh, P. L. O'Brien, J. A. Shomphe, L. A. Flegel, K. M. Copley-Merriman, C. Sigler, C. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther. 2000 Jan;22(1):116-27.
148. Chapman AEK, G. Game, P. Foster, B. O'Brien, P. Ham, J. Maddern, G. J. Laparoscopic adjustable gastric banding in the treatment of obesity: a systematic literature review. Surgery. 2004 Mar;135(3):326-51.
149. Cheskin LJM, A. M. Jhaveri, A. D. Mitola, A. H. Davis, L. M. Lewis, R. A. Yep, M. A. Lycan, T. W. Efficacy of meal replacements versus a standard food-based diet for weight loss in type 2 diabetes: a controlled clinical trial. Diabetes Educ. 2008 Jan-Feb;34(1):118-27.
150. Chiasson JLG, R. Hanefeld, M. Josse, R. G. Karasik, A. Laakso, M. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care. 1998 Oct;21(10):1720-5.
151. Dasgupta KG, S. A. Da Costa, D. Lowensteyn, I. Yale, J. F. Rahme, E. Impact of modified glucose target and exercise interventions on vascular risk factors. Diabetes Res Clin Pract. 2006 Apr;72(1):53-60.
152. Davidson JAS, A. J. Howlett, H. C. Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus. Drug Saf. 2004;27(15):1205-16.
153. Davis-Smith YMB, J. M. Seale, J. P. Shellenberger, S. Blalock, T. Tobin, B. Implementing a diabetes prevention program in a rural African-American church. J Natl Med Assoc. 2007 Apr;99(4):440-6.
154. Davis NJT, N. Schechter, C. Isasi, C. R. Segal-Isaacson, C. J. Stein, D. Zonszein, J. Wylie-Rosett, J. Comparative study of the effects of a 1-year dietary intervention of a low-carbohydrate diet versus a low-fat diet on weight and glycemic control in type 2 diabetes. Diabetes Care. 2009 Jul;32(7):1147-52.
155. Delea TEE, J. S. Hagiwara, M. Oster, G. Phillips, L. S. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003 Nov;26(11):2983-9.
156. Dixon JBOB, P. E. Changes in comorbidities and improvements in quality of life after LAP-BAND placement. Am J Surg. 2002 Dec;184(6B):51S-4S.
157. Dowse GKG, H. Alberti, K. G. Zimmet, P. Tuomilehto, J. Purran, A. Fareed, D. Chitson, P. Collins, V. R. Changes in population cholesterol concentrations and other cardiovascular risk factor levels after five years of the non-communicable disease intervention programme in Mauritius. Mauritius Non-communicable Disease Study Group. BMJ. 1995 Nov 11;311(7015):1255-9.
158. Ferchak CVM, L. F. Obesity, bariatric surgery and type 2 diabetes--a systematic review. Diabetes Metab Res Rev. 2004 Nov-Dec;20(6):438-45.
159. Fox SRO, K. H. Fox, K. Vertical Banded Gastroplasty and Distal Gastric Bypass as Primary Procedures: A Comparison. Obes Surg. 1996 Oct;6(5):421-5.

160. Frost GD, A. The relevance of the glycaemic index to our understanding of dietary carbohydrates. Diabet Med. 2000 May;17(5):336-45.
161. Furbetta FG, G. Robortella, E. M. 28-month experience with the lap-band technique: results and critical points of the method. Obes Surg. 1999 Feb;9(1):56-8.
162. Ganesh RL, T. Rao, A. D. Baladas, H. G. Laparoscopic adjustable gastric banding for severe obesity. Singapore Med J. 2006 Aug;47(8):661-9.
163. Genuth S. Supplemented fasting in the treatment of obesity and diabetes. Am J Clin Nutr. 1979 Dec;32(12):2579-86.
164. Gupta AKB, George A. Greenway, Frank L. Martin, Corby K. Johnson, William D. Smith, Steven R. Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. Journal of Diabetes and its Complications. [doi: DOI: 10.1016/j.jdiacomp.2009.05.004].In Press, Corrected Proof.
165. Hamilton ECS, T. L. Hamilton, T. T. Mullican, M. A. Jones, D. B. Provost, D. A. Clinical predictors of leak after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Surg Endosc. 2003 May;17(5):679-84.
166. Han SHG, C. Mehran, A. Basa, N. Hines, J. Suleman, L. Vira, D. Dutson, E. Improved outcomes using a systematic and evidence-based approach to the laparoscopic Roux-en-Y gastric bypass in a single academic institution. Am Surg. 2007 Oct;73(10):955-8.
167. Hayes CK, A. Role of physical activity in diabetes management and prevention. J Am Diet Assoc. 2008 Apr;108(4 Suppl 1):S19-23.
168. Hell EM, K. A. Moorehead, M. K. Norman, S. Evaluation of health status and quality of life after bariatric surgery: comparison of standard Roux-en-Y gastric bypass, vertical banded gastroplasty and laparoscopic adjustable silicone gastric banding. Obes Surg. 2000 Jun;10(3):214-9.
169. Hutter MMR, S. Khuri, S. F. Henderson, W. G. Abbott, W. M. Warshaw, A. L. Laparoscopic versus open gastric bypass for morbid obesity: a multicenter, prospective, risk-adjusted analysis from the National Surgical Quality Improvement Program. Ann Surg. 2006 May;243(5):657-62; discussion 62-6.
170. Jones KB, Jr. Afram, J. D. Benotti, P. N. Capella, R. F. Cooper, C. G. Flanagan, L. Hendrick, S. Howell, L. M. Jaroch, M. T. Kole, K. Lirio, O. C. Sapala, J. A. Schuhknecht, M. P. Shapiro, R. P. Sweet, W. A. Wood, M. H. Open versus laparoscopic Roux-en-Y gastric bypass: a comparative study of over 25,000 open cases and the major laparoscopic bariatric reported series. Obes Surg. 2006 Jun;16(6):721-7.
171. Kaukua JKP, T. A. Rissanen, A. M. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes Relat Metab Disord. 2004 Apr;28(4):600-5.
172. Keech AC, D. Best, J. Kirby, A. Simes, R. J. Hunt, D. Hague, W. Beller, E. Arulchelvam, M. Baker, J. Tonkin, A. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003 Oct;26(10):2713-21.
173. Khan MASP, J. V. Breen, G. A. Hartley, G. G. Vessey, J. T. Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants. Obes Res. 2000 Jan;8(1):43-8.
174. Kim DM, L. Zhuang, D. Kothare, P. A. Trautmann, M. Fineman, M. Taylor, K. Effects of once-weekly dosing of a long-acting release formulation of exenatide on

glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007 Jun;30(6):1487-93.
175. Lacey LAW, A. O'Shea, D. Erny, S. Ruof, J. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes (Lond). 2005 Aug;29(8):975-82.
176. Lee WJW, W. Bariatric surgery: Asia-Pacific perspective. Obes Surg. 2005 Jun-Jul;15(6):751-7.
177. Lee WJW, W. Wei, P. L. Huang, M. T. Weight loss and improvement of obesity-related illness following laparoscopic adjustable gastric banding procedure for morbidly obese patients in Taiwan. J Formos Med Assoc. 2006 Nov;105(11):887-94.
178. Look AHEAD Research Group Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes. Diabetes Care. 2007 June 2007;30(6):1374-83.
179. Ma JK, Abby Wilson, Sandra Xiao, Lan Stafford, Randall. Evaluation of lifestyle interventions to treat elevated cardiometabolic risk in primary care (E-LITE): a randomized controlled trial. BMC Family Practice. 2009;10(1):71.
180. Madan AKW, J. D. Fain, J. N. Beech, B. M. Ternovits, C. A. Menachery, S. Tichansky, D. S. Are African-Americans as successful as Caucasians after laparoscopic gastric bypass? Obes Surg. 2007 Apr;17(4):460-4.
181. Marceau PH, F. S. Simard, S. Lebel, S. Bourque, R. A. Potvin, M. Biron, S. Biliopancreatic diversion with duodenal switch. World J Surg. 1998 Sep;22(9):947-54.
182. Mathus-Vliegen EM. Long-term health and psychosocial outcomes from surgically induced weight loss: results obtained in patients not attending protocolled follow-up visits. Int J Obes (Lond). 2007 Feb;31(2):299-307.
183. McNulty SJU, E. Williams, G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care. 2003 Jan;26(1):125-31.
184. Miles JML, L. Hollander, P. Wadden, T. Anderson, J. W. Doyle, M. Foreyt, J. Aronne, L. Klein, S. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002 Jul;25(7):1123-8.
185. Morinigo RC, R. Delgado, S. Lacy, A. Deulofeu, R. Conget, I. Barcelo-Batllori, S. Gomis, R. Vidal, J. Insulin resistance, inflammation, and the metabolic syndrome following Roux-en-Y gastric bypass surgery in severely obese subjects. Diabetes Care. 2007 Jul;30(7):1906-8.
186. Nguyen NTV, E. Sabio, A. Tran, C. L. Stamos, M. Wilson, S. E. Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass. J Am Coll Surg. 2006 Jul;203(1):24-9.
187. Nield LM, H. J. Hooper, L. Cruickshank, J. K. Vyas, A. Whittaker, V. Summerbell, C. D. Dietary advice for treatment of type 2 diabetes mellitus in adults. Cochrane Database Syst Rev. 2007(3):CD004097.
188. Nwobu COJ, C. C. Targeting obesity to reduce the risk for type 2 diabetes and other co-morbidities in African American youth: a review of the literature and recommendations for prevention. Diab Vasc Dis Res. 2007 Dec;4(4):311-9.
189. O'Brien PED, J. B. Lap-band: outcomes and results. J Laparoendosc Adv Surg Tech A. 2003 Aug;13(4):265-70.

190. Parikh ML, Helen Chang, Christopher Collings, Dinee Fielding, George Ren, Christine. Comparison of outcomes after laparoscopic adjustable gastric banding in African-Americans and whites. Surgery for Obesity and Related Diseases. [doi: DOI: 10.1016/j.soard.2006.08.012].2(6):607-10.
191. Pedersen OG, P. Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. Metabolism. 2003 Aug;52(8 Suppl 1):19-23.
192. Pories WJM, K. G., Jr. Morgan, E. J. Sinha, M. K. Dohm, G. L. Swanson, M. S. Barakat, H. A. Khazanie, P. G. Leggett-Frazier, N. Long, S. D. et al.,. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr. 1992 Feb;55(2 Suppl):582S-5S.
193. Redmon JBB, A. G. Connelly, S. Fenney, P. A. Glasser, S. Glick, H. Greenway, F. Hesson, L. A. Lawlor, M. S. Montez, M. Montgomery, B. Effect of the Look AHEAD Study Intervention on Medication Use and Related Cost to Treat Cardiovascular Disease Risk Factors in Individuals with Type 2 Diabetes. Diabetes Care. 2010 Mar 23.
194. Redmon JBR, S. K. Reck, K. P. Swanson, J. E. Kwong, C. A. Fan, Q. Thomas, W. Bantle, J. P. One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. Diabetes Care. 2003 Sep;26(9):2505-11.
195. Redmon JBR, K. P. Raatz, S. K. Swanson, J. E. Kwong, C. A. Ji, H. Thomas, W. Bantle, J. P. Two-year outcome of a combination of weight loss therapies for type 2 diabetes. Diabetes Care. 2005 Jun;28(6):1311-5.
196. Richelsen BT, S. Rossner, S. Toubro, S. Niskanen, L. Madsbad, S. Mustajoki, P. Rissanen, A. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care. 2007 Jan;30(1):27-32.
197. Ross R. Does exercise without weight loss improve insulin sensitivity? Diabetes Care. 2003 Mar;26(3):944-5.
198. Saenz AF-E, I. Mataix, A. Ausejo, M. Roque, M. Moher, D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005(3):CD002966.
199. Schauer PRB, B. Ikramuddin, S. Cottam, D. Gourash, W. Hamad, G. Eid, G. M. Mattar, S. Ramanathan, R. Barinas-Mitchel, E. Rao, R. H. Kuller, L. Kelley, D. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003 Oct;238(4):467-84; discussion 84-5.
200. Schouten RW, D. van Dielen, F. Greve, J. Laparoscopic adjustable gastric banding (LAGB) versus open vertical banded gastroplasty (VBG): long-term results of a prospective randomized trial. Obes Surg 2008;18:459.
201. See CC, P. L. Elliott, D. Mullenix, P. Eggebroten, W. Porter, C. Watts, D. An institutional experience with laparoscopic gastric bypass complications seen in the first year compared with open gastric bypass complications during the same period. Am J Surg. 2002 May;183(5):533-8.
202. Segal JBD, S.M. Millman, E.A. Herbert, R. Bass, E. B. Wu, A.W. Who Uses Exenatide for Glucose Control in Diabetes Mellitus? A Retrospective Cohort Study of a New Therapy. Rockville, MD: (Prepared by Johns Hopkins University DEcIDE Center under Contract No. 290-2005-0034-1) Agency for Healthcare Research and Quality; 2010 July Contract No.: Document Number|.

203. Sjostrom LL, A. K. Peltonen, M. Torgerson, J. Bouchard, C. Carlsson, B. Dahlgren, S. Larsson, B. Narbro, K. Sjostrom, C. D. Sullivan, M. Wedel, H. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004 Dec 23;351(26):2683-93.
204. Skroubis GA, S. Kehagias, I. Mead, N. Vagenas, K. Kalfarentzos, F. Roux-en-Y gastric bypass versus a variant of biliopancreatic diversion in a non-superobese population: prospective comparison of the efficacy and the incidence of metabolic deficiencies. Obes Surg. 2006 Apr;16(4):488-95.
205. Slim KB, J. Kwiatkowski, F. Lescure, G. Pezet, D. Chipponi, J. Quality of life before and after laparoscopic fundoplication. Am J Surg. 2000 Jul;180(1):41-5.
206. Smith SCE, C. B. Goodman, G. N. Changes in Diabetic Management After Roux-en-Y Gastric Bypass. Obes Surg. 1996 Aug;6(4):345-8.
207. Stumvoll MN, N. Perriello, G. Dailey, G. Gerich, J. E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995 Aug 31;333(9):550-4.
208. Sugerman HJK, J. M., Jr. DeMaria, E. J. Reines, H. D. Conversion of failed or complicated vertical banded gastroplasty to gastric bypass in morbid obesity. Am J Surg. 1996 Feb;171(2):263-9.
209. Tan JTK, S. Wijeratne, T. Chandraratna, H. S. Diagnosis and management of gastric leaks after laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg. 2010 Apr;20(4):403-9.
210. Taskin MZ, K. Apaydin, B. B. Unal, E. Laparoscopy in Turkish bariatric surgery: initial experience. Obes Surg. 2000 Jun;10(3):263-5.
211. Titi MJ, J. T. Modak, P. Galloway, D. J. Quality of life and alteration in comorbidity following laparoscopic adjustable gastric banding. Postgrad Med J. 2007 Jul;83(981):487-91.
212. Toplak HH, A. Moore, R. Masson, E. Gorska, M. Vercruysse, F. Sun, X. Fitchet, M. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes (Lond). 2007 Jan;31(1):138-46.
213. Toppino MM, M. Bonnet, G. Nigra, I. Siliquini, R. Laparoscopic surgery for morbid obesity: preliminary results from SICE registry (Italian Society of Endoscopic and Minimally Invasive Surgery). Obes Surg. 1999 Feb;9(1):62-5.
214. Wadden TAW, D. S. Delahanty, L. Jakicic, J. Rejeski, J. Williamson, D. Berkowitz, R. I. Kelley, D. E. Tomchee, C. Hill, J. O. Kumanyika, S. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring). 2006 May;14(5):737-52.
215. Weiner RAK, M. Matzig, E. Weiner, S. Karcz, W. K. Junginger, T. Early results with a new telemetrically adjustable gastric banding. Obes Surg. 2007 Jun;17(6):717-21.
216. Weinstock RSD, H. Wadden, T. A. Diet and exercise in the treatment of obesity: effects of 3 interventions on insulin resistance. Arch Intern Med. 1998 Dec 7-21;158(22):2477-83.
217. Williams KVK, D. E. Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes. Diabetes Obes Metab. 2000 Jun;2(3):121-9.

218. Wittgrove ACC, G. W. Tremblay, L. J. Laparoscopic Gastric Bypass, Roux-en-Y: Preliminary Report of Five Cases. Obes Surg. 1994 Nov;4(4):353-7.
219. Yang K. A review of yoga programs for four leading risk factors of chronic diseases. Evid Based Complement Alternat Med. 2007 Dec;4(4):487-91.
220. Yates TK, K. Bull, F. Gorely, T. Davies, M. J. The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia. 2007 Jun;50(6):1116-26.
221. Zingmond DSM, M. L. Ko, C. Y. Hospitalization before and after gastric bypass surgery. JAMA. 2005 Oct 19;294(15):1918-24.
222. Zorrilla PGS, R. J. Salinas-Martinez, A. M. Vertical banded gastroplasty-gastric bypass with and without the interposition of jejunum: preliminary report. Obes Surg. 1999 Feb;9(1):29-32.
223. Dietary measures for type 2 diabetes. Weight loss and a Mediterranean-type diet, with no foods off-limits. Prescrire Int. 2009 Oct;18(103):224.
224. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA. 1996 Nov 6;276(17):1409-15.
225. Randomised trial of jejunoileal bypass versus medical treatment in morbid obesity. The Danish Obesity Project. Lancet. 1979 Dec 15;2(8155):1255-8.
226. Adami GFC, R. Camerini, G. Marinari, G. M. Scopinaro, N. Long-term normalization of insulin sensitivity following biliopancreatic diversion for obesity. Int J Obes Relat Metab Disord. 2004 May;28(5):671-3.
227. Agren GN, K. Naslund, I. Sjostrom, L. Peltonen, M. Long-term effects of weight loss on pharmaceutical costs in obese subjects. A report from the SOS intervention study. Int J Obes Relat Metab Disord. 2002 Feb;26(2):184-92.
228. Alekseeva RIS, KhKh Plotnikova, O. A. Meshcheriakova, V. A. Mal'tsev, GIu Kulakova, S. N. [Effects of diet therapy including eiconol on clinical and metabolic parameters in patients with type 2 diabetes mellitus]. Vopr Pitan. 2000;69(5):36-9.
229. Almbrand BJ, M. Sjostrand, B. Malmberg, K. Ryden, L. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. Eur Heart J. 2000 May;21(9):733-9.
230. Angrisani LF, F. Doldi, S. B. Basso, N. Lucchese, M. Giacomelli, F. Zappa, M. Di Cosmo, L. Veneziani, A. Turicchia, G. U. Alkilani, M. Forestieri, P. Lesti, G. Puglisi, F. Toppino, M. Campanile, F. Capizzi, F. D. D'Atri, C. Sciptoni, L. Giardiello, C. Di Lorenzo, N. Lacitignola, S. Belvederesi, N. Marzano, B. Bernate, P. Iuppa, A. Borrelli, V. Lorenzo, M. Lap Band adjustable gastric banding system: the Italian experience with 1863 patients operated on 6 years. Surg Endosc. 2003 Mar;17(3):409-12.
231. Ashy ARM, A. A. A prospective study comparing vertical banded gastroplasty versus laparoscopic adjustable gastric banding in the treatment of morbid and super-obesity. Int Surg. 1998 Apr-Jun;83(2):108-10.
232. Barnard RJM, M. R. Cherny, S. O'Brien, L. T. Pritikin, N. Long-term use of a high-complex-carbohydrate, high-fiber, low-fat diet and exercise in the treatment of NIDDM patients. Diabetes Care. 1983 May-Jun;6(3):268-73.
233. Batsis JAR-C, A. Collazo-Clavell, M. L. Sarr, M. G. Somers, V. K. Lopez-Jimenez, F. Effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study. Mayo Clin Proc. 2008 Aug;83(8):897-907.

234. Belachew ML, M. J. Vincent, V. Defechereux, T. H. Jourdan, J.L. Monami, B. Jacquet, N. Laparoscopic placement of adjustable silicone gastric banding in the treatment of morbid obesity. Obes Surg. 1992;5:66-9.
235. Belalcazar LMR, David M. Haffner, Steven M. Reeves, Rebecca S. Schwenke, Dawn C. Hoogeveen, Ron C. Pi-Sunyer, F. Xavier Ballantyne, Christie M. Marine ω-3 Fatty Acid Intake. Diabetes Care. 2010 January 2010;33(1):197-9.
236. Bjorntorp PK, M. Exercise treatment in diabetes mellitus. Acta Med Scand. 1985;217(1):3-7.
237. Bray GA. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diabetes and Vascular Disease Research. 2006 December 1, 2006;3(3):202-15.
238. Brehm BJL, B. L. Summer, S. S. Boback, J. A. Gilchrist, G. M. Jandacek, R. J. D'Alessio, D. A. One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. Diabetes Care. 2009 Feb;32(2):215-20.
239. Briatore LS, B. Andraghetti, G. Danovaro, C. Sferrazzo, E. Scopinaro, N. Adami, G. F. Maggi, D. Cordera, R. Restoration of acute insulin response in T2DM subjects 1 month after biliopancreatic diversion. Obesity (Silver Spring). 2008 Jan;16(1):77-81.
240. Buchwald HE, R. Fahrbach, K. Banel, D. Jensen, M. D. Pories, W. J. Bantle, J. P. Sledge, I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009 Mar;122(3):248-56 e5.
241. Butner KN-R, Sharon Clark, Susan Ramp, Warren Herbert, William. A Review of Weight Loss Following Roux-en-Y Gastric Bypass vs Restrictive Bariatric Surgery: Impact on Adiponectin and Insulin. Obesity Surgery. [10.1007/s11695-010-0089-z]. 2010;20(5):559-68.
242. Cariani SN, D. Grani, S. Vittimberga, G. Lucchi, A. Amenta, E. Complications after gastroplasty and gastric bypass as a primary operation and as a reoperation. Obes Surg. 2001 Aug;11(4):487-90.
243. Carlson LAO, J. Effect of chlorpropamide treatment on serum lipid levels in diabetes mellitus. Acta Med Scand. 1961 Nov;170:561-4.
244. Carson JLR, M. E. Duff, A. E. Holmes, N. J. Cody, R. P. Brolin, R. E. The effect of gastric bypass surgery on hypertension in morbidly obese patients. Arch Intern Med. 1994 Jan 24;154(2):193-200.
245. Catona AG, M. Mussini, G. La Manna, L. De Bastiani, T. Armeni, E. Videolaparoscopic Vertical Banded Gastroplasty. Obes Surg. 1995 Aug;5(3):323-6.
246. Ceelen WW, J. Cardon, A. Van Renterghem, K. Hesse, U. El Malt, M. Pattyn, P. Surgical treatment of severe obesity with a low-pressure adjustable gastric band: experimental data and clinical results in 625 patients. Ann Surg. 2003 Jan;237(1):10-6.
247. Champagne CM. Magnesium in hypertension, cardiovascular disease, metabolic syndrome, and other conditions: a review. Nutr Clin Pract. 2008 Apr-May;23(2):142-51.
248. Charbonnel BK, A. Liu, J. Wu, M. Meininger, G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006 Dec;29(12):2638-43.
249. Chen JF. A hemorrheological study on the effect of acupuncture in treating diabetes mellitus. J Tradit Chin Med. 1987 Jun;7(2):95-100.

250. Chevallier JMP, M. Rodde-Dunet, M. H. Marty, M. Nogues, F. Slim, K. Basdevant, A. Predictive factors of outcome after gastric banding: a nationwide survey on the role of center activity and patients' behavior. Ann Surg. 2007 Dec;246(6):1034-9.
251. Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract. 2006 Jan-Feb;12 Suppl 1:25-30.
252. Chikunguwo SD, Patricia W. Meador, Jill G. Wolfe, Luke G. Baugh, Nancy Kellum, John M. Maher, James W. PL-101: Durable resolution of diabetes after Roux-en-Y gastric bypass is associated with maintenance of weight loss. Surgery for Obesity and Related Diseases. [doi: DOI: 10.1016/j.soard.2009.03.007]. 2009;5(3, Supplement 1):S1-S.
253. Christou NVS, J. S. Liberman, M. Look, D. Auger, S. McLean, A. P. MacLean, L. D. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg. 2004 Sep;240(3):416-23; discussion 23-4.
254. Closset JM, A. Barea, M. Buedts, K. Gelin, M. Houben, J. J. Results of silastic ring vertical gastroplasty more than 6 years after surgery: analysis of a cohort of 214 patients. Obes Surg. 2004 Oct;14(9):1233-6.
255. Cohen BEC, A. A. Grady, D. Kanaya, A. M. Restorative yoga in adults with metabolic syndrome: a randomized, controlled pilot trial. Metab Syndr Relat Disord. 2008 Fall;6(3):223-9.
256. Cottam DRA, J. Anderson, A. Grace, B. Fisher, B. A case-controlled matched-pair cohort study of laparoscopic Roux-en-Y gastric bypass and Lap-Band patients in a single US center with three-year follow-up. Obes Surg. 2006 May;16(5):534-40.
257. Cramer JSS, R. F. Bartlett, D. P. Kahn, L. S. Loffredo, L. An adaptation of the diabetes prevention program for use with high-risk, minority patients with type 2 diabetes. Diabetes Educ. 2007 May-Jun;33(3):503-8.
258. Cunneen SAP, E. Fielding, G. Banel, D. Estok, R. Fahrbach, K. Sledge, I. Studies of Swedish adjustable gastric band and Lap-Band: systematic review and meta-analysis. Surg Obes Relat Dis. 2008 Mar-Apr;4(2):174-85.
259. Dapri GC, G. B. Himpens, J. Reinforcing the staple line during laparoscopic sleeve gastrectomy: prospective randomized clinical study comparing three different techniques. Obes Surg. 2010 Apr;20(4):462-7.
260. Davila-Cervantes AB, D. Dominguez-Cherit, G. Gamino, R. Vargas-Vorackova, F. Gonzalez-Barranco, J. Herrera, M. F. Open versus laparoscopic vertical banded gastroplasty: a randomized controlled double blind trial. Obes Surg. 2002 Dec;12(6):812-8.
261. Deakin TM, C. E. Cade, J. E. Williams, R. D. Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005(2):CD003417.
262. Delgado HL, T. Bobbioni-Harsch, E. Ybarra, J. Golay, A. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab. 2002 Jun;28(3):195-200.
263. Diabetes Prevention Program Research Group. Effects of Withdrawal From Metformin on the Development of Diabetes in the Diabetes Prevention Program. Diabetes Care. 2003 April 2003;26(4):977-80.

264. Dibble CTG, E. V. Cannon, C. P. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients. Curr Atheroscler Rep. 2007 Nov;9(5):359-66.
265. DiGiorgi MC, Jenny Jee-Eun Milone, Luca Schrope, Beth Olivero-Rivera, Lorraine Restuccia, Nancy Urban-Skuro, Meredith C. Inabnet, William B. Bessler, Marc. PL-213: Recurrence of diabetes after gastric bypass in patients with mid to long-term follow up. Surgery for Obesity and Related Diseases. [doi: DOI: 10.1016/j.soard.2009.03.041]. 2009;5(3, Supplement 1):S13-S.
266. Dixon JBOB, P. E. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care. 2002 Feb;25(2):358-63.
267. Doar JWW, C. E. Thompson, M. E. Sewell, P. F. Influence of treatment with diet alone on oral glucose-tolerance test and plasma sugar and insulin levels in patients with maturity-onset diabetes mellitus. Lancet. 1975 Jun 7;1(7919):1263-6.
268. Dolan KB, R. Fielding, G. Treating diabetes in the morbidly obese by laparoscopic gastric banding. Obes Surg. 2003 Jun;13(3):439-43.
269. Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab. 2004 Jul;6(4):280-5.
270. Dyson PAB, S. Matthews, D. R. A low-carbohydrate diet is more effective in reducing body weight than healthy eating in both diabetic and non-diabetic subjects. Diabet Med. 2007 Dec;24(12):1430-5.
271. Eastman RCJ, J. C. Herman, W. H. Dasbach, E. J. Copley-Merriman, C. Maier, W. Dong, F. Manninen, D. Zbrozek, A. S. Kotsanos, J. Garfield, S. A. Harris, M. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997 May;20(5):735-44.
272. Encinosa WEB, D. M. Chen, C. C. Steiner, C. A. Healthcare utilization and outcomes after bariatric surgery. Med Care. 2006 Aug;44(8):706-12.
273. Encinosa WEB, D. M. Du, D. Steiner, C. A. Recent improvements in bariatric surgery outcomes. Med Care. 2009 May;47(5):531-5.
274. Fernandez AZ, Jr. DeMaria, E. J. Tichansky, D. S. Kellum, J. M. Wolfe, L. G. Meador, J. Sugerman, H. J. Experience with over 3,000 open and laparoscopic bariatric procedures: multivariate analysis of factors related to leak and resultant mortality. Surg Endosc. 2004 Feb;18(2):193-7.
275. Fielding GAD, Jennifer E. Laparoscopic adjustable gastric banding in severely obese adolescents. Surgery for Obesity and Related Diseases. [doi: DOI: 10.1016/j.soard.2005.04.006].1(4):399-405.
276. Flum DRD, E. P. Impact of gastric bypass operation on survival: a population-based analysis. J Am Coll Surg. 2004 Oct;199(4):543-51.
277. Fobi MAL, H. Igwe, D., Jr. Stanczyk, M. Tambi, J. N. Prospective comparative evaluation of stapled versus transected silastic ring gastric bypass: 6-year follow-up. Obes Surg. 2001 Feb;11(1):18-24.
278. Fontbonne AA, P. Eschwege, E. BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance. Diabete Metab. 1991 May;17(1 Pt 2):249-54.

279. Foster GDW, H. R. Hill, J. O. McGuckin, B. G. Brill, C. Mohammed, B. S. Szapary, P. O. Rader, D. J. Edman, J. S. Klein, S. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003 May 22;348(21):2082-90.
280. Fragasso GPM, P. M. Monti, L. Palloshi, A. Setola, E. Puccetti, P. Calori, G. Lopaschuk, G. D. Margonato, A. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003 Nov;146(5):E18.
281. Freys SMT, H. Heimbucher, J. Fuchs, K. H. Fein, M. Thiede, A. Quality of life following laparoscopic gastric banding in patients with morbid obesity. J Gastrointest Surg. 2001 Jul-Aug;5(4):401-7.
282. Frutos MDL, J. Hernandez, Q. Valero, G. Parrilla, P. Results of laparoscopic gastric bypass in patients > or =55 years old. Obes Surg. 2006 Apr;16(4):461-4.
283. Gaede PHJ, P. V. Larsen, J. N. Jensen, G. V. Parving, H. H. Pedersen, O. B. [The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes]. Ugeskr Laeger. 2003 Jun 23;165(26):2658-61.
284. Gaede PV, P. Larsen, N. Jensen, G. V. Parving, H. H. Pedersen, O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan 30;348(5):383-93.
285. Gan SSHT, Michael L. Jorgensen, John O. EFFICACY OF SURGERY IN THE MANAGEMENT OF OBESITY-RELATED TYPE 2 DIABETES MELLITUS. ANZ Journal of Surgery. 2007;77(11):958-62.
286. Garcia RS, R. Diabetes education in the elderly: a 5-year follow-up of an interactive approach. Patient Educ Couns. 1996 Oct;29(1):87-97.
287. Garg AB, J. P. Henry, R. R. Coulston, A. M. Griver, K. A. Raatz, S. K. Brinkley, L. Chen, Y. D. Grundy, S. M. Huet, B. A. et al.,. Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA. 1994 May 11;271(18):1421-8.
288. Gautier JFS, A. Lefebvre, P. J. Exercise in the management of non-insulin-dependent (type 2) diabetes mellitus. Int J Obes Relat Metab Disord. 1995 Oct;19 Suppl 4:S58-61.
289. Gerhard GTA, A. Meeuws, K. McMurry, M. P. Duell, P. B. Connor, W. E. Effects of a low-fat diet compared with those of a high-monounsaturated fat diet on body weight, plasma lipids and lipoproteins, and glycemic control in type 2 diabetes. Am J Clin Nutr. 2004 Sep;80(3):668-73.
290. Gleysteen JJ. Results of surgery: long-term effects on hyperlipidemia. Am J Clin Nutr. 1992 Feb;55(2 Suppl):591S-3S.
291. Gokcel AK, H. Ertorer, E. M. Tanaci, N. Tutuncu, N. B. Guvener, N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care. 2001 Nov;24(11):1957-60.
292. Gonzalez RL, E. Mattar, S. G. Venkatesh, K. R. Smith, C. D. Gastric bypass for morbid obesity in patients 50 years or older: is laparoscopic technique safer? Am Surg. 2003 Jul;69(7):547-53; discussion 53-4.
293. Grey MB, D. Davidson, M. Galasso, P. Gustafson, E. Melkus, G. Preliminary testing of a program to prevent type 2 diabetes among high-risk youth. J Sch Health. 2004 Jan;74(1):10-5.

294. Grunberger GJ, K. L. Artiss, J. D. The benefits of early intervention in obese diabetic patients with FBCx: a new dietary fibre. Diabetes Metab Res Rev. 2007 Jan;23(1):56-62.
295. Guidone CM, M. Valera-Mora, E. Iaconelli, A. Gniuli, D. Mari, A. Nanni, G. Castagneto, M. Calvani, M. Mingrone, G. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006 Jul;55(7):2025-31.
296. Gumbiner BL, C. C. Reaven, P. D. Effects of a monounsaturated fatty acid-enriched hypocaloric diet on cardiovascular risk factors in obese patients with type 2 diabetes. Diabetes Care. 1998 Jan;21(1):9-15.
297. Gumbiner BW, J. A. McDermott, M. P. Effects of diet composition and ketosis on glycemia during very-low-energy-diet therapy in obese patients with non-insulin-dependent diabetes mellitus. Am J Clin Nutr. 1996 Jan;63(1):110-5.
298. Harland JW, M. Drinkwater, C. Chinn, D. Farr, L. Howel, D. The Newcastle exercise project: a randomised controlled trial of methods to promote physical activity in primary care. BMJ. 1999 Sep 25;319(7213):828-32.
299. Henry RRS, L. Olefsky, J. M. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1985 Nov;61(5):917-25.
300. Herman WHH, T. J. Brandle, M. Hicks, K. Sorensen, S. Zhang, P. Hamman, R. F. Ackermann, R. T. Engelgau, M. M. Ratner, R. E. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005 Mar 1;142(5):323-32.
301. Hermann LSS, B. Melander, A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med. 1994 Dec;11(10):953-60.
302. Hertzman P. The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden : a treatment responder approach. Pharmacoeconomics. 2005;23(10):1007-20.
303. Higa KDB, K. B. Ho, T. Complications of the laparoscopic Roux-en-Y gastric bypass: 1,040 patients--what have we learned? Obes Surg. 2000 Dec;10(6):509-13.
304. Himpens JD, G. Cadiere, G. B. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years. Obes Surg. 2006 Nov;16(11):1450-6.
305. Huisman SdG, V. Maes, S. Schroevers, M. Chatrou, M. Haak, H. Self-regulation and weight reduction in patients with type 2 diabetes: a pilot intervention study. Patient Educ Couns. 2009 Apr;75(1):84-90.
306. Iordache NV, R. Iorgulescu, A. Zmeu, B. Iordache, M. [Laparoscopic adjustable gastric-banding treatment for morbid obesity our first year experience]. Chirurgia (Bucur). 2003 Mar-Apr;98(2):135-42.
307. Kalfarentzos FD, A. Kehagias, I. Loukidi, A. Mead, N. Vertical banded gastroplasty versus standard or distal Roux-en-Y gastric bypass based on specific selection criteria in the morbidly obese: preliminary results. Obes Surg. 1999 Oct;9(5):433-42.
308. Karter AJM, H. H. Liu, J. Parker, M. M. Ahmed, A. T. Go, A. S. Selby, J. V. Glycemic response to newly initiated diabetes therapies. Am J Manag Care. 2007 Nov;13(11):598-606.

309. Kelley DE. Action for health in diabetes: the look AHEAD clinical trial. Curr Diab Rep. 2002 Jun;2(3):207-9.
310. Kelly TMJ, S. B. Changes in serum lipids after gastric bypass surgery. Lack of a relationship to weight loss. Int J Obes. 1986;10(6):443-52.
311. Klein SS, N. F. Pi-Sunyer, X. Daly, A. Wylie-Rosett, J. Kulkarni, K. Clark, N. G. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004 Aug;27(8):2067-73.
312. Knowler WCN, K. M. Hanson, R. L. Nelson, R. G. Bennett, P. H. Tuomilehto, J. Schersten, B. Pettitt, D. J. Preventing non-insulin-dependent diabetes. Diabetes. 1995 May;44(5):483-8.
313. Knowler WCS, G. Melander, A. Schersten, B. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia. 1997 Jun;40(6):680-6.
314. Korenkov MS, S. Sauerland, S. Duenschede, F. Junginger, Th. Impact of Laparoscopic Adjustable Gastric Banding on Obesity Co-morbidities in the Medium- and Long-Term. Obesity Surgery. [10.1007/s11695-007-9118-y]. 2007;17(5):679-83.
315. Korner JI, W. Conwell, I. M. Taveras, C. Daud, A. Olivero-Rivera, L. Restuccia, N. L. Bessler, M. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring). 2006 Sep;14(9):1553-61.
316. Kothari SND, E. J. Sugerman, H. J. Kellum, J. M. Meador, J. Wolfe, L. Lap-band failures: conversion to gastric bypass and their preliminary outcomes. Surgery. 2002 Jun;131(6):625-9.
317. Kramer MKM, R. Venditti, E. Orchard, T. Group Lifestyle Intervention for Diabetes Prevention in those with Metabolic Syndrome in Primary Care Practice. Diabetes Care. [Journal]. 2006;55((suppl.)):A517.
318. Kushner RFS, Melissa. Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With Pioglitazone. Obesity. 2009;17(5):1017-22.
319. Kuzmak LIY, I. S. McGuire, L. Dixon, J. S. Young, M. P. Surgery for morbid obesity. Using an inflatable gastric band. AORN J. 1990 May;51(5):1307-24.
320. Lakka TAL, D. E. Physical activity in prevention and treatment of the metabolic syndrome. Appl Physiol Nutr Metab. 2007 Feb;32(1):76-88.
321. Lankisch ML, P. Rizza, R. A. DiMagno, E. P. Acute postprandial gastrointestinal and metabolic effects of wheat amylase inhibitor (WAI) in normal, obese, and diabetic humans. Pancreas. 1998 Aug;17(2):176-81.
322. Lee AM, J. E. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998 Jan;6(1):47-53.
323. Lee WJL, I. R. Huang, M.T. Et al. Laparoscopic versus open vertical banded gastroplasty for the treatment of morbid obesity. Surg Laparosc Endosc Percut Techn. 2001;11:9-13.
324. Livingston EHH, S. Arthur, D. Lee, S. De Shields, S. Heber, D. Male gender is a predictor of morbidity and age a predictor of mortality for patients undergoing gastric bypass surgery. Ann Surg. 2002 Nov;236(5):576-82.

325. Lonroth HD, J. Haglind, E. Josefsson, K. Olbe, L. Fagevik Olsen, M. Lundell, L. Vertical banded gastroplasty by laparoscopic technique in the treatment of morbid obesity. Surg Laparosc Endosc. 1996 Apr;6(2):102-7.
326. Low CCG, E. B. Gumbiner, B. Potentiation of effects of weight loss by monounsaturated fatty acids in obese NIDDM patients. Diabetes. 1996 May;45(5):569-75.
327. Macgregor AMR, C. S. Gastric surgery in morbid obesity. Outcome in patients aged 55 years and older. Arch Surg. 1993 Oct;128(10):1153-7.
328. MacLean LDR, B. M. Nohr, C. W. Late outcome of isolated gastric bypass. Ann Surg. 2000 Apr;231(4):524-8.
329. Maetzel AR, J. Covington, M. Wolf, A. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics. 2003;21(7):501-12.
330. Maggio CAP-S, F. X. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care. 1997 Nov;20(11):1744-66.
331. Marinari GMP, F. S. Briatore, L. Adami, G. Scopinaro, N. Type 2 diabetes and weight loss following biliopancreatic diversion for obesity. Obes Surg. 2006 Nov;16(11):1440-4.
332. Mason EEP, K. J. Blommers, T. J. Scott, D. H. Gastric bypass for obesity after ten years experience. Int J Obes. 1978;2(2):197-206.
333. Masoudi FAI, S. E. Wang, Y. Havranek, E. P. Foody, J. M. Krumholz, H. M. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005 Feb 8;111(5):583-90.
334. Matvienko OAH, James D. A Lifestyle Intervention Study in Patients with Diabetes or Impaired Glucose Tolerance: Translation of a Research Intervention into Practice. J Am Board Fam Med. 2009 September 1, 2009;22(5):535-43.
335. Mayer-Davis EJDA, A. M. Smith, S. M. Kirkner, G. Levin Martin, S. Parra-Medina, D. Schultz, R. Pounds off with empowerment (POWER): a clinical trial of weight management strategies for black and white adults with diabetes who live in medically underserved rural communities. Am J Public Health. 2004 Oct;94(10):1736-42.
336. McBride PEE, J. A. Grant, H. Sargent, C. Underbakke, G. Vitcenda, M. Zeller, L. Stein, J. H. Putting the Diabetes Prevention Program into practice: a program for weight loss and cardiovascular risk reduction for patients with metabolic syndrome or type 2 diabetes mellitus. J Nutr Health Aging. 2008 Dec;12(10):745S-9S.
337. McNeely WG, K. L. Sibutramine. A review of its contribution to the management of obesity. Drugs. 1998 Dec;56(6):1093-124.
338. McTigue KMC, Molly B. Bigi, Lori Murphy, Cynthia McNeil, Melissa. Weight Loss Through Living Well: Translating an Effective Lifestyle Intervention Into Clinical Practice. The Diabetes Educator. 2009 March 1, 2009;35(2):199-208.
339. Meece J. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Curr Med Res Opin. 2007 Apr;23(4):933-44.
340. Meneghini CVFLF. Obesity, bariatric surgery and type 2 diabetes - a systematic review. Diabetes/Metabolism Research and Reviews. 2004;20(6):438-45.
341. Mijailovic VM, D. Mijailovic, M. [Effects of a one-year weight reduction program and physical activity on obesity and comorbid conditions]. Med Pregl. 2004 Jan-Feb;57(1-2):55-9.

342. Miller KM, E. Pichler, M. Hell, E. . Quality-of-life outcomes of patients with the Lap-Band registered versus non-operative treatment of obesity. Preliminary results of an ongoing long-term follow-up study. Obes Surg 1997;7:280.
343. Mittermair RPW, H. Nehoda, H. Kirchmayr, W. Aigner, F. Laparoscopic Swedish adjustable gastric banding: 6-year follow-up and comparison to other laparoscopic bariatric procedures. Obes Surg. 2003 Jun;13(3):412-7.
344. Moo TAR, F. Gastrointestinal surgery as treatment for type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2008 Apr;15(2):153-8.
345. Morinigo RV, J. Lacy, A. M. Delgado, S. Casamitjana, R. Gomis, R. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects. Ann Surg. 2008 Feb;247(2):270-5.
346. Morris JHW, D. A. Bolinger, R. E. Effect of Oral Sulfonylurea on Plasma Triglycerides in Diabetics. Diabetes. 1964 Jan-Feb;13:87-9.
347. Mumme DE, Mathiason MA, Kallies KJ, Kothari SN. Effect of laparoscopic Roux-en-Y gastric bypass surgery on hemoglobin A1c levels in diabetic patients: a matched-cohort analysis. Surg Obes Relat Dis. 2009 Jan-Feb;5(1):4-10.
348. Murr MMS, M. R. Sarr, M. G. Results of Bariatric Surgery for Morbid Obesity in Patients Older than 50 Years. Obes Surg. 1995 Nov;5(4):399-402.
349. Muscelli EM, G. Camastra, S. Manco, M. Pereira, J. A. Pareja, J. C. Ferrannini, E. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med. 2005 Jan;118(1):51-7.
350. Nelson RHM, J. M. The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes. Expert Opin Pharmacother. 2005 Nov;6(14):2483-91.
351. Nguyen NTH, M. Fayad, C. Varela, E. Wilson, S. E. Use and outcomes of laparoscopic versus open gastric bypass at academic medical centers. J Am Coll Surg. 2007 Aug;205(2):248-55.
352. Nielsen JVJ, E. Low-carbohydrate diet in type 2 diabetes. Stable improvement of bodyweight and glycemic control during 22 months follow-up. Nutr Metab (Lond). 2006;3:22.
353. Nilsell KT, A. Sjostedt, S. Apelman, J. Pettersson, N. Prospective randomised comparison of adjustable gastric banding and vertical banded gastroplasty for morbid obesity. Eur J Surg. 2001 Jul;167(7):504-9.
354. Nugent CB, C. Elariny, H. Gopalakrishnan, P. Quigley, C. Garone, M., Jr. Afendy, M. Chan, O. Wheeler, A. Afendy, A. Younossi, Z. M. Metabolic syndrome after laparoscopic bariatric surgery. Obes Surg. 2008 Oct;18(10):1278-86.
355. Nuttall FQG, M. C. Saeed, A. Jordan, K. Hoover, H. The metabolic response of subjects with type 2 diabetes to a high-protein, weight-maintenance diet. J Clin Endocrinol Metab. 2003 Aug;88(8):3577-83.
356. Olbers TB, S. Lindroos, A. Maleckas, A. Lonn, L. Sjostrom, L. Lonroth, H. Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial. Ann Surg. 2006 Nov;244(5):715-22.
357. Olbers TL, H. Dalenback, J. Haglind, E. Lundell, L. Laparoscopic vertical banded gastroplasty--an effective long-term therapy for morbidly obese patients? Obes Surg. 2001 Dec;11(6):726-30.

358. Orchard TJT, M. Goldberg, R. Haffner, S. Ratner, R. Marcovina, S. Fowler, S. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005 Apr 19;142(8):611-9.
359. Padwal RSM, S. R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007 Jan 6;369(9555):71-7.
360. Paisey RBH, P. Rice, S. Belka, I. Bower, L. Dunn, M. Taylor, P. Paisey, R. M. Frost, J. Ash, I. An intensive weight loss programme in established type 2 diabetes and controls: effects on weight and atherosclerosis risk factors at 1 year. Diabet Med. 1998 Jan;15(1):73-9.
361. Paran HS, Liat Shwartz, Ivan Gutman, Mordechai. Long-term Follow-up on the Effect of Silastic Ring Vertical Gastroplasty on Weight and Co-Morbidities. Obesity Surgery. [10.1007/s11695-007-9136-9]. 2007;17(6):737-41.
362. Pascale RWW, R. R. Butler, B. A. Mullen, M. Bononi, P. Effects of a behavioral weight loss program stressing calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM or a family history of diabetes. Diabetes Care. 1995 Sep;18(9):1241-8.
363. Pasnik KK, J. Stanowski, E. Vertical banded gastroplasty: 6 years experience at a center in Poland. Obes Surg. 2005 Feb;15(2):223-7.
364. Pedersen SDK, J. Kline, G. A. Portion control plate for weight loss in obese patients with type 2 diabetes mellitus: a controlled clinical trial. Arch Intern Med. 2007 Jun 25;167(12):1277-83.
365. Penn LW, Martin Oldroyd, John Walker, Mark Alberti, K George Mathers, John. Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health. 2009;9(1):342.
366. Phelan SW, T. A. Berkowitz, R. I. Sarwer, D. B. Womble, L. G. Cato, R. K. Rothman, R. Impact of weight loss on the metabolic syndrome. Int J Obes (Lond). 2007 Sep;31(9):1442-8.
367. Pi-Sunyer FXA, L. J. Heshmati, H. M. Devin, J. Rosenstock, J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006 Feb 15;295(7):761-75.
368. Pi-Sunyer XB, G. Brancati, F. L. Bray, G. A. Bright, R. Clark, J. M. Curtis, J. M. Espeland, M. A. Foreyt, J. P. Graves, K. Haffner, S. M. Harrison, B. Hill, J. O. Horton, E. S. Jakicic, J. Jeffery, R. W. Johnson, K. C. Kahn, S. Kelley, D. E. Kitabchi, A. E. Knowler, W. C. Lewis, C. E. Maschak-Carey, B. J. Montgomery, B. Nathan, D. M. Patricio, J. Peters, A. Redmon, J. B. Reeves, R. S. Ryan, D. H. Safford, M. Van Dorsten, B. Wadden, T. A. Wagenknecht, L. Wesche-Thobaben, J. Wing, R. R. Yanovski, S. Z. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007 Jun;30(6):1374-83.
369. Pinkney JK, D. Current status of bariatric surgery in the treatment of type 2 diabetes. Obes Rev. 2004 Feb;5(1):69-78.
370. Pories WJS, M. S. MacDonald, K. G. Long, S. B. Morris, P. G. Brown, B. M. Barakat, H. A. deRamon, R. A. Israel, G. Dolezal, J. M. et al.,. Who would have thought

it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995 Sep;222(3):339-50; discussion 50-2.
371. Rae AB, D. Evans, S. North, F. Roberman, B. Walters, B. A randomised controlled trial of dietary energy restriction in the management of obese women with gestational diabetes. Aust N Z J Obstet Gynaecol. 2000 Nov;40(4):416-22.
372. Raynor HAJ, R. W. Ruggiero, A. M. Clark, J. M. Delahanty, L. M. Weight loss strategies associated with BMI in overweight adults with type 2 diabetes at entry into the Look AHEAD (Action for Health in Diabetes) trial. Diabetes Care. 2008 Jul;31(7):1299-304.
373. Reaven GS, K. Hauptman, J. Boldrin, M. Lucas, C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol. 2001 Apr 1;87(7):827-31.
374. Redmon JBR, S. K. Kwong, C. A. Swanson, J. E. Thomas, W. Bantle, J. P. Pharmacologic induction of weight loss to treat type 2 diabetes. Diabetes Care. 1999 Jun;22(6):896-903.
375. Reinhold RB. Late results of gastric bypass surgery for morbid obesity. J Am Coll Nutr. 1994 Aug;13(4):326-31.
376. Ricciardi RT, R. J. Kellogg, T. A. Ikramuddin, S. Baxter, N. N. Outcomes after open versus laparoscopic gastric bypass. Surg Laparosc Endosc Percutan Tech. 2006 Oct;16(5):317-20.
377. Rosenstock JH, P. Gadde, K. M. Sun, X. Strauss, R. Leung, A. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care. 2007 Jun;30(6):1480-6.
378. Rubenstein RB. Laparoscopic adjustable gastric banding at a U.S. center with up to 3-year follow-up. Obes Surg. 2002 Jun;12(3):380-4.
379. Sahay BK. Yoga and diabetes. J Assoc Physicians India. 1986 Sep;34(9):645-8.
380. Salmela SP, M. Kasila, K. Vahasarja, K. Vanhala, M. Transtheoretical model-based dietary interventions in primary care: a review of the evidence in diabetes. Health Educ Res. 2009 Apr;24(2):237-52.
381. Salmon PA. The results of small intestine bypass operations for the treatment of obesity. Surg Gynecol Obstet. 1971 Jun;132(6):965-79.
382. Sampalis JSL, M. Auger, S. Christou, N. V. The impact of weight reduction surgery on health-care costs in morbidly obese patients. Obes Surg. 2004 Aug;14(7):939-47.
383. Scheen AJ. [Info-congress. Prevention of type 2 diabetes in obese patients: first results with orlistat in the XENDOS study]. Rev Med Liege. 2002 Sep;57(9):617-21.
384. Scheen AJP, N. Lefebvre, P. J. [United Kingdom Prospective Diabetes Study (UKPDS): 10 years later]. Rev Med Liege. 2008 Oct;63(10):624-9.
385. Scheen AJVG, L. F. [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Rev Med Liege. 2007 Feb;62(2):81-5.
386. Schindler KP, G. Ballaban, T. Kretschmer, S. Riener, R. Buranyi, B. Maier, C. Luger, A. Ludvik, B. Impact of laparoscopic adjustable gastric banding on plasma ghrelin, eating behaviour and body weight. Eur J Clin Invest. 2004 Aug;34(8):549-54.
387. Scopinaro NP, F. Camerini, G. Marinari, G. Civalleri, D. Gian Franco, A. A comparison of a personal series of biliopancreatic diversion and literature data on gastric

bypass help to explain the mechanisms of resolution of type 2 diabetes by the two operations. Obes Surg. 2008 Aug;18(8):1035-8.
388. Segal JBC, J. M. Shore, A.D. Dominici, F. Magnuson, T. Richards, T.M. Weiner, J.P. Bass, E. B. Wu, A.W. Makary, M.A. Prompt Reducation in Use of Medications for Comorbid Conditions After Bariatric Surgery. Rockville, MD: (Prepared by Johns Hopkins University DEcIDE Center under Contract No. HHSA29020050034-1TO2) Agency for Healthcare Research and Quality; 2010 June Contract No.: Document Number|.
389. Selby JVE, B. Swain, B. E. Brown, J. B. First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care. 1999 Jan;22(1):38-44.
390. Serra-Majem LR, B. Estruch, R. Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutr Rev. 2006 Feb;64(2 Pt 2):S27-47.
391. Singer DLH, D. Long-term experience with sulfonylureas and placebo. N Engl J Med. 1967 Aug 31;277(9):450-6.
392. Sjostrom CDP, M. Sjostrom, L. Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study. Obes Res. 2001 Mar;9(3):188-95.
393. Sjostrom LR, A. Andersen, T. Boldrin, M. Golay, A. Koppeschaar, H. P. Krempf, M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998 Jul 18;352(9123):167-72.
394. St Peter SDC, R. O. Tiede, J. L. Swain, J. M. Impact of advanced age on weight loss and health benefits after laparoscopic gastric bypass. Arch Surg. 2005 Feb;140(2):165-8.
395. Stenlof KR, S. Vercruysse, F. Kumar, A. Fitchet, M. Sjostrom, L. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab. 2007 May;9(3):360-8.
396. Stern LI, N. Seshadri, P. Chicano, K. L. Daily, D. A. McGrory, J. Williams, M. Gracely, E. J. Samaha, F. F. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med. 2004 May 18;140(10):778-85.
397. Stoeckli RC, R. Langer, I. Keller, U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res. 2004 Feb;12(2):346-50.
398. Sugerman HJL, G. L. Kellum, J. M. Wolf, L. Liszka, T. Engle, K. M. Birkenhauer, R. Starkey, J. V. Weight loss with vertical banded gastroplasty and Roux-Y gastric bypass for morbid obesity with selective versus random assignment. Am J Surg. 1989 Jan;157(1):93-102.
399. Summerbell CDW, C. Higgins, J. P. Garrow, J. S. Randomised controlled trial of novel, simple, and well supervised weight reducing diets in outpatients. BMJ. 1998 Nov 28;317(7171):1487-9.
400. Taylor CL, Laurent. Laparoscopic Adjustable Gastric Banding in Patients ≥60 Years Old: Is it Worthwhile? Obesity Surgery. [10.1381/096089206779319310]. 2006;16(12):1579-83.

401. Temple PCT, B. Sachs, L. Strasser, S. Choban, P. Flancbaum, L. Functioning and well-being of patients before and after elective surgical procedures. J Am Coll Surg. 1995 Jul;181(1):17-25.
402. Thomas DEE, E. J. Naughton, G. A. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;3:CD002968.
403. Tinker LFB, D. E. Margolis, K. L. Manson, J. E. Howard, B. V. Larson, J. Perri, M. G. Beresford, S. A. Robinson, J. G. Rodriguez, B. Safford, M. M. Wenger, N. K. Stevens, V. J. Parker, L. M. Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women's Health Initiative randomized controlled dietary modification trial. Arch Intern Med. 2008 Jul 28;168(14):1500-11.
404. Toplak HM, K. [Reduction of obesity and improvement in metabolic parameters by inhibition of intestinal lipases: current results with orlistat]. Acta Med Austriaca. 1998;25(4-5):142-5.
405. Torgerson JSH, J. Boldrin, M. N. Sjostrom, L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004 Jan;27(1):155-61.
406. Torquati AL, R. Abumrad, N. Richards, W. O. Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? J Gastrointest Surg. 2005 Nov;9(8):1112-6; discussion 7-8.
407. Torquati AW, K. Melvin, W. Richards, W. Effect of gastric bypass operation on Framingham and actual risk of cardiovascular events in class II to III obesity. J Am Coll Surg. 2007 May;204(5):776-82; discussion 82-3.
408. Trakhtenbroit MAL, J. G. Algahim, M. F. Miller, C. C., 3rd Moody, F. G. Lux, T. R. Taegtmeyer, H. Body weight, insulin resistance, and serum adipokine levels 2 years after 2 types of bariatric surgery. Am J Med. 2009 May;122(5):435-42.
409. Tsujiuchi TK, H. Yoshiuchi, K. He, D. Tsujiuchi, Y. Kuboki, T. Suematsu, H. Hirao, K. The effect of Qi-gong relaxation exercise on the control of type 2 diabetes mellitus: a randomized controlled trial. Diabetes Care. 2002 Jan;25(1):241-2.
410. Umpierrez GEC, W. S. Steen, M. T. Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises. Diabetes Care. 1997 Apr;20(4):479-83.
411. Van Gaal LFR, A. M. Scheen, A. J. Ziegler, O. Rossner, S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005 Apr 16-22;365(9468):1389-97.
412. van Gemert WGA, E. M. Kop, M. Vos, G. Greve, J. W. Soeters, P. B. A prospective cost-effectiveness analysis of vertical banded gastroplasty for the treatment of morbid obesity. Obes Surg. 1999 Oct;9(5):484-91.
413. van Gemert WGA, E. M. Greve, J. W. Soeters, P. B. Quality of life assessment of morbidly obese patients: effect of weight-reducing surgery. Am J Clin Nutr. 1998 Feb;67(2):197-201.
414. Vasudevan ARB, A. Fonseca, V. A. The effectiveness of intensive glycemic control for the prevention of vascular complications in diabetes mellitus. Treat Endocrinol. 2006;5(5):273-86.

415. Vertruyen M. Experience with Lap-band System up to 7 years. Obes Surg. 2002 Aug;12(4):569-72.
416. Vetter MLC, S. Rickels, M. R. Iqbal, N. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med. 2009 Jan 20;150(2):94-103.
417. Vijgen SMH, M. Baan, C. A. de Wit, G. A. Limburg, W. Feenstra, T. L. Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review. Pharmacoeconomics. 2006;24(5):425-41.
418. Walker EAM, M. Kramer, M. K. Kahn, S. Ma, Y. Edelstein, S. Smith, K. Johnson, M. K. Kitabchi, A. Crandall, J. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care. 2006 Sep;29(9):1997-2002.
419. West DSD, V. Bursac, Z. Gore, S. A. Greene, P. G. Motivational interviewing improves weight loss in women with type 2 diabetes. Diabetes Care. 2007 May;30(5):1081-7.
420. White SB, E. Jurikova, L. Stubbs, R. S. Long-term outcomes after gastric bypass. Obes Surg. 2005 Feb;15(2):155-63.
421. Wing RRA, K. Effectiveness of a behavioral weight control program for blacks and whites with NIDDM. Diabetes Care. 1996 May;19(5):409-13.
422. Wing RRB, E. H. Bononi, P. Marcus, M. D. Watanabe, R. Bergman, R. N. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care. 1994 Jan;17(1):30-6.
423. Wing RRE, L. H. Paternostro-Bayles, M. Kriska, A. Nowalk, M. P. Gooding, W. Exercise in a behavioural weight control programme for obese patients with Type 2 (non-insulin-dependent) diabetes. Diabetologia. 1988 Dec;31(12):902-9.
424. Wing RRM, M. D. Salata, R. Epstein, L. H. Miaskiewicz, S. Blair, E. H. Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects. Arch Intern Med. 1991 Jul;151(7):1334-40.
425. Wing RRV, E. Jakicic, J. M. Polley, B. A. Lang, W. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care. 1998 Mar;21(3):350-9.
426. Wittgrove ACC, G. W. Laparoscopic Gastric Bypass, Roux-en-Y: Experience of 27 Cases, with 3-18 Months Follow-up. Obes Surg. 1996 Feb;6(1):54-7.
427. Wittgrove ACC, G. W. Schubert, K. R. Laparoscopic Gastric Bypass, Roux-en-Y: Technique and Results in 75 Patients With 3-30 Months Follow-up. Obes Surg. 1996 Dec;6(6):500-4.
428. Wolf AMB, U. Kortner, B. Kuhlmann, H. W. Does gastric restriction surgery reduce the risks of metabolic diseases? Obes Surg. 1998 Feb;8(1):9-13.

Non Systematic Review:

1. Jackson L. Translating the Diabetes Prevention Program Into Practice: A Review of Community Interventions. The Diabetes Educator. 2009 March 1, 2009;35(2):309-20.
2. Kelley DEG, B. H. Effects of physical activity on insulin action and glucose tolerance in obesity. Med Sci Sports Exerc. 1999 Nov;31(11 Suppl):S619-23.

3. Scheen AJVG, L. G. Despres, J. P. Pi-Sunyer, X. Golay, A. Hanotin, C. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies]. Rev Med Suisse. 2006 Aug 23;2(76):1916-23.
4. Schulman APdG, F. Sinha, N. Rubino, F. "Metabolic" surgery for treatment of type 2 diabetes mellitus. Endocr Pract. 2009 Sep-Oct;15(6):624-31.
5. Sherwin RSA, R. M. Buse, J. B. Chin, M. H. Eddy, D. Fradkin, J. Ganiats, T. G. Ginsberg, H. N. Kahn, R. Nwankwo, R. Rewers, M. Schlessinger, L. Stern, M. Vinicor, F. Zinman, B. Prevention or delay of type 2 diabetes. Diabetes Care. 2004 Jan;27 Suppl 1:S47-54.

Non-Surgical Treatment with Follow-Up < 1 year:

1. Abbott WGB, V. L. Grundy, S. M. Howard, B. V. Effects of replacing saturated fat with complex carbohydrate in diets of subjects with NIDDM. Diabetes Care. 1989 Feb;12(2):102-7.
2. Abramson EA, R. A. Treatment of the obese diabetic. A comparative study of placebo, sulfonylurea and phenformin. Metabolism. 1967 Mar;16(3):204-12.
3. Albarracin CAF, B. C. Evans, J. L. Goldfine, I. D. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev. 2008 Jan-Feb;24(1):41-51.
4. Amano YS, M. Lee, J. S. Kawakubo, K. Mori, K. Tang, A. C. Akabayashi, A. Glycemic index-based nutritional education improves blood glucose control in Japanese adults: a randomized controlled trial. Diabetes Care. 2007 Jul;30(7):1874-6.
5. Andersen EH, P. Kindstedt, K. Hellstrom, K. Effects of a high-protein and low-fat diet vs a low-protein and high-fat diet on blood glucose, serum lipoproteins, and cholesterol metabolism in noninsulin-dependent diabetics. Am J Clin Nutr. 1987 Feb;45(2):406-13.
6. Anderson JWB-K, V. Hamilton, C. C. Logan, J. E. Collins, R. W. Gustafson, N. J. Food-containing hypocaloric diets are as effective as liquid-supplement diets for obese individuals with NIDDM. Diabetes Care. 1994 Jun;17(6):602-4.
7. Aro AU, M. Voutilainen, E. Hersio, K. Korhonen, T. Siitonen, O. Improved diabetic control and hypocholesterolaemic effect induced by long-term dietary supplementation with guar gum in type 2 (insulin-independent) diabetes. Diabetologia. 1981 Jul;21(1):29-33.
8. Baldi JCS, N. Resistance training improves glycaemic control in obese type 2 diabetic men. Int J Sports Med. 2003 Aug;24(6):419-23.
9. Barnard RJL, L. Holly, R. G. Cherny, S. Pritikin, N. Response of non-insulin-dependent diabetic patients to an intensive program of diet and exercise. Diabetes Care. 1982 Jul-Aug;5(4):370-4.
10. Barnes AJG, K. J. Crowley, M. F. Bloom, A. Effect of short and long term chlorpropamide treatment of insulin release and blood-glucose. Lancet. 1974 Jul 13;2(7872):69-72.
11. Barratt RF, G. Millward, D. J. Truby, H. A randomised controlled trial investigating the effect of an intensive lifestyle intervention v. standard care in adults with type 2 diabetes immediately after initiating insulin therapy. Br J Nutr. 2008 May;99(5):1025-31.

12. Bianchi RB, V. Bravenboer, B. Erkelens, D. W. Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. Diabetes Care. 1993 Apr;16(4):557-9.
13. Bjorgaas MRV, J. T. Stolen, T. Lydersen, S. Grill, V. Regular use of pedometer does not enhance beneficial outcomes in a physical activity intervention study in type 2 diabetes mellitus. Metabolism. 2008 May;57(5):605-11.
14. Bogardus CR, E. Robbins, D. C. Wolfe, R. R. Horton, E. S. Sims, E. A. Effects of physical training and diet therapy on carbohydrate metabolism in patients with glucose intolerance and non-insulin-dependent diabetes mellitus. Diabetes. 1984 Apr;33(4):311-8.
15. Bonanome AV, A. Lusiani, L. Beltramello, G. Confortin, L. Biffanti, S. Sorgato, F. Costa, F. Pagnan, A. Carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus: effects of a low-fat, high-carbohydrate diet vs a diet high in monounsaturated fatty acids. Am J Clin Nutr. 1991 Sep;54(3):586-90.
16. Brand JCC, S. Crossman, S. Allen, A. Roberts, D. C. Truswell, A. S. Low-glycemic index foods improve long-term glycemic control in NIDDM. Diabetes Care. 1991 Feb;14(2):95-101.
17. Bratusch-Marrain PD, R. Waldhausl, W. [Weight reduction in obese diabetics: a double-blind study of diethylpropionate (author's transl)]. Wien Klin Wochenschr. 1979 Jun 22;91(13):455-8.
18. Brunerova LS, V. Potockova, J. Andel, M. A comparison of the influence of a high-fat diet enriched in monounsaturated fatty acids and conventional diet on weight loss and metabolic parameters in obese non-diabetic and Type 2 diabetic patients. Diabet Med. 2007 May;24(5):533-40.
19. Brunzell JDL, R. L. Porte, D., Jr. Bierman, E. L. Effect of a fat free, high carbohydrate diet on diabetic subjects with fasting hyperglycemia. Diabetes. 1974 Feb;23(2):138-42.
20. Brunzell JDL, R. L. Hazzard, W. R. Porte, D., Jr. Bierman, E. L. Improved glucose tolerance with high carbohydrate feeding in mild diabetes. N Engl J Med. 1971 Mar 11;284(10):521-4.
21. Brussard HEGL, J.A. Frohlich, M. Kluft, C. Krans, H. M. Short-term oestrogen replacement improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia. [Journal Artice]. 1997;40:843-9.
22. Buse JBH, R. R. Han, J. Kim, D. D. Fineman, M. S. Baron, A. D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004 Nov;27(11):2628-35.
23. Cabrera-Pivaral CEG-P, G. Vega-Lopez, M. G. Centeno-Lopez, M. [Effects of an educational intervention on plasma levels of LDL cholesterol in type 2 diabetics]. Salud Publica Mex. 2001 Nov-Dec;43(6):556-62.
24. Cabrera-Pivaral CEG-P, G. Vega-Lopez, M. G. Arias-Merino, E. D. [Impact of participatory education on body mass index and blood glucose in obese type-2 diabetics]. Cad Saude Publica. 2004 Jan-Feb;20(1):275-81.
25. Campbell IWD, C. Patton, N. W. Broadhead, T. Tucker, G. T. Woods, H. F. The effect of metformin on glycaemic control, intermediary metabolism and blood pressure in non-insulin-dependent diabetes mellitus. Diabet Med. 1987 Jul-Aug;4(4):337-41.

26. Campbell LVB, R. Gosper, J. K. Jupp, J. J. Simons, L. A. Chisholm, D. J. Impact of intensive educational approach to dietary change in NIDDM. Diabetes Care. 1990 Aug;13(8):841-7.
27. Castaneda CL, J. E. Munoz-Orians, L. Gordon, P. L. Walsmith, J. Foldvari, M. Roubenoff, R. Tucker, K. L. Nelson, M. E. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care. 2002 Dec;25(12):2335-41.
28. Cederholm J. Short-term treatment of glucose intolerance in middle-aged subjects by diet, exercise and sulfonylurea. Ups J Med Sci. 1985;90(3):229-42.
29. Chapman IP, B. Doran, S. Feinle-Bisset, C. Wishart, J. Strobel, S. Wang, Y. Burns, C. Lush, C. Weyer, C. Horowitz, M. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005 May;48(5):838-48.
30. Chazova IA, V. A. Shlyakhto, E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes Obes Metab. 2006 Jul;8(4):456-65.
31. Chow CCK, G. T. Tsang, L. W. Yeung, V. T. Chan, J. C. Cockram, C. S. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. Diabetes Care. 1997 Jul;20(7):1122-7.
32. Christiansen ES, S. Palmvig, B. Tauber-Lassen, E. Pedersen, O. Intake of a diet high in trans monounsaturated fatty acids or saturated fatty acids. Effects on postprandial insulinemia and glycemia in obese patients with NIDDM. Diabetes Care. 1997 May;20(5):881-7.
33. Colman EK, L. I. Rogus, E. Coon, P. Muller, D. Goldberg, A. P. Weight loss reduces abdominal fat and improves insulin action in middle-aged and older men with impaired glucose tolerance. Metabolism. 1995 Nov;44(11):1502-8.
34. Coniff RFS, J. A. Seaton, T. B. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1994 Nov 14;154(21):2442-8.
35. Connolly VMG, A. Kesson, C. M. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet Med. 1995 May;12(5):416-8.
36. Coyle DP, A. J. Tam, R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics. 2002;20 Suppl 1:31-42.
37. Cuff DJM, G. S. Martin, A. Ignaszewski, A. Tildesley, H. D. Frohlich, J. J. Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. Diabetes Care. 2003 Nov;26(11):2977-82.
38. Damsbo PH, L. S. Vaag, A. Hother-Nielsen, O. Beck-Nielsen, H. Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin. Diabetes Care. 1998 Sep;21(9):1489-94.
39. Davey Smith GB, Y. Svendsen, K. H. Neaton, J. D. Haffner, S. M. Kuller, L. H. Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med. 2005 Mar 1;142(5):313-22.
40. Davidson JAM, S. O. Waterhouse, B. R. Cobitz, A. R. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and

tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Clin Ther. 2007 Sep;29(9):1900-14.
41. De Filippis EC, K. Ocampo, G. Berria, R. Buck, S. Consoli, A. Mandarino, L. J. Exercise-induced improvement in vasodilatory function accompanies increased insulin sensitivity in obesity and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006 Dec;91(12):4903-10.
42. De Jager JK, A. Lehert, P. Bets, D. Wulffele, M. G. Teerlink, T. Scheffer, P. G. Schalkwijk, C. G. Donker, A. J. Stehouwer, C. D. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2005 Jan;257(1):100-9.
43. de Luis DAI, O. Aller, R. Cuellar, L. Terroba, M. C. Martin, T. Cabezas, G. Rojo, S. Domingo, M. A randomized clinical trial with two enteral diabetes-specific supplements in patients with diabetes mellitus type 2: metabolic effects. Eur Rev Med Pharmacol Sci. 2008 Jul-Aug;12(4):261-6.
44. Dejager SR, S. Foley, J. E. Schweizer, A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007 Mar;39(3):218-23.
45. Dekker MJL, S. Hudson, R. Kilpatrick, K. Graham, T. E. Ross, R. Robinson, L. E. An exercise intervention without weight loss decreases circulating interleukin-6 in lean and obese men with and without type 2 diabetes mellitus. Metabolism. 2007 Mar;56(3):332-8.
46. Derosa GDA, A. Salvadeo, S. A. Ferrari, I. Gravina, A. Fogari, E. Maffioli, P. Cicero, A. F. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism. 2008 Nov;57(11):1552-7.
47. Derosa GF, E. Cicero, A. F. D'Angelo, A. Ciccarelli, L. Piccinni, M. N. Pricolo, F. Salvadeo, S. A. Gravina, A. Ferrari, I. Fogari, R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res. 2007 May;30(5):387-94.
48. Didangelos TPT, A. K. Bousboulas, S. H. Sambanis, C. L. Athyros, V. G. Spanou, E. A. Dimitriou, K. C. Pappas, S. I. Karamanos, B. G. Karamitsos, D. T. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin. 2004 Sep;20(9):1393-401.
49. Dornan TLH, S. R. Peck, G. M. Tattersall, R. B. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care. 1991 Apr;14(4):342-4.
50. Dunstan DWD, R. M. Owen, N. Jolley, D. De Courten, M. Shaw, J. Zimmet, P. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care. 2002 Oct;25(10):1729-36.
51. Dunstan DWD, R.M. Owen, N. et al. High resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care. [Journal Article]. 2003;25:1729-36.
52. Einhorn DR, M. Rosenzweig, J. Egan, J. W. Mathisen, A. L. Schneider, R. L. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2000 Dec;22(12):1395-409.

53. Eliasson BG, S. Cederholm, J. Liang, Y. Vercruysse, F. Smith, U. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes (Lond). 2007 Jul;31(7):1140-7.
54. Fanghanel GS-R, L. Trujillo, C. Sotres, D. Espinosa-Campos, J. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care. 1996 Nov;19(11):1185-9.
55. Fanghanel GS, U. Sanchez-Reyes, L. Sisson, D. Sotres, D. Torres, E. M. Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes. Rev Invest Clin. 1998 Sep-Oct;50(5):389-94.
56. Feinbock CL, A. Klingler, A. Egger, T. Bielesz, G. K. Winkler, F. Siebenhofer, A. Grossschadl, F. Frank, E. Irsigler, K. Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. Diabetes Nutr Metab. 2003 Aug;16(4):214-21.
57. Filippatos TDK, D. N. Liberopoulos, E. N. Georgoula, M. Mikhailidis, D. P. Elisaf, M. S. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin. 2005 Dec;21(12):1997-2006.
58. Fineman MSS, L. Z. Taylor, K. Kim, D. D. Baron, A. D. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev. 2004 Sep-Oct;20(5):411-7.
59. Finer NB, S. R. Frost, G. S. Banks, L. M. Griffiths, J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab. 2000 Apr;2(2):105-12.
60. Fritsche AS, M. A. Haring, H. U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003 Jun 17;138(12):952-9.
61. Fuh MML, M. M. Jeng, C. Y. Ma, F. Chen, Y. D. Reaven, G. M. Effect of low fat-high carbohydrate diets in hypertensive patients with non-insulin-dependent diabetes mellitus. Am J Hypertens. 1990 Jul;3(7):527-32.
62. Fujii SO, Y. Okada, K. Tanaka, S. Seki, J. Wada, M. Iseki, T. Effects of physical training on glucose tolerance and insulin response in diabetics. Osaka City Med J. 1982;28(1):1-8.
63. Fujioka KS, T. B. Rowe, E. Jelinek, C. A. Raskin, P. Lebovitz, H. E. Weinstein, S. P. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2000 Jun;2(3):175-87.
64. Gannon MCN, F. Q. Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes. Diabetes. 2004 Sep;53(9):2375-82.
65. Garg AB, A. Grundy, S. M. Zhang, Z. J. Unger, R. H. Comparison of a high-carbohydrate diet with a high-monounsaturated-fat diet in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1988 Sep 29;319(13):829-34.

66. Garg AG, S. M. Unger, R. H. Comparison of effects of high and low carbohydrate diets on plasma lipoproteins and insulin sensitivity in patients with mild NIDDM. Diabetes. 1992 Oct;41(10):1278-85.
67. Glass LCQ, Y. Lenox, S. Kim, D. Gates, J. R. Brodows, R. Trautmann, M. Bergenstal, R. M. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin. 2008 Mar;24(3):639-44.
68. Goldhaber-Fiebert JDG-F, S. N. Tristan, M. L. Nathan, D. M. Randomized controlled community-based nutrition and exercise intervention improves glycemia and cardiovascular risk factors in type 2 diabetic patients in rural Costa Rica. Diabetes Care. 2003 Jan;26(1):24-9.
69. Greco AVM, G. Capristo, E. De Gaetano, A. Ghirlanda, G. Castagneto, M. Effects of dexfenfluramine on free fatty acid turnover and oxidation in obese patients with type 2 diabetes mellitus. Metabolism. 1995 Feb;44(2 Suppl 2):57-61.
70. Gregorio FA, F. Angelici, F. Cristallini, S. Dini, F. L. Vespasiani, G. Santeusanio, F. Filipponi, P. [Body mass index, blood lactate and therapeutic effectiveness of metformin in type II diabetes mellitus]. Medicina (Firenze). 1989 Apr-Jun;9(2):200-4.
71. Gunton JEC, N. W. Hitchman, R. Hams, G. O'Sullivan, C. Foster-Powell, K. McElduff, A. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care. 2005 Mar;28(3):712-3.
72. Gupta AG, R. Lal, B. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. J Assoc Physicians India. 2001 Nov;49:1057-61.
73. Guy-Grand BD, P. Eschwege, E. Gin, H. Joubert, J. M. Valensi, P. Effects of orlistat on obesity-related diseases - a six-month randomized trial. Diabetes Obes Metab. 2004 Sep;6(5):375-83.
74. Haisch JR, W. [Effectiveness and efficiency of ambulatory diabetes education programs. A comparison of specialty practice and general practice]. Dtsch Med Wochenschr. 2000 Feb 18;125(7):171-6.
75. Halimi SLB, M. A. Grange, V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract. 2000 Sep;50(1):49-56.
76. Halpern AM, M. C. Suplicy, H. Zanella, M. T. Repetto, G. Gross, J. Jadzinsky, M. Barranco, J. Aschner, P. Ramirez, L. Matos, A. G. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab. 2003 May;5(3):180-8.
77. Han JRD, B. Sun, J. Chen, C. G. Corkey, B. E. Kirkland, J. L. Ma, J. Guo, W. Effects of dietary medium-chain triglyceride on weight loss and insulin sensitivity in a group of moderately overweight free-living type 2 diabetic Chinese subjects. Metabolism. 2007 Jul;56(7):985-91.
78. Heilbronn LKN, M. Clifton, P. M. The effect of high- and low-glycemic index energy restricted diets on plasma lipid and glucose profiles in type 2 diabetic subjects with varying glycemic control. J Am Coll Nutr. 2002 Apr;21(2):120-7.

79. Hermansen KK, M. Luo, E. Fanurik, D. Khatami, H. Stein, P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007 Sep;9(5):733-45.
80. Hoffmann JS, M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care. 1994 Jun;17(6):561-6.
81. Holman RRT, R. C. Basal normoglycemia attained with chlorpropamide in mild diabetes. Metabolism. 1978 May;27(5):539-47.
82. Horton ESC, C. Gatlin, M. Foley, J. Mallows, S. Shen, S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000 Nov;23(11):1660-5.
83. Howard BVA, W. G. Swinburn, B. A. Evaluation of metabolic effects of substitution of complex carbohydrates for saturated fat in individuals with obesity and NIDDM. Diabetes Care. 1991 Sep;14(9):786-95.
84. Hughes VAF, M. A. Fielding, R. A. Ferrara, C. M. Elahi, D. Evans, W. J. Long-term effects of a high-carbohydrate diet and exercise on insulin action in older subjects with impaired glucose tolerance. Am J Clin Nutr. 1995 Aug;62(2):426-33.
85. Hussain SA. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. J Med Food. 2007 Sep;10(3):543-7.
86. Jenkins DJK, C. W. McKeown-Eyssen, G. Josse, R. G. Silverberg, J. Booth, G. L. Vidgen, E. Josse, A. R. Nguyen, T. H. Corrigan, S. Banach, M. S. Ares, S. Mitchell, S. Emam, A. Augustin, L. S. Parker, T. L. Leiter, L. A. Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA. 2008 Dec 17;300(23):2742-53.
87. Jimenez-Cruz AB-G, M. Turnbull, W. H. Rosales-Garay, P. Severino-Lugo, I. A flexible, low-glycemic index mexican-style diet in overweight and obese subjects with type 2 diabetes improves metabolic parameters during a 6-week treatment period. Diabetes Care. 2003 Jul;26(7):1967-70.
88. Josephkutty SP, J. M. Comparison of tolbutamide and metformin in elderly diabetic patients. Diabet Med. 1990 Jul;7(6):510-4.
89. Jun JKG, W. C. Mathur, R. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients. Am J Health Syst Pharm. 2003 Mar 1;60(5):469-73.
90. Kadoglou NPI, F. Liapis, C. D. Perrea, D. Angelopoulou, N. Alevizos, M. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2007 Sep;30(9):2242-4.
91. Kang JR, R. J. Hagberg, J. M. Kelley, D. E. Goss, F. L. DaSilva, S. G. Suminski, R. R. Utter, A. C. Effect of exercise intensity on glucose and insulin metabolism in obese individuals and obese NIDDM patients. Diabetes Care. 1996 Apr;19(4):341-9.
92. Karlander SA, I. Efendic, S. Metabolic effects and clinical value of beet fiber treatment in NIDDM patients. Diabetes Res Clin Pract. 1991 Feb;11(2):65-71.
93. Kattelmann KKC, K. Ren, C. The medicine wheel nutrition intervention: a diabetes education study with the Cheyenne River Sioux Tribe. J Am Diet Assoc. 2009 Sep;109(9):1532-9.

94. Keller UW, C. Messer, C. Riesen, W. [Comparison of a calorie-defined diet with the conventional exchange diet in Type 2 diabetes mellitus]. Schweiz Med Wochenschr. 1991 Jul 9;121(27-28):1014-9.
95. Kelley DEW, R. Buonocore, C. Sturis, J. Polonsky, K. Fitzsimmons, M. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993 Nov;77(5):1287-93.
96. King ABA, D. U. Chinnapongse, S. Comparison of glycemic and lipid response to pioglitazone treatment in Mexican-Americans and non-Hispanic Caucasians with type 2 diabetes. Diabetes Care. 2003 Jan;26(1):245-6.
97. Kipnes MSK, A. Rendell, M. S. Egan, J. W. Mathisen, A. L. Schneider, R. L. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001 Jul;111(1):10-7.
98. Kuo CSP, D. Yao, C. Y. Hsieh, M. C. Kuo, S. W. Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2006 Aug;60(8):906-10.
99. Kutnowski MD, J. C. Friedman, H. Kolanowski, J. Krzentowski, G. Scheen, A. Van Gaal, L. Fluoxetine therapy in obese diabetic and glucose intolerant patients. Int J Obes Relat Metab Disord. 1992 Dec;16 Suppl 4:S63-6.
100. Lambers SVL, C. Van Acker, K. Calders, P. Influence of combined exercise training on indices of obesity, diabetes and cardiovascular risk in type 2 diabetes patients. Clin Rehabil. 2008 Jun;22(6):483-92.
101. Lamotte MA, L. Lefever, A. Nechelput, M. Masure, J. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care. 2002 Feb;25(2):303-8.
102. Lee SK, J. L. Davidson, L. E. Hudson, R. Kilpatrick, K. Graham, T. E. Ross, R. Exercise without weight loss is an effective strategy for obesity reduction in obese individuals with and without Type 2 diabetes. J Appl Physiol. 2005 Sep;99(3):1220-5.
103. Lemon CCL, K. Lohse, B. Hubacher, D. O. Klawitter, B. Palta, M. Outcomes monitoring of health, behavior, and quality of life after nutrition intervention in adults with type 2 diabetes. J Am Diet Assoc. 2004 Dec;104(12):1805-15.
104. Leutenegger MB, B. Brun, J. M. Guillon-Metz, F. Martin, C. Nicolino-Peltier, C. Richard, J. L. Vannereau, D. Added benfluorex in obese insulin-requiring type 2 diabetes. Diabetes Metab. 1998 Feb;24(1):55-61.
105. Liu GCC, A. M. Lardinois, C. K. Hollenbeck, C. B. Moore, J. G. Reaven, G. M. Moderate weight loss and sulfonylurea treatment of non-insulin-dependent diabetes mellitus. Combined effects. Arch Intern Med. 1985 Apr;145(4):665-9.
106. Lousley SEJ, D. B. Slaughter, P. Carter, R. D. Jelfs, R. Mann, J. I. High carbohydrate-high fibre diets in poorly controlled diabetes. Diabet Med. 1984 May;1(1):21-5.
107. Lucas CPP, S. Stepke, T. Kinhal, V. Darga, L. L. Carroll-Michals, L. Spafford, T. R. Kasim, S. Achieving therapeutic goals in insulin-using diabetic patients with non-insulin-dependent diabetes mellitus. A weight reduction-exercise-oral agent approach. Am J Med. 1987 Sep 18;83(3A):3-9.
108. Ludvik BHM, K. Waldhaeusl, W. Hofer, A. Prager, R. Kautzky-Willer, A. Pacini, G. The effect of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol

in patients with type 2 diabetes: a randomized study. Diabetes Care. 2002 Jan;25(1):239-40.
109. Ludvik BN, B. Pacini, G. Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet. Diabetes Care. 2004 Feb;27(2):436-40.
110. Luis Bautista JB, C. Dirnberger, G. Atherton, T. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2003 Jan;25(1):194-209.
111. Maeda HY, R. Hirao, K. Tochikubo, O. Effects of agar (kanten) diet on obese patients with impaired glucose tolerance and type 2 diabetes. Diabetes Obes Metab. 2005 Jan;7(1):40-6.
112. Maheux PD, F. Bourque, J. Garon, J. Chiasson, J. L. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord. 1997 Feb;21(2):97-102.
113. Markovic TPC, L. V. Balasubramanian, S. Jenkins, A. B. Fleury, A. C. Simons, L. A. Chisholm, D. J. Beneficial effect on average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes. Diabetes Care. 1998 May;21(5):695-700.
114. Markovic TPJ, A. B. Campbell, L. V. Furler, S. M. Kraegen, E. W. Chisholm, D. J. The determinants of glycemic responses to diet restriction and weight loss in obesity and NIDDM. Diabetes Care. 1998 May;21(5):687-94.
115. Mattoo VE, D. Widel, M. Duran, S. Fajardo, C. Strand, J. Knight, D. Grossman, L. Oakley, D. Tan, M. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther. 2005 May;27(5):554-67.
116. McAuley KAW, S. M. Mann, J. I. Goulding, A. Chisholm, A. Wilson, N. Story, G. McLay, R. T. Harper, M. J. Jones, I. E. Intensive lifestyle changes are necessary to improve insulin sensitivity: a randomized controlled trial. Diabetes Care. 2002 Mar;25(3):445-52.
117. McKibbin CLP, T. L. Norman, G. Patrick, K. Jin, H. Roesch, S. Mudaliar, S. Barrio, C. O'Hanlon, K. Griver, K. Sirkin, A. Jeste, D. V. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr Res. 2006 Sep;86(1-3):36-44.
118. McLaughlin TC, S. Lamendola, C. Abbasi, F. Schaaf, P. Basina, M. Reaven, G. Clinical efficacy of two hypocaloric diets that vary in overweight patients with type 2 diabetes: comparison of moderate fat versus carbohydrate reductions. Diabetes Care. 2007 Jul;30(7):1877-9.
119. Meckling KAOS, C. Saari, D. Comparison of a low-fat diet to a low-carbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free-living, overweight men and women. J Clin Endocrinol Metab. 2004 Jun;89(6):2717-23.
120. Meneilly GSG, N. Tildesley, H. Habener, J. F. Egan, J. M. Elahi, D. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care. 2003 Oct;26(10):2835-41.

121. Miller CKE, L. Kissling, G. Sanville, L. Evaluation of a theory-based nutrition intervention for older adults with diabetes mellitus. J Am Diet Assoc. 2002 Aug;102(8):1069-81.
122. Miyashita YK, N. Ohtsuka, M. Ozaki, H. Itoh, Y. Oyama, T. Uetake, T. Ariga, K. Shirai, K. Beneficial effect of low carbohydrate in low calorie diets on visceral fat reduction in type 2 diabetic patients with obesity. Diabetes Res Clin Pract. 2004 Sep;65(3):235-41.
123. Miyazaki YM, A. Matsuda, M. Glass, L. Mahankali, S. Ferrannini, E. Cusi, K. Mandarino, L. J. DeFronzo, R. A. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001 Apr;24(4):710-9.
124. Muchmore DBS, J. Miller, M. Self-monitoring of blood glucose in overweight type 2 diabetic patients. Acta Diabetol. 1994 Dec;31(4):215-9.
125. Nagulesparan MS, P. J. Bennion, L. J. Unger, R. H. Bennett, P. H. Diminished effect of caloric restriction on control of hyperglycemia with increasing known duration of type II diabetes mellitus. J Clin Endocrinol Metab. 1981 Sep;53(3):560-8.
126. Nam SYK, K. R. Cha, B. S. Song, Y. D. Lim, S. K. Lee, H. C. Huh, K. B. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. Int J Obes Relat Metab Disord. 2001 Aug;25(8):1101-7.
127. Nathan DMR, A. Godine, J. E. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study. Ann Intern Med. 1988 Mar;108(3):334-40.
128. Nolan JJJ, N. P. Patwardhan, R. Deacon, L. F. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. Diabet Med. 2000 Apr;17(4):287-94.
129. Noury JN, A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabete Metab. 1991 May;17(1 Pt 2):209-12.
130. Nuttall FQG, M. C. The metabolic response to a high-protein, low-carbohydrate diet in men with type 2 diabetes mellitus. Metabolism. 2006 Feb;55(2):243-51.
131. Osei KB, B. Dietary fructose as a natural sweetener in poorly controlled type 2 diabetes: a 12-month crossover study of effects on glucose, lipoprotein and apolipoprotein metabolism. Diabet Med. 1989 Aug;6(6):506-11.
132. Osei KF, J. Bossetti, B. M. Holland, G. C. Metabolic effects of fructose as a natural sweetener in the physiologic meals of ambulatory obese patients with type II diabetes. Am J Med. 1987 Aug;83(2):249-55.
133. Paniagua JAdlS, A. G. Sanchez, E. Romero, I. Vidal-Puig, A. Berral, F. J. Escribano, A. Moyano, M. J. Perez-Martinez, P. Lopez-Miranda, J. Perez-Jimenez, F. A MUFA-rich diet improves posprandial glucose, lipid and GLP-1 responses in insulin-resistant subjects. J Am Coll Nutr. 2007 Oct;26(5):434-44.
134. Parker BN, M. Luscombe, N. Clifton, P. Effect of a high-protein, high-monounsaturated fat weight loss diet on glycemic control and lipid levels in type 2 diabetes. Diabetes Care. 2002 Mar;25(3):425-30.
135. Pathan MFL, Z. A. Nazneen, N. E. Mili, S. U. Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience. Bangladesh Med Res Counc Bull. 2004 Apr;30(1):1-8.

136. Pereira MAJ, D. R., Jr. Pins, J. J. Raatz, S. K. Gross, M. D. Slavin, J. L. Seaquist, E. R. Effect of whole grains on insulin sensitivity in overweight hyperinsulinemic adults. Am J Clin Nutr. 2002 May;75(5):848-55.
137. Peters Harmel ALK, D. M. Buse, J. B. Boyle, P. J. Marchetti, A. Lau, H. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin. 2004;20(2):215-23.
138. Petersen KFD, S. Befroy, D. Lehrke, M. Hendler, R. E. Shulman, G. I. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005 Mar;54(3):603-8.
139. Phillips LSG, G. Miller, E. Patwardhan, R. Rappaport, E. B. Salzman, A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001 Feb;24(2):308-15.
140. Pi-Sunyer FXS, A. Mills, D. Dejager, S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract. 2007 Apr;76(1):132-8.
141. Pijl HO, S. Matsuda, M. Miyazaki, Y. Mahankali, A. Kumar, V. Pipek, R. Iozzo, P. Lancaster, J. L. Cincotta, A. H. DeFronzo, R. A. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000 Aug;23(8):1154-61.
142. Pontiroli AEP, M. Piatti, P. M. Cassisa, C. Camisasca, R. Pozza, G. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. J Clin Endocrinol Metab. 1996 Oct;81(10):3727-32.
143. Poon TN, P. Shen, L. Mihm, M. Taylor, K. Fineman, M. Kim, D. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther. 2005 Jun;7(3):467-77.
144. Poppitt SDK, G. F. Prentice, A. M. Williams, D. E. Sonnemans, H. M. Valk, E. E. Robinson, E. Wareham, N. J. Long-term effects of ad libitum low-fat, high-carbohydrate diets on body weight and serum lipids in overweight subjects with metabolic syndrome. Am J Clin Nutr. 2002 Jan;75(1):11-20.
145. Pratley RER, J. Pi-Sunyer, F. X. Banerji, M. A. Schweizer, A. Couturier, A. Dejager, S. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007 Dec;30(12):3017-22.
146. Rabkin SWB, E. Wilson, A. Streja, D. A. A randomized clinical trial comparing behavior modification and individual counseling in the nutritional therapy of non-insulin-dependent diabetes mellitus: comparison of the effect on blood sugar, body weight, and serum lipids. Diabetes Care. 1983 Jan-Feb;6(1):50-6.
147. Rains SGW, G. A. Richmond, W. Elkeles, R. S. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabet Med. 1988 Oct;5(7):653-8.
148. Raskin PR, M. Riddle, M. C. Dole, J. F. Freed, M. I. Rosenstock, J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001 Jul;24(7):1226-32.
149. Rasmussen OWT, C. Hansen, K. W. Vesterlund, M. Winther, E. Hermansen, K. Effects on blood pressure, glucose, and lipid levels of a high-monounsaturated fat diet compared with a high-carbohydrate diet in NIDDM subjects. Diabetes Care. 1993 Dec;16(12):1565-71.

150. Rave KR, K. Dellweg, S. Heise, T. tom Dieck, H. Improvement of insulin resistance after diet with a whole-grain based dietary product: results of a randomized, controlled cross-over study in obese subjects with elevated fasting blood glucose. Br J Nutr. 2007 Nov;98(5):929-36.
151. Reaven GM. Beneficial effect of moderate weight loss in older patients with non-insulin-dependent diabetes mellitus poorly controlled with insulin. J Am Geriatr Soc. 1985 Feb;33(2):93-5.
152. Reboussin DMG, D. C., Jr. Lipkin, E. W. Herrington, D. M. Summerson, J. Steffes, M. Crouse, R. J., 3rd Jovanovic, L. Feinglos, M. N. Probstfield, J. L. Banerji, M. A. Pettitt, D. J. Williamson, J. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. Diabet Med. 2004 Oct;21(10):1082-9.
153. Richter HK, K. Kleinwechter, H. Demandt, N. Meincke, G. Dabelstein, A. Weisser, B. [Effects of a telephone intervention in patients with type 2 diabetes]. Dtsch Med Wochenschr. 2008 Oct;133(43):2203-8.
154. Riddle MCR, J. Gerich, J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003 Nov;26(11):3080-6.
155. Rizkalla SWT, L. Laromiguiere, M. Huet, D. Boillot, J. Rigoir, A. Elgrably, F. Slama, G. Improved plasma glucose control, whole-body glucose utilization, and lipid profile on a low-glycemic index diet in type 2 diabetic men: a randomized controlled trial. Diabetes Care. 2004 Aug;27(8):1866-72.
156. Rodriguez-Villar CM, J. M. Casals, E. Perez-Heras, A. Zambon, D. Gomis, R. Ros, E. High-monounsaturated fat, olive oil-rich diet has effects similar to a high-carbohydrate diet on fasting and postprandial state and metabolic profiles of patients with type 2 diabetes. Metabolism. 2000 Dec;49(12):1511-7.
157. Roger PA, J. Drain, P. Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo. J Diabetes Complications. 1999 Mar-Apr;13(2):62-7.
158. Ronnemaa TM, J. Puukka, P. Kuusi, T. Effects of long-term physical exercise on serum lipids, lipoproteins and lipid metabolizing enzymes in type 2 (non-insulin-dependent) diabetic patients. Diabetes Res. 1988 Feb;7(2):79-84.
159. Rosenstock JE, D. Hershon, K. Glazer, N. B. Yu, S. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002 May;56(4):251-7.
160. Rosenstock JR, J. Bush, M. Yang, F. Stewart, M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009 Oct;32(10):1880-6.
161. Ruderman NBG, O. P. Johansen, K. The effect of physical training on glucose tolerance and plasma lipids in maturity-onset diabetes. Diabetes. 1979 Jan;28 Suppl 1:89-92.
162. Rudnick PAT, K. W. Effect of Prolonged Carbohydrate Restriction on Serum-Insulin Levels in Mild Diabetes. Br Med J. 1965 May 8;1(5444):1225-8.
163. Sahin MT, N. B. Ertugrul, D. Tanaci, N. Guvener, N. D. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in

patients with type 2 diabetes mellitus. J Diabetes Complications. 2007 Mar-Apr;21(2):118-23.
164. Saldalamacchia GM, P. Pacioni, D. Giordano, C. Tia, V. N. Pellegrino, S. Lilli, S. Riccardi, G. Rivellese, A. A. Weight loss in obese type 2 diabetic patients on an intensive therapeutic programme: Importance of an initial short hospitalization period. Nutr Metab Cardiovasc Dis. 2008 Feb;18(2):e1-2.
165. Salman SS, F. Satman, I. Yilmaz, Y. Ozer, E. Sengul, A. Demirel, H. O. Karsidag, K. Dinccag, N. Yilmaz, M. T. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr Med Res Opin. 2001;16(4):296-306.
166. Sanchez-Tainta AE, R. Bullo, M. Corella, D. Gomez-Gracia, E. Fiol, M. Algorta, J. Covas, M. I. Lapetra, J. Zazpe, I. Ruiz-Gutierrez, V. Ros, E. Martinez-Gonzalez, M. A. Adherence to a Mediterranean-type diet and reduced prevalence of clustered cardiovascular risk factors in a cohort of 3,204 high-risk patients. Eur J Cardiovasc Prev Rehabil. 2008 Oct;15(5):589-93.
167. Sargrad KRH, C. Mozzoli, M. Boden, G. Effect of high protein vs high carbohydrate intake on insulin sensitivity, body weight, hemoglobin A1c, and blood pressure in patients with type 2 diabetes mellitus. J Am Diet Assoc. 2005 Apr;105(4):573-80.
168. Scarlett JAG, R. S. Griffin, J. Olefsky, J. M. Kolterman, O. G. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care. 1982 Jul-Aug;5(4):353-63.
169. Schnack CR, G. Luger, A. Schernthaner, G. Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients. Eur J Clin Pharmacol. 1986;30(4):417-9.
170. Scott RW, M. Sanchez, M. Stein, P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007 Jan;61(1):171-80.
171. Segal KRE, A. Abalos, A. Albu, J. Blando, L. Tomas, M. B. Pi-Sunyer, F. X. Effect of exercise training on insulin sensitivity and glucose metabolism in lean, obese, and diabetic men. J Appl Physiol. 1991 Dec;71(6):2402-11.
172. Shahar DRA, R. Elhayany, A. Vardi, H. Fraser, D. Does dairy calcium intake enhance weight loss among overweight diabetic patients? Diabetes Care. 2007 Mar;30(3):485-9.
173. Shaw KMW, M. S. Campbell, D. B. Ward, J. D. Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial. Diabet Med. 1985 Nov;2(6):484-90.
174. Shi YFP, C. Y. Hill, J. Gao, Y. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes. Diabet Med. 2005 Dec;22(12):1737-43.
175. Simpson HCS, R. W. Lousley, S. Carter, R. D. Geekie, M. Hockaday, T. D. Mann, J. I. A high carbohydrate leguminous fibre diet improves all aspects of diabetic control. Lancet. 1981 Jan 3;1(8210):1-5.
176. Slama GS, A. Hautecouverture, M. Tchobroutsky, G. Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients. Diabete Metab. 1978 Sep;4(3):193-9.

177. Smutok MAR, C. Kokkinos, P. F. Farmer, C. M. Dawson, P. K. DeVane, J. Patterson, J. Goldberg, A. P. Hurley, B. F. Effects of exercise training modality on glucose tolerance in men with abnormal glucose regulation. Int J Sports Med. 1994 Aug;15(6):283-9.
178. Solomon TPH, J. M. Kelly, K. R. Cook, M. D. Riccardi, M. Rocco, M. Kashyap, S. R. Barkoukis, H. Kirwan, J. P. Randomized trial on the effects of a 7-d low-glycemic diet and exercise intervention on insulin resistance in older obese humans. Am J Clin Nutr. 2009 Nov;90(5):1222-9.
179. Sun JW, Y. Chen, X. Chen, Y. Feng, Y. Zhang, X. Pan, Y. Hu, T. Xu, J. Du, L. Zhou, W. Zhao, H. Riley, R. E. Mustad, V. A. An integrated intervention program to control diabetes in overweight Chinese women and men with type 2 diabetes. Asia Pac J Clin Nutr. 2008;17(3):514-24.
180. Suter SLN, J. J. Wallace, P. Gumbiner, B. Olefsky, J. M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992 Feb;15(2):193-203.
181. Takami KT, N. Nakashima, K. Takami, R. Hayashi, M. Ozeki, S. Yamada, A. Kokubo, Y. Sato, M. Kawachi, S. Sasaki, A. Yasuda, K. Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2002 Apr;25(4):658-62.
182. Tankova TD, G. Lazarova, M. Dakovska, L. Kirilov, G. Koev, D. Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. Acta Diabetol. 2004 Dec;41(4):146-53.
183. Tariq SHK, E. Thomas, D. R. Thomson, K. Philpot, C. Chapel, D. L. Morley, J. E. The use of a no-concentrated-sweets diet in the management of type 2 diabetes in nursing homes. J Am Diet Assoc. 2001 Dec;101(12):1463-6.
184. Trovati MC, Q. Cavalot, F. Vitali, S. Banaudi, C. Lucchina, P. G. Fiocchi, F. Emanuelli, G. Lenti, G. Influence of physical training on blood glucose control, glucose tolerance, insulin secretion, and insulin action in non-insulin-dependent diabetic patients. Diabetes Care. 1984 Sep-Oct;7(5):416-20.
185. Turner-McGrievy GMB, N. D. Cohen, J. Jenkins, D. J. Gloede, L. Green, A. A. Changes in nutrient intake and dietary quality among participants with type 2 diabetes following a low-fat vegan diet or a conventional diabetes diet for 22 weeks. J Am Diet Assoc. 2008 Oct;108(10):1636-45.
186. Uusitupa ML, M. Sarlund, H. Majander, H. Takala, J. Penttila, I. Long term effects of a very low calorie diet on metabolic control and cardiovascular risk factors in the treatment of obese non-insulin-dependent diabetics. Int J Obes. 1989;13 Suppl 2:163-4.
187. Valensi PM, I. Le Magoarou, M. Paries, J. Perret, G. Attali, J. R. Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin-dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment. Diabetes Metab. 1997 Feb;23(1):51-7.
188. Van Duyn MAL, T. A. McIvor, M. E. Behall, K. M. Michnowski, J. E. Mendeloff, A. I. Nutritional risk of high-carbohydrate, guar gum dietary supplementation in non-insulin-dependent diabetes mellitus. Diabetes Care. 1986 Sep-Oct;9(5):497-503.

189. Vancea DMMV, José Nelson Pires, Maria Izabel Fernandes Reis, Marco Antonio Moura, Rafael Brandão Dib, Sergio Atala. Effect of frequency of physical exercise on glycemic control and body composition in type 2 diabetic patients. Arquivos Brasileiros de Cardiologia. 2009;92:23-30.
190. Verdy MC, L. Verdy, I. Belanger, R. Bolte, E. Chiasson, J. L. Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect. Int J Obes. 1983;7(4):289-97.
191. Vernon MCM, J. Transue, M. Yancy, W. S. Westman, E. C. Clinical experience of a carbohydrate-restricted diet: effect on diabetes mellitus. Metab Syndr Relat Disord. 2003 Sep;1(3):233-7.
192. Vukovic ML, M. Kalezic, N. Gvozdenovic, B. S. [The effect of metformin on fasting and postprandial insulin secretion in obese patients with diabetes mellitus type 2]. Srp Arh Celok Lek. 2007 Jul-Aug;135(7-8):447-52.
193. Vuksan VJ, D. J. Spadafora, P. Sievenpiper, J. L. Owen, R. Vidgen, E. Brighenti, F. Josse, R. Leiter, L. A. Bruce-Thompson, C. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care. 1999 Jun;22(6):913-9.
194. Wales JK. The effect of fenfluramine on obese, maturity-onset diabetic patients. Acta Endocrinol (Copenh). 1979 Apr;90(4):616-23.
195. Wall JRP, D. A. Oakley, W. G. Effect of carbohydrate restriction in obese diabetics: relationship of control to weight loss. Br Med J. 1973 Mar 10;1(5853):577-8.
196. Wang TFP, D. Li, J. C. Tsai, W. C. Tsai, C. C. Yao, C. Y. Chang, E. T. Hsieh, M. C. Su, K. Y. Kuo, S. W. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2005 Jul;59(7):746-50.
197. Watanabe MO, A. Shimamoto, K. Ueshima, H. Short-term effectiveness of an individual counseling program for impaired fasting glucose and mild type 2 diabetes in Japan: a multi-center randomized control trial. Asia Pac J Clin Nutr. 2007;16(3):489-97.
198. Weinsier RLS, A. Herrera, M. G. Assal, J. P. Soeldner, J. S. Gleason, R. E. High- and low-carbohydrate diets in diabetes mellitus. Study of effects on diabetic control, insulin secretion, and blood lipids. Ann Intern Med. 1974 Mar;80(3):332-41.
199. Willey KAM, L. M. Overland, J. E. Yue, D. K. The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. Diabet Med. 1992 May;9(4):341-3.
200. Willms BR, D. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med. 1999 Sep;16(9):755-61.
201. Wing RRN, M. P. Epstein, L. H. Koeske, R. Calorie-counting compared to exchange system diets in the treatment of overweight patients with type II diabetes. Addict Behav. 1986;11(2):163-8.
202. Winnick JJG, T. Schuster, D. P. Resistance training differentially affects weight loss and glucose metabolism of White and African American patients with type 2 diabetes mellitus. Ethn Dis. 2008 Spring;18(2):152-6.
203. Winnick JJS, W. M. Habash, D. L. Stout, M. B. Failla, M. L. Belury, M. A. Schuster, D. P. Short-term aerobic exercise training in obese humans with type 2 diabetes mellitus improves whole-body insulin sensitivity through gains in peripheral, not hepatic insulin sensitivity. J Clin Endocrinol Metab. 2008 Mar;93(3):771-8.

204. Wolffenbuttel BHW, R. F. Van Koetsveld, P. M. Verschoor, L. Limitations of diet therapy in patients with non-insulin-dependent diabetes mellitus. Int J Obes. 1989;13(2):173-82.
205. Woo JS, M. M. Tong, P. Ko, G. T. Lee, Z. Chan, J. Chow, F. C. Effectiveness of a lifestyle modification programme in weight maintenance in obese subjects after cessation of treatment with Orlistat. J Eval Clin Pract. 2007 Dec;13(6):853-9.
206. Wycherley TPB, G. D. Noakes, M. Buckley, J. D. Clifton, P. M. Effect of caloric restriction with and without exercise training on oxidative stress and endothelial function in obese subjects with type 2 diabetes. Diabetes Obes Metab. 2008 Nov;10(11):1062-73.
207. Yamanouchi KS, T. Chikada, K. Nishikawa, T. Ito, K. Shimizu, S. Ozawa, N. Suzuki, Y. Maeno, H. Kato, K. et al.,. Daily walking combined with diet therapy is a useful means for obese NIDDM patients not only to reduce body weight but also to improve insulin sensitivity. Diabetes Care. 1995 Jun;18(6):775-8.
208. Yancy WS, Jr. Olsen, M. K. Guyton, J. R. Bakst, R. P. Westman, E. C. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med. 2004 May 18;140(10):769-77.
209. Yip IG, V. L. DeShields, S. Saltsman, P. Bellman, M. Thames, G. Murray, S. Wang, H. J. Elashoff, R. Heber, D. Liquid meal replacements and glycemic control in obese type 2 diabetes patients. Obes Res. 2001 Nov;9 Suppl 4:341S-7S.
210. Ziemer DCB, K. J. Panayioto, R. M. El-Kebbi, I. M. Musey, V. C. Anderson, L. A. Wanko, N. S. Fowke, M. L. Brazier, C. W. Dunbar, V. G. Slocum, W. Bacha, G. M. Gallina, D. L. Cook, C. B. Phillips, L. S. A simple meal plan emphasizing healthy food choices is as effective as an exchange-based meal plan for urban African Americans with type 2 diabetes. Diabetes Care. 2003 Jun;26(6):1719-24.

Published Before 1990:

1. Ackerman NB. Observations on the improvements in carbohydrate metabolism in diabetic and other morbidly obese patients after jejunoileal bypass. Surg Gynecol Obstet. 1981 May;152(5):581-6.
2. Bendezu RW, R. G. Green, S. G. Hallberg, M. C. Marsters, R. W. Certain metabolic consequences of jejunoileal bypass. Am J Clin Nutr. 1976 Apr;29(4):366-70.
3. Buchwald H. Ileal bypass in the treatment of the hyperlipidemias. J Atheroscler Res. 1969 Jul-Aug;10(1):1-4.
4. Buchwald H. Lowering of Cholesterol Absorption and Blood Levels by Ileal Exclusion. Experimental Basis and Preliminary Clinical Report. Circulation. 1964 May;29:713-20.
5. Buchwald HM, R. B. Frantz, I. D., Jr. Varco, R. L. Cholesterol reduction by partial ileal bypass in a pediatric population. Surgery. 1970 Dec;68(6):1101-11.
6. Buchwald HV, R. L. Partial ileal bypass for hypercholesterolemia and atherosclerosis. Surg Gynecol Obstet. 1967 Jun;124(6):1231-8.
7. Dobrea GMW, R. G. Johnson, M. W. The effect of rapid weight loss due to jejunoileal bypass on total cholesterol and high-density lipoprotein. Am J Clin Nutr. 1981 Oct;34(10):1994-6.
8. Flickinger EGP, W. J. Meelheim, H. D. Sinar, D. R. Blose, I. L. Thomas, F. T. The Greenville gastric bypass. Progress report at 3 years. Ann Surg. 1984 May;199(5):555-62.

9. Gleysteen JJB, J. J. Improvement in heart disease risk factors after gastric bypass. Arch Surg. 1983 Jun;118(6):681-4.
10. Goldberg RBW, R. B. Landau, R. L. Changes in plasma apolipoproteins A-I, A-II, and B, and lipoprotein cholesterol after jejunoileal bypass. Gastroenterology. 1983 Apr;84(4):732-6.
11. Gomez CA. Gastroplasty in the surgical treatment of morbid obesity. Am J Clin Nutr. 1980 Feb;33(2 Suppl):406-15.
12. Gonen BH, J. D. Schonfeld, G. Lipoprotein levels in morbidly obese patients with massive, surgically-induced weight loss. Metabolism. 1983 May;32(5):492-6.
13. Halverson JDK, J. Cave, A. Permutt, A. Santiago, J. Altered glucose tolerance, insulin response, and insulin sensitivity after massive weight reduction subsequent to gastric bypass. Surgery. 1982 Aug;92(2):235-40.
14. Hardie GHS, G. CoBabe, T. Gastric bypass: a safe, effective procedure? Wis Med J. 1979 Nov;78(11):34-8.
15. Herbst CAH, T. A. Gwynne, J. T. Buckwalter, J. A. Gastric bariatric operation in insulin-treated adults. Surgery. 1984 Feb;95(2):209-14.
16. Hocking MPD, M. C. O'Leary, J. P. Woodward, E. R. Jejunoileal bypass for morbid obesity. Late follow-up in 100 cases. N Engl J Med. 1983 Apr 28;308(17):995-9.
17. Holt JBC, C. L. Trowbridge, P. E. Immediate and long-term results of vertical banded gastroplasty for morbid obesity. Conn Med. 1987 Oct;51(10):638-42.
18. Hughes TAG, J. T. Switzer, B. R. Herbst, C. White, G. Effects of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus. Am J Med. 1984 Jul;77(1):7-17.
19. Lewis LAT, R. B., Jr. Page, I. H. Effects of jejunocolic shunt on obesity, serum lipoproteins, lipids, and electrolytes. Arch Intern Med. 1966 Jan;117(1):4-16.
20. Mason EEI, C. Gastric bypass in obesity. Surg Clin North Am. 1967 Dec;47(6):1345-51.
21. Moore RBB, H. Varco, R. L. The effect of partial ileal bypass on plasma lipoproteins. Circulation. 1980 Sep;62(3):469-76.
22. Naslund I. Gastric bypass versus gastroplasty. A prospective study of differences in two surgical procedures for morbid obesity. Acta Chir Scand Suppl. 1987;536:1-60.
23. Naslund IW, G. Christoffersson, E. Agren, G. A prospective randomized comparison of gastric bypass and gastroplasty. Complications and early results. Acta Chir Scand. 1986 Nov;152:681-9.
24. Olsson SAP, B. G. Sorbris, R. Nilsson-Ehle, P. Effects of weight reduction after gastroplasty on glucose and lipid metabolism. Am J Clin Nutr. 1984 Dec;40(6):1273-80.
25. Payne JHD, L. T. Surgical treatment of obesity. Am J Surg. 1969 Aug;118(2):141-7.
26. Pories WJC, J. F. Flickinger, E. G. Meelheim, H. D. Swanson, M. S. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Ann Surg. 1987 Sep;206(3):316-23.
27. Pories WJF, E. G. Meelheim, D. Van Rij, A. M. Thomas, F. T. The effectiveness of gastric bypass over gastric partition in morbid obesity: consequence of distal gastric and duodenal exclusion. Ann Surg. 1982 Oct;196(4):389-99.

28. Quaade FB, O. Stokholm, K. H. Andersen, T. The Copenhagen PLAFA project: a randomized trial of gastroplasty versus very-low-calorie diet in the treatment of severe obesity (preliminary results). Int J Obes. 1981;5(3):257-61.
29. Ranlov PJ. Serum lipid changes after gastroplasty for morbid obesity. Acta Med Scand. 1984;216(5):503-8.
30. Rossner SH, D. Serum lipoproteins in massive obesity. A study and after jejunoileal shunt operation. Acta Med Scand. 1978;204(1-2):103-10.
31. Rucker RD, Jr. Goldenberg, F. Varco, R. L. Buchwald, H. Lipid effects of obesity operations. J Surg Res. 1981 Mar;30(3):229-35.
32. Sanderson ID, M. Bojm, M. A. The handling of glucose and insulin response before and after weight loss with jejuno-ileal bypass: a preliminary report. JPEN J Parenter Enteral Nutr. 1983 May-Jun;7(3):274-6.
33. Schrumpf EB, A. Djoseland, O. Fausa, O. Flaten, O. Skagen, D. W. Tronier, B. The effect of gastric bypass operation on glucose tolerance in obesity. Scand J Gastroenterol Suppl. 1985;107:24-31.
34. Schwartz RWS, W. E. Simpson, W. S. Griffen, W. O., Jr. Gastric bypass revision: lessons learned from 920 cases. Surgery. 1988 Oct;104(4):806-12.
35. Scott HW, Jr. Dean, R. H. Younger, R. K. Butts, W. H. Changes in hyperlipidemia and hyperlipoproteinemia in morbidly obese patients treated by jejunoileal bypass. Surg Gynecol Obstet. 1974 Mar;138(3):353-8.
36. Scott HW, Jr. Dean, R. H. Shull, H. J. Gluck, F. Results of jejunoileal bypass in two hundred patients with morbid obesity. Surg Gynecol Obstet. 1977 Nov;145(5):661-73.
37. Sherman CD, Jr. May, A. G. Nye, W. Waterhouse, C. Clinical and metabolic studies following bowel by-passing for obesity. Ann N Y Acad Sci. 1965 Oct 8;131(1):614-22.
38. Shibata HRM, J. R. Long, R. C. Metabolic effects of controlled jejunocolic bypass. Arch Surg. 1967 Sep;95(3):413-28.
39. Solhaug JHG, I. Metabolic changes after jejuno-ileal bypass for obesity. Scand J Gastroenterol. 1978;13(2):169-75.
40. Sugerman HJS, J. V. Birkenhauer, R. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters. Ann Surg. 1987 Jun;205(6):613-24.
41. Vessby BB, M. Lindahl, B. Lithell, H. Thoren, L. Werner, I. Serum lipoprotein lipid and apolipoprotein concentrations in grossly obese patients before and after jejuno-ileal shunt operation. Eur J Clin Invest. 1981 Feb;11(1):49-54.
42. Yale CE. Gastric surgery for morbid obesity. Complications and long-term weight control. Arch Surg. 1989 Aug;124(8):941-6.

Treatment Not of Interest:

1. Babio NB, M. Basora, J. Martinez-Gonzalez, M. A. Fernandez-Ballart, J. Marquez-Sandoval, F. Molina, C. Salas-Salvado, J. Adherence to the Mediterranean diet and risk of metabolic syndrome and its components. Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):563-70.

2. Belcher GL, C. Goh, K. L. Edwards, G. Valbuena, M. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract. 2004 Sep;58(9):833-7.
3. Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. Diabet Med. 2005 May;22(5):612-8.
4. Birkeland KIR, U. Hanssen, K. F. Vaaler, S. NIDDM: a rapid progressive disease. Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. Diabetologia. 1996 Dec;39(12):1629-33.
5. Buse JBK, D. C. Nielsen, L. L. Guan, X. Bowlus, C. L. Holcombe, J. H. Maggs, D. G. Wintle, M. E. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007 Jan;29(1):139-53.
6. Campbell IWM, D. G. Chalmers, J. McBain, A. M. Brown, I. R. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab. 1994 Jul-Aug;20(4):394-400.
7. Castagneto MDG, A. Mingrone, G. Tacchino, R. Nanni, G. Capristo, E. Benedetti, G. Tataranni, P. A. Greco, A. V. Normalization of Insulin Sensitivity in the Obese Patient after Stable Weight Reduction with Biliopancreatic Diversion. Obes Surg. 1994 May;4(2):161-8.
8. Chiasson JLJ, R. G. Hunt, J. A. Palmason, C. Rodger, N. W. Ross, S. A. Ryan, E. A. Tan, M. H. Wolever, T. M. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med. 1994 Dec 15;121(12):928-35.
9. Clark MH, S. E. Implementing a psychological intervention to improve lifestyle self-management in patients with type 2 diabetes. Patient Educ Couns. 2001 Mar;42(3):247-56.
10. Clarke BFD, L. J. Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics. Lancet. 1968 Jan 20;1(7534):123-6.
11. Dansinger MLG, J. A. Griffith, J. L. Selker, H. P. Schaefer, E. J. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005 Jan 5;293(1):43-53.
12. de Fine Olivarius NA, A. H. Siersma, V. Richelsen, B. Beck-Nielsen, H. Changes in patient weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes mellitus. Diabetologia. 2006 Sep;49(9):2058-67.
13. Derosa GC, A. F. Murdolo, G. Ciccarelli, L. Fogari, R. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr Metab. 2004 Aug;17(4):222-9.
14. Derosa GC, A. F. Gaddi, A. Ragonesi, P. D. Fogari, E. Bertone, G. Ciccarelli, L. Piccinni, M. N. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther. 2004 May;26(5):744-54.

15. Derosa GDA, A. Ragonesi, P. D. Ciccarelli, L. Piccinni, M. N. Pricolo, F. Salvadeo, S. A. Montagna, L. Gravina, A. Ferrari, I. Paniga, S. Cicero, A. F. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J. 2007 Feb;37(2):79-86.
16. Draeger KEW-P, K. Lomp, H. J. Schuler, E. Rosskamp, R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res. 1996 Sep;28(9):419-25.
17. Gerstein HCM, M. E. Byington, R. P. Goff, D. C., Jr. Bigger, J. T. Buse, J. B. Cushman, W. C. Genuth, S. Ismail-Beigi, F. Grimm, R. H., Jr. Probstfield, J. L. Simons-Morton, D. G. Friedewald, W. T. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59.
18. Goke BH, K. Kerr, D. Calle Pascual, A. Schweizer, A. Foley, J. Shao, Q. Dejager, S. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res. 2008 Dec;40(12):892-5.
19. Harrower AD. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas. Curr Med Res Opin. 1985;9(10):676-80.
20. Hollander PAL, P. Fineman, M. S. Maggs, D. G. Shen, L. Z. Strobel, S. A. Weyer, C. Kolterman, O. G. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003 Mar;26(3):784-90.
21. Holman RRT, K. I. Farmer, A. J. Davies, M. J. Keenan, J. F. Paul, S. Levy, J. C. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007 Oct 25;357(17):1716-30.
22. Horton ESW, F. Ghazzi, M. N. Venable, T. C. Whitcomb, R. W. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care. 1998 Sep;21(9):1462-9.
23. James SAJ, L. Raghunathan, T. E. Strogatz, D. S. Furth, E. D. Khazanie, P. G. Physical activity and NIDDM in African-Americans. The Pitt County Study. Diabetes Care. 1998 Apr;21(4):555-62.
24. Josse RG. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial. Diabetes Res Clin Pract. 1995 Aug;28 Suppl:S167-72.
25. Kahn SEH, S. M. Heise, M. A. Herman, W. H. Holman, R. R. Jones, N. P. Kravitz, B. G. Lachin, J. M. O'Neill, M. C. Zinman, B. Viberti, G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006 Dec 7;355(23):2427-43.
26. Keyserling TCA, A. S. Samuel-Hodge, C. D. Ingram, A. F. Skelly, A. H. Elasy, T. A. Johnston, L. F. Cole, A. S. Henriquez-Roldan, C. F. A diabetes management program for African American women with type 2 diabetes. Diabetes Educ. 2000 Sep-Oct;26(5):796-805.
27. Knowler WCH, R. F. Edelstein, S. L. Barrett-Connor, E. Ehrmann, D. A. Walker, E. A. Fowler, S. E. Nathan, D. M. Kahn, S. E. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005 Apr;54(4):1150-6.
28. Laaksonen MK, Paul Rissanen, Harri Härkänen, Tommi Virtala, Esa Marniemi, Jukka Aromaa, Arpo Heliövaara, Markku Reunanen, Antti. The relative importance of

modifiable potential risk factors of type 2 diabetes: a meta-analysis of two cohorts. European Journal of Epidemiology. [10.1007/s10654-009-9405-0]. 2010;25(2):115-24.
29. Manson JEN, D. M. Krolewski, A. S. Stampfer, M. J. Willett, W. C. Hennekens, C. H. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA. 1992 Jul 1;268(1):63-7.
30. Merriam PAT, T. L. Rosal, M. C. Olendzki, B. C. Ma, Y. Pagoto, S. L. Ockene, I. S. Methodology of a diabetes prevention translational research project utilizing a community-academic partnership for implementation in an underserved Latino community. BMC Med Res Methodol. 2009;9:20.
31. Mertes G. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract. 2001 Jun;52(3):193-204.
32. Ong CRM, L. M. Constantino, M. I. Twigg, S. M. Yue, D. K. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care. 2006 Nov;29(11):2361-4.
33. Paisey RE, R. S. Hambley, J. Magill, P. The effects of chlorpropamide and insulin on serum lipids, lipoproteins and fractional triglyceride removal. Diabetologia. 1978 Aug;15(2):81-5.
34. Ratner REM, D. Nielsen, L. L. Stonehouse, A. H. Poon, T. Zhang, B. Bicsak, T. A. Brodows, R. G. Kim, D. D. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006 Jul;8(4):419-28.
35. Raz IS, V. Stein, P. Influence of small-group education sessions on glucose homeostasis in NIDDM. Diabetes Care. 1988 Jan;11(1):67-71.
36. Ribisl PML, W. Jaramillo, S. A. Jakicic, J. M. Stewart, K. J. Bahnson, J. Bright, R. Curtis, J. F. Crow, R. S. Soberman, J. E. Exercise capacity and cardiovascular/metabolic characteristics of overweight and obese individuals with type 2 diabetes: the Look AHEAD clinical trial. Diabetes Care. 2007 Oct;30(10):2679-84.
37. Riddle MCH, R. R. Poon, T. H. Zhang, B. Mac, S. M. Holcombe, J. H. Kim, D. D. Maggs, D. G. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev. 2006 Nov-Dec;22(6):483-91.
38. Schernthaner GM, D. R. Charbonnel, B. Hanefeld, M. Brunetti, P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004 Dec;89(12):6068-76.
39. Schouten RvD, F. M. van Gemert, W. G. Greve, J. W. Conversion of vertical banded gastroplasty to Roux-en-Y gastric bypass results in restoration of the positive effect on weight loss and co-morbidities: evaluation of 101 patients. Obes Surg. 2007 May;17(5):622-30.
40. Schrier RWE, R. O. Mehler, P. S. Hiatt, W. R. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol. 2007 Aug;3(8):428-38.
41. Suter MG, V. Heraief, E. Zysset, F. Calmes, J. M. Laparoscopic gastric banding. Surg Endosc. 2003 Sep;17(9):1418-25.
42. Tan MJ, D. Gonzalez Galvez, G. Antunez, O. Fabian, G. Flores-Lozano, F. Zuniga Guajardo, S. Garza, E. Morales, H. Konkoy, C. Herz, M. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type

2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. Clin Ther. 2004 May;26(5):680-93.
43. Taylor KGJ, W. G. Matthews, K. A. Wright, A. D. A prospective study of the effect of 12 months treatment on serum lipids and apolipoproteins A-I and B in Type 2 (non-insulin-dependent) diabetes. Diabetologia. 1982 Dec;23(6):507-10.
44. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. [doi: DOI: 10.1016/S0140-6736(98)07037-8]. 1998;352(9131):854-65.
45. Wake NH, A. Katayama, T. Kishikawa, H. Ohkubo, Y. Sakai, M. Araki, E. Shichiri, M. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract. 2000 Jun;48(3):201-10.
46. Yates TD, M. Gorely, T. Bull, F. Khunti, K. Rationale, design and baseline data from the Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: a randomized controlled trial. Patient Educ Couns. 2008 Nov;73(2):264-71.
47. Zinman BH, S. B. Neuman, J. Gerstein, H. C. Retnakaran, R. R. Raboud, J. Qi, Y. Hanley, A. J. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet. 2010 Jul 10;376(9735):103-11.

Non-Surgical Already Included in Systematic Reviews:

1. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000 Jan 22;355(9200):253-9.
2. Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade. Diabet Med. 1994 Oct;11(8):773-82.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53.
4. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care. 1999 Jul;22(7):1125-36.
5. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism. 1990 Sep;39(9):905-12.
6. UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia. 1983 Jun;24(6):404-11.
7. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med. 1998 Feb 1;128(3):165-75.

8. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995 Jan 14;310(6972):83-8.
9. Absetz PV, R. Oldenburg, B. Heinonen, H. Nissinen, A. Fogelholm, M. Ilvesmaki, V. Talja, M. Uutela, A. Type 2 diabetes prevention in the "real world": one-year results of the GOAL Implementation Trial. Diabetes Care. 2007 Oct;30(10):2465-70.
10. Ackermann RTF, E. A. Brizendine, E. Zhou, H. Marrero, D. G. Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med. 2008 Oct;35(4):357-63.
11. Aldana SGB, M. Smith, R. Yanowitz, F. G. Adams, T. Loveday, L. Arbuckle, J. LaMonte, M. J. The diabetes prevention program: a worksite experience. AAOHN J. 2005 Nov;53(11):499-505; quiz 6-7.
12. Anderson JWW, K. Long-term effects of high-carbohydrate, high-fiber diets on glucose and lipid metabolism: a preliminary report on patients with diabetes. Diabetes Care. 1978 Mar-Apr;1(2):77-82.
13. Anderssen SAH, I. Urdal, P. Torjesen, P. A. Holme, I. Improved carbohydrate metabolism after physical training and dietary intervention in individuals with the "atherothrombogenic syndrome'. Oslo Diet and Exercise Study (ODES). A randomized trial. J Intern Med. 1996 Oct;240(4):203-9.
14. Ash SR, M. M. Yeo, S. Morrison, G. Carey, D. Capra, S. Effect of intensive dietetic interventions on weight and glycaemic control in overweight men with Type II diabetes: a randomised trial. Int J Obes Relat Metab Disord. 2003 Jul;27(7):797-802.
15. Balducci SL, F. Di Mario, U. Fallucca, F. Is a long-term aerobic plus resistance training program feasible for and effective on metabolic profiles in type 2 diabetic patients? Diabetes Care. 2004 Mar;27(3):841-2.
16. Banerji MAC, R. L. Lebovitz, H. E. Prolongation of near-normoglycemic remission in black NIDDM subjects with chronic low-dose sulfonylurea treatment. Diabetes. 1995 Apr;44(4):466-70.
17. Barnard NDC, Joshua Jenkins, David JA Turner-McGrievy, Gabrielle Gloede, Lise Green, Amber Ferdowsian, Hope. A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74-wk clinical trial. Am J Clin Nutr. 2009 May 1, 2009;89(5):1588S-96.
18. Ben-Avraham SH-B, Ilana Schwarzfuchs, Dan Shai, Iris. Dietary strategies for patients with type 2 diabetes in the era of multi-approaches; review and results from the Dietary Intervention Randomized Controlled Trial (DIRECT). Diabetes Research and Clinical Practice. [doi: DOI: 10.1016/S0168-8227(09)70008-7]. 2009;86(Supplement 1):S41-S8.
19. Blonde LK, E. J. Han, J. Zhang, B. Mac, S. M. Poon, T. H. Taylor, K. L. Trautmann, M. E. Kim, D. D. Kendall, D. M. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006 Jul;8(4):436-47.
20. Blonk MCJ, M. A. Biesheuvel, E. H. Weeda-Mannak, W. L. Heine, R. J. Influences on weight loss in type 2 diabetic patients: little long-term benefit from group behaviour therapy and exercise training. Diabet Med. 1994 Jun;11(5):449-57.

21. Bloomgarden ZTK, W. Metzger, M. J. Brothers, M. Nechemias, C. Bookman, J. Faierman, D. Ginsberg-Fellner, F. Rayfield, E. Brown, W. V. Randomized, controlled trial of diabetic patient education: improved knowledge without improved metabolic status. Diabetes Care. 1987 May-Jun;10(3):263-72.
22. Bo SC, G. Baldi, C. Benini, L. Dusio, F. Forastiere, G. Lucia, C. Nuti, C. Durazzo, M. Cassader, M. Gentile, L. Pagano, G. Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. J Gen Intern Med. 2007 Dec;22(12):1695-703.
23. Boltri JMD-S, Y. M. Seale, J. P. Shellenberger, S. Okosun, I. S. Cornelius, M. E. Diabetes prevention in a faith-based setting: results of translational research. J Public Health Manag Pract. 2008 Jan-Feb;14(1):29-32.
24. Bosch JL, E. Pogue, J. Arnold, J. M. Dagenais, G. R. Yusuf, S. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation. 2005 Aug 30;112(9):1339-46.
25. Bourn DMM, J. I. McSkimming, B. J. Waldron, M. A. Wishart, J. D. Impaired glucose tolerance and NIDDM: does a lifestyle intervention program have an effect? Diabetes Care. 1994 Nov;17(11):1311-9.
26. Brinkworth GDN, M. Keogh, J. B. Luscombe, N. D. Wittert, G. A. Clifton, P. M. Long-term effects of a high-protein, low-carbohydrate diet on weight control and cardiovascular risk markers in obese hyperinsulinemic subjects. Int J Obes Relat Metab Disord. 2004 May;28(5):661-70.
27. Brinkworth GDN, M. Buckley, J. D. Keogh, J. B. Clifton, P. M. Long-term effects of a very-low-carbohydrate weight loss diet compared with an isocaloric low-fat diet after 12 mo. Am J Clin Nutr. 2009 Jul;90(1):23-32.
28. Brinkworth GDN, M. Parker, B. Foster, P. Clifton, P. M. Long-term effects of advice to consume a high-protein, low-fat diet, rather than a conventional weight-loss diet, in obese adults with type 2 diabetes: one-year follow-up of a randomised trial. Diabetologia. 2004 Oct;47(10):1677-86.
29. Brown SAB, S. A. Kouzekanani, K. Garcia, A. A. Winchell, M. Hanis, C. L. Dosage effects of diabetes self-management education for Mexican Americans: the Starr County Border Health Initiative. Diabetes Care. 2005 Mar;28(3):527-32.
30. Bruce DGC, E. M. Campbell, L. V. Chisholm, D. J. Insulin therapy in patients with poorly controlled non-insulin dependent diabetes mellitus. Med J Aust. 1987 Mar 2;146(5):240-2.
31. Brun JFB, S. Mercier, J. Jaussent, A. Picot, M. C. Prefaut, C. Cost-sparing effect of twice-weekly targeted endurance training in type 2 diabetics: a one-year controlled randomized trial. Diabetes Metab. 2008 Jun;34(3):258-65.
32. Buchanan TAX, A. H. Peters, R. K. Kjos, S. L. Marroquin, A. Goico, J. Ochoa, C. Tan, S. Berkowitz, K. Hodis, H. N. Azen, S. P. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002 Sep;51(9):2796-803.
33. Buse JBG, B. Mathias, N. P. Nelson, D. M. Faja, B. W. Whitcomb, R. W. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group. Diabetes Care. 1998 Sep;21(9):1455-61.

34. Calle-Pascual ALR, C. Camacho, F. Sanchez, R. Martin-Alvarez, P. J. Yuste, E. Hidalgo, I. Diaz, R. J. Calle, J. R. Charro, A. L. Behaviour modification in obese subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract. 1992 Feb;15(2):157-62.
35. Campbell EMR, S. Moffitt, P. S. Sanson-Fisher, R. W. The relative effectiveness of educational and behavioral instruction programs for patients with NIDDM: a randomized trial. Diabetes Educ. 1996 Jul-Aug;22(4):379-86.
36. Carr DBU, K. M. Boyko, E. J. Asberry, P. J. Hull, R. L. Kodama, K. Callahan, H. S. Matthys, C. C. Leonetti, D. L. Schwartz, R. S. Kahn, S. E. Fujimoto, W. Y. A reduced-fat diet and aerobic exercise in Japanese Americans with impaired glucose tolerance decreases intra-abdominal fat and improves insulin sensitivity but not beta-cell function. Diabetes. 2005 Feb;54(2):340-7.
37. Chiasson J-LJ, Robert G. Gomis, Ramon Hanefeld, Markolf Karasik, Avraham Laakso, Markku. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. The Lancet. [doi: DOI: 10.1016/S0140-6736(02)08905-5]. 2002;359(9323):2072-7.
38. Chiasson JLJ, R. G. Gomis, R. Hanefeld, M. Karasik, A. Laakso, M. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia. 2004 Jun;47(6):969-75; discussion 76-7.
39. Chiasson JLJ, R. G. Gomis, R. Hanefeld, M. Karasik, A. Laakso, M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003 Jul 23;290(4):486-94.
40. Christian JGB, D. H. Byers, T. E. Christian, K. K. Goldstein, M. G. Bock, B. C. Clinic-based support to help overweight patients with type 2 diabetes increase physical activity and lose weight. Arch Intern Med. 2008 Jan 28;168(2):141-6.
41. Clark MH, S. E. Avery, L. Simpson, R. Effects of a tailored lifestyle self-management intervention in patients with type 2 diabetes. Br J Health Psychol. 2004 Sep;9(Pt 3):365-79.
42. Clarke PG, A. Adler, A. Stevens, R. Raikou, M. Cull, C. Stratton, I. Holman, R. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia. 2001 Mar;44(3):298-304.
43. Collins RA, J. Parish, S. Sleigh, P. Peto, R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003 Jun 14;361(9374):2005-16.
44. Corpeleijn EF, E. J. Jansen, E. H. Mensink, M. Saris, W. H. de Bruin, T. W. Blaak, E. E. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia. 2006 Oct;49(10):2392-401.
45. Crandall JS, D. Ma, Y. Fujimoto, W. Y. Barrett-Connor, E. Fowler, S. Dagogo-Jack, S. Andres, R. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci. 2006 Oct;61(10):1075-81.
46. Daly RMD, D. W. Owen, N. Jolley, D. Shaw, J. E. Zimmet, P. Z. Does high-intensity resistance training maintain bone mass during moderate weight loss in older overweight adults with type 2 diabetes? Osteoporos Int. 2005 Dec;16(12):1703-12.

47. Davis TMC, C. A. Holman, R. R. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55). Diabetes Care. 2001 Jul;24(7):1167-74.
48. Deakin TAC, J. E. Williams, R. Greenwood, D. C. Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med. 2006 Sep;23(9):944-54.
49. Despres JPG, A. Sjostrom, L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005 Nov 17;353(20):2121-34.
50. Di Loreto CF, C. Lucidi, P. Murdolo, G. De Cicco, A. Parlanti, N. Ranchelli, A. Fatone, C. Taglioni, C. Santeusanio, F. De Feo, P. Make your diabetic patients walk: long-term impact of different amounts of physical activity on type 2 diabetes. Diabetes Care. 2005 Jun;28(6):1295-302.
51. Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002 February 7, 2002;346(6):393-403.
52. Dixon ANV, G. Hanif, M. W. Field, A. Boutsiadis, A. Harte, A. McTernan, P. G. Barnett, A. H. Kumar, S. Effect of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in South Asian individuals with impaired glucose tolerance. Int J Clin Pract. 2008 Jul;62(7):1124-9.
53. DREAM. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1608-10.
54. Dunstan DWD, R. M. Owen, N. Jolley, D. Vulikh, E. Shaw, J. Zimmet, P. Home-based resistance training is not sufficient to maintain improved glycemic control following supervised training in older individuals with type 2 diabetes. Diabetes Care. 2005 Jan;28(1):3-9.
55. Ebbeling CBL, M. M. Sinclair, K. B. Seger-Shippee, L. G. Feldman, H. A. Ludwig, D. S. Effects of an ad libitum low-glycemic load diet on cardiovascular disease risk factors in obese young adults. Am J Clin Nutr. 2005 May;81(5):976-82.
56. Eeley EAS, I. M. Hadden, D. R. Turner, R. C. Holman, R. R. UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group. Diabet Med. 1996 Jul;13(7):656-62.
57. Eriksson JL, J. Valle, T. Aunola, S. Hamalainen, H. Ilanne-Parikka, P. Keinanen-Kiukaanniemi, S. Laakso, M. Lauhkonen, M. Lehto, P. Lehtonen, A. Louheranta, A. Mannelin, M. Martikkala, V. Rastas, M. Sundvall, J. Turpeinen, A. Viljanen, T. Uusitupa, M. Tuomilehto, J. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia. 1999 Jul;42(7):793-801.
58. Eriksson KFL, F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia. 1998 Sep;41(9):1010-6.
59. Eriksson KFL, F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia. 1991 Dec;34(12):891-8.

60. Esposito KM, M. I. Ciotola, M. Di Palo, C. Scognamiglio, P. Gicchino, M. Petrizzo, M. Saccomanno, F. Beneduce, F. Ceriello, A. Giugliano, D. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med. 2009 Sep 1;151(5):306-14.
61. Fitz JDS, E. M. Fein, H. G. A hypocaloric high-protein diet as primary therapy for adults with obesity-related diabetes: effective long-term use in a community hospital. Diabetes Care. 1983 Jul-Aug;6(4):328-33.
62. Fontbonne AD, I. Baccara-Dinet, M. Eschwege, E. Charles, M. A. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. Diabetes Metab. 2009 Nov;35(5):385-91.
63. Forlani GL, C. Moscatiello, S. Ridolfi, V. Melchionda, N. Di Domizio, S. Marchesini, G. Are behavioural approaches feasible and effective in the treatment of type 2 diabetes? A propensity score analysis vs. prescriptive diet. Nutrition, Metabolism and Cardiovascular Diseases. [doi: DOI: 10.1016/j.numecd.2008.06.004]. 2009;19(5):313-20.
64. Fraser AA, R. Lawlor, D. A. Fraser, D. Elhayany, A. A modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: results of a quasi-randomised controlled trial. Diabetologia. 2008 Sep;51(9):1616-22.
65. Freeman DJN, J. Sattar, N. Neely, R. D. Cobbe, S. M. Ford, I. Isles, C. Lorimer, A. R. Macfarlane, P. W. McKillop, J. H. Packard, C. J. Shepherd, J. Gaw, A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001 Jan 23;103(3):357-62.
66. Fujimoto WYJ, K. A. Bray, G. A. Kriska, A. Barrett-Connor, E. Haffner, S. Hanson, R. Hill, J. O. Hubbard, V. Stamm, E. Pi-Sunyer, F. X. Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes. 2007 Jun;56(6):1680-5.
67. Gaede PL-A, H. Parving, H. H. Pedersen, O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 Feb 7;358(6):580-91.
68. Gallagher AH, W. Abraira, C. Dietary patterns and metabolic control in diabetic diets: a prospective study of 51 outpatient men on unmeasured and exchange diets. J Am Coll Nutr. 1987 Dec;6(6):525-32.
69. Gerstein HCY, S. Bosch, J. Pogue, J. Sheridan, P. Dinccag, N. Hanefeld, M. Hoogwerf, B. Laakso, M. Mohan, V. Shaw, J. Zinman, B. Holman, R. R. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006 Sep 23;368(9541):1096-105.
70. Gilliland SSA, S. P. Perez, G. E. Carter, J. S. Strong in body and spirit: lifestyle intervention for Native American adults with diabetes in New Mexico. Diabetes Care. 2002 Jan;25(1):78-83.
71. Group TDPPR. Effect of weight loss with lifestyle intervention on risk of diabetes. . Diabetes Care. 2006;29:2192-07.
72. Gruesser MB, U. Ellermann, P. Kronsbein, P. Joergens, V. Evaluation of a structured treatment and teaching program for non-insulin-treated type II diabetic

outpatients in Germany after the nationwide introduction of reimbursement policy for physicians. Diabetes Care. 1993 Sep;16(9):1268-75.
73. Guare JCW, R. R. Grant, A. Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss. Obes Res. 1995 Jul;3(4):329-35.
74. Gurka MJW, A. M. Conaway, M. R. Crowther, J. Q. Nadler, J. L. Bovbjerg, V. E. Lifestyle intervention in obese patients with type 2 diabetes: impact of the patient's educational background. Obesity (Silver Spring). 2006 Jun;14(6):1085-92.
75. Gurlek AE, T. Gedik, O. Frequency of severe hypoglycaemia in type 1 and type 2 diabetes during conventional insulin therapy. Exp Clin Endocrinol Diabetes. 1999;107(3):220-4.
76. Haffner ST, M. Crandall, J. Fowler, S. Goldberg, R. Horton, E. Marcovina, S. Mather, K. Orchard, T. Ratner, R. Barrett-Connor, E. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005 May;54(5):1566-72.
77. Haimoto HI, M. Wakai, K. Umegaki, H. Long-term effects of a diet loosely restricting carbohydrates on HbA1c levels, BMI and tapering of sulfonylureas in type 2 diabetes: a 2-year follow-up study. Res Clin Pract. 2008;79:350-6.
78. Hamalainen HR, T. Virtanen, A. Lindstrom, J. Eriksson, J. G. Valle, T. T. Ilanne-Parikka, P. Keinanen-Kiukaanniemi, S. Rastas, M. Aunola, S. Uusitupa, M. Tuomilehto, J. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia. 2005 Nov;48(11):2248-53.
79. Hamman RFW, R. R. Edelstein, S. L. Lachin, J. M. Bray, G. A. Delahanty, L. Hoskin, M. Kriska, A. M. Mayer-Davis, E. J. Pi-Sunyer, X. Regensteiner, J. Venditti, B. Wylie-Rosett, J. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006 Sep;29(9):2102-7.
80. Hanefeld MF, S. Schmechel, H. Rothe, G. Schulze, J. Dude, H. Schwanebeck, U. Julius, U. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care. 1991 Apr;14(4):308-17.
81. Hanefeld MS, G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2002 Nov;4(6):415-23.
82. Heath GWW, R. H. Smith, J. Leonard, B. E. Community-based exercise and weight control: diabetes risk reduction and glycemic control in Zuni Indians. Am J Clin Nutr. 1991 Jun;53(6 Suppl):1642S-6S.
83. Heitzmann CAK, R. M. Wilson, D. K. Sandler, J. Sex differences in weight loss among adults with type II diabetes mellitus. J Behav Med. 1987 Apr;10(2):197-211.
84. Heller SRC, P. Daly, H. Davis, I. McCulloch, D. K. Allison, S. P. Tattersall, R. B. Group education for obese patients with type 2 diabetes: greater success at less cost. Diabet Med. 1988 Sep;5(6):552-6.
85. Herder CP, M. Koenig, W. Kraft, I. Muller-Scholze, S. Martin, S. Lakka, T. Ilanne-Parikka, P. Eriksson, J. G. Hamalainen, H. Keinanen-Kiukaanniemi, S. Valle, T. T. Uusitupa, M. Lindstrom, J. Kolb, H. Tuomilehto, J. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes. 2006 Aug;55(8):2340-6.

86. Hockaday TDH, J. M. Mann, J. I. Turner, R. C. Prospective comparison of modified fat-high-carbohydrate with standard low-carbohydrate dietary advice in the treatment of diabetes: one year follow-up study. Br J Nutr. 1978 Mar;39(2):357-62.
87. Hollander P. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Am J Med. 2007 Feb;120(2 Suppl 1):S18-28; discussion S9-32.
88. Hollander PAE, S. C. Hirsch, I. B. Kelley, D. McGill, J. Taylor, T. Weiss, S. R. Crockett, S. E. Kaplan, R. A. Comstock, J. Lucas, C. P. Lodewick, P. A. Canovatchel, W. Chung, J. Hauptman, J. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998 Aug;21(8):1288-94.
89. Holloszy JOS, J. Kusnierkiewicz, J. Hagberg, J. M. Ehsani, A. A. Effects of exercise on glucose tolerance and insulin resistance. Brief review and some preliminary results. Acta Med Scand Suppl. 1986;711:55-65.
90. Holman RRC, C. A. Turner, R. C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care. 1999 Jun;22(6):960-4.
91. Horrocks PMB, R. Wright, A. D. A long-term follow-up of dietary advice in maturity onset diabetes: the experience of one centre in the UK prospective study. Diabet Med. 1987 May-Jun;4(3):241-4.
92. Hughes TAK, J. O. Segrest, J. P. Effects of glyburide therapy on lipoproteins in non-insulin-dependent diabetes mellitus. Am J Med. 1985 Sep 20;79(3B):86-91.
93. Jarrett RJK, H. Fuller, J. H. McCartney, M. Worsening to diabetes in men with impaired glucose tolerance ("borderline diabetes"). Diabetologia. 1979 Jan;16(1):25-30.
94. Johnston PSL, H. E. Coniff, R. F. Simonson, D. C. Raskin, P. Munera, C. L. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab. 1998 May;83(5):1515-22.
95. Jonsson BC, J. R. Pedersen, T. R. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia. 1999 Nov;42(11):1293-301.
96. Kaplan RMH, S. L. Wilson, D. K. Wallace, J. P. Effects of diet and exercise interventions on control and quality of life in non-insulin-dependent diabetes mellitus. J Gen Intern Med. 1987 Jul-Aug;2(4):220-8.
97. Karlstrom BN, M. Vessby, B. Dietary habits and effects of dietary advice in patients with type 2 diabetes. Results from a one-year intervention study. Eur J Clin Nutr. 1989 Jan;43(1):59-68.
98. Kawamori RT, N. Iwamoto, Y. Kashiwagi, A. Shimamoto, K. Kaku, K. [Alpha-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance]. Nippon Rinsho. 2009 Sep;67(9):1821-5.
99. Kawamori RT, N. Iwamoto, Y. Kashiwagi, A. Shimamoto, K. Kaku, K. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009 May 9;373(9675):1607-14.
100. Keech AS, R. J. Barter, P. Best, J. Scott, R. Taskinen, M. R. Forder, P. Pillai, A. Davis, T. Glasziou, P. Drury, P. Kesaniemi, Y. A. Sullivan, D. Hunt, D. Colman, P.

d'Emden, M. Whiting, M. Ehnholm, C. Laakso, M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61.
101. Keen HJ, R. J. Ward, J. D. Fuller, J. H. Borderline diabetics and their response to tolbutamide. Adv Metab Disord. 1973;2:Suppl 2:521-31.
102. Keen HJ, R. J. McCartney, P. The ten-year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes. Diabetologia. 1982 Feb;22(2):73-8.
103. Kilo CD, J. Kalb, E. Evaluation of saftey and efficacy of gliclazide in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract. 1991(14):79S-82S.
104. Kirk AM, N. MacIntyre, P. Fisher, M. Effects of a 12-month physical activity counselling intervention on glycaemic control and on the status of cardiovascular risk factors in people with Type 2 diabetes. Diabetologia. 2004 May;47(5):821-32.
105. Kirkman MSW, M. Landsman, P. B. Samsa, G. P. Shortliffe, E. A. Simel, D. L. Feussner, J. R. A telephone-delivered intervention for patients with NIDDM. Effect on coronary risk factors. Diabetes Care. 1994 Aug;17(8):840-6.
106. Kitabchi AET, M. Knowler, W. C. Kahn, S. E. Fowler, S. E. Haffner, S. M. Andres, R. Saudek, C. Edelstein, S. L. Arakaki, R. Murphy, M. B. Shamoon, H. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005 Aug;54(8):2404-14.
107. Klonoff DCB, J. B. Nielsen, L. L. Guan, X. Bowlus, C. L. Holcombe, J. H. Wintle, M. E. Maggs, D. G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008 Jan;24(1):275-86.
108. Knowler WCB-C, E. Fowler, S. E. Hamman, R. F. Lachin, J. M. Walker, E. A. Nathan, D. M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.
109. Korhonen TU, M. Aro, A. Kumpulainen, T. Siitonen, O. Voutilainen, E. Pyorala, K. Efficacy of dietary instructions in newly diagnosed non-insulin-dependent diabetic patients. Comparison of two different patient education regimens. Acta Med Scand. 1987;222(4):323-31.
110. Kosaka KN, M. Kuzuya, T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005 Feb;67(2):152-62.
111. Kramer MKK, A. M. Venditti, E. M. Miller, R. G. Brooks, M. M. Burke, L. E. Siminerio, L. M. Solano, F. X. Orchard, T. J. Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery. Am J Prev Med. 2009 Dec;37(6):505-11.
112. Kudlacek SS, G. The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study. Horm Metab Res. 1992 Oct;24(10):478-83.
113. Kulzer BH, Norbert Gorges, Daniela Schwarz, Peter Haak, Thomas. Prevention of Diabetes Self-Management Program (PREDIAS): Effects on Weight, Metabolic Risk Factors, and Behavioral Outcomes. Diabetes Care. 2009 July 2009;32(7):1143-6.
114. Laaksonen DEL, J. Lakka, T. A. Eriksson, J. G. Niskanen, L. Wikstrom, K. Aunola, S. Keinanen-Kiukaanniemi, S. Laakso, M. Valle, T. T. Ilanne-Parikka, P.

Louheranta, A. Hamalainen, H. Rastas, M. Salminen, V. Cepaitis, Z. Hakumaki, M. Kaikkonen, H. Harkonen, P. Sundvall, J. Tuomilehto, J. Uusitupa, M. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes. 2005 Jan;54(1):158-65.
115. Lachin JMC, C. A. Edelstein, S. L. Ehrmann, D. A. Hamman, R. F. Kahn, S. E. Knowler, W. C. Nathan, D. M. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes. 2007 Apr;56(4):1153-9.
116. Laitinen JHA, I. E. Sarkkinen, E. S. Winberg, R. L. Harmaakorpi-Iivonen, P. A. Uusitupa, M. I. Impact of intensified dietary therapy on energy and nutrient intakes and fatty acid composition of serum lipids in patients with recently diagnosed non-insulin-dependent diabetes mellitus. J Am Diet Assoc. 1993 Mar;93(3):276-83.
117. Lehtovirta MF, B. Gullstrom, M. Haggblom, M. Eriksson, J. G. Taskinen, M. R. Groop, L. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med. 2001 Jul;18(7):578-83.
118. Lewis EJH, L. G. Clarke, W. R. Berl, T. Pohl, M. A. Lewis, J. B. Ritz, E. Atkins, R. C. Rohde, R. Raz, I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60.
119. Ley SJM, P. A. Scragg, R. K. Swinburn, B. A. Long-term effects of a reduced fat diet intervention on cardiovascular disease risk factors in individuals with glucose intolerance. Diabetes Res Clin Pract. 2004 Feb;63(2):103-12.
120. Li CLP, C. Y. Lu, J. M. Zhu, Y. Wang, J. H. Deng, X. X. Xia, F. C. Wang, H. Z. Wang, H. Y. Effect of metformin on patients with impaired glucose tolerance. Diabet Med. 1999 Jun;16(6):477-81.
121. Li ZH, K. Saltsman, P. DeShields, S. Bellman, M. Thames, G. Liu, Y. Wang, H. J. Elashoff, R. Heber, D. Long-term efficacy of soy-based meal replacements vs an individualized diet plan in obese type II DM patients: relative effects on weight loss, metabolic parameters, and C-reactive protein. Eur J Clin Nutr. 2005 Mar;59(3):411-8.
122. Liao DA, P. J. Shofer, J. B. Callahan, H. Matthys, C. Boyko, E. J. Leonetti, D. Kahn, S. E. Austin, M. Newell, L. Schwartz, R. S. Fujimoto, W. Y. Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance. Diabetes Care. 2002 Sep;25(9):1504-10.
123. Lindahl BN, T. K. Jansson, J. H. Asplund, K. Hallmans, G. Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance. J Intern Med. 1999 Jul;246(1):105-12.
124. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med. 2000 Sep;248(3):245-54.
125. Lindstrom JE, J. G. Valle, T. T. Aunola, S. Cepaitis, Z. Hakumaki, M. Hamalainen, H. Ilanne-Parikka, P. Keinanen-Kiukaanniemi, S. Laakso, M. Louheranta, A. Mannelin, M. Martikkala, V. Moltchanov, V. Rastas, M. Salminen, V. Sundvall, J. Uusitupa, M. Tuomilehto, J. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S108-13.

126. Lindstrom JI-P, P. Peltonen, M. Aunola, S. Eriksson, J. G. Hemio, K. Hamalainen, H. Harkonen, P. Keinanen-Kiukaanniemi, S. Laakso, M. Louheranta, A. Mannelin, M. Paturi, M. Sundvall, J. Valle, T. T. Uusitupa, M. Tuomilehto, J. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006 Nov 11;368(9548):1673-9.
127. Lindstrom JL, A. Mannelin, M. Rastas, M. Salminen, V. Eriksson, J. Uusitupa, M. Tuomilehto, J. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003 Dec;26(12):3230-6.
128. Lindstrom JP, M. Eriksson, J. G. Aunola, S. Hamalainen, H. Ilanne-Parikka, P. Keinanen-Kiukaanniemi, S. Uusitupa, M. Tuomilehto, J. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care. 2008 May;31(5):857-62.
129. Lindstrom JP, M. Eriksson, J. G. Louheranta, A. Fogelholm, M. Uusitupa, M. Tuomilehto, J. High-fibre, low-fat diet predicts long-term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia. 2006 May;49(5):912-20.
130. Lindstrom JP, M. Tuomilehto, J. Lifestyle strategies for weight control: experience from the Finnish Diabetes Prevention Study. Proc Nutr Soc. 2005 Feb;64(1):81-8.
131. Manning RMJ, R. T. Leese, G. P. Newton, R. W. The comparison of four weight reduction strategies aimed at overweight diabetic patients. Diabet Med. 1995 May;12(5):409-15.
132. Manning RMJ, R. T. Leese, G. P. Newton, R. W. The comparison of four weight reduction strategies aimed at overweight patients with diabetes mellitus: four-year follow-up. Diabet Med. 1998 Jun;15(6):497-502.
133. Mazzuca SAM, N. H. Wheeler, M. L. Norton, J. A. Fineberg, N. S. Vinicor, F. Cohen, S. J. Clark, C. M., Jr. The diabetes education study: a controlled trial of the effects of diabetes patient education. Diabetes Care. 1986 Jan-Feb;9(1):1-10.
134. McAuley KAS, K. J. Taylor, R. W. McLay, R. T. Williams, S. M. Mann, J. I. Long-term effects of popular dietary approaches on weight loss and features of insulin resistance. Int J Obes (Lond). 2006 Feb;30(2):342-9.
135. McCarron DAR, M. E. Reducing cardiovascular disease risk with diet. Obes Res. 2001 Nov;9 Suppl 4:335S-40S.
136. Mensink MB, E. E. Corpeleijn, E. Saris, W. H. de Bruin, T. W. Feskens, E. J. Lifestyle intervention according to general recommendations improves glucose tolerance. Obes Res. 2003 Dec;11(12):1588-96.
137. Mensink MB, E. E. Wagenmakers, A. J. Saris, W. H. Lifestyle intervention and fatty acid metabolism in glucose-intolerant subjects. Obes Res. 2005 Aug;13(8):1354-62.
138. Mensink MF, E. J. Saris, W. H. De Bruin, T. W. Blaak, E. E. Study on Lifestyle Intervention and Impaired Glucose Tolerance Maastricht (SLIM): preliminary results after one year. Int J Obes Relat Metab Disord. 2003 Mar;27(3):377-84.
139. Mertes G. Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study. Diabetes Res Clin Pract. 1998 Apr;40(1):63-70.
140. Metz JAS, J. S. Kris-Etherton, P. Reusser, M. E. Morris, C. D. Hatton, D. C. Oparil, S. Haynes, R. B. Resnick, L. M. Pi-Sunyer, F. X. Clark, S. Chester, L. McMahon, M. Snyder, G. W. McCarron, D. A. A randomized trial of improved weight loss with a

prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med. 2000 Jul 24;160(14):2150-8.
141. Molitch MEF, W. Hamman, R. F. Knowler, W. C. The diabetes prevention program and its global implications. J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S103-7.
142. New JPM, J. M. Freemantle, N. Teasdale, S. Wong, L. M. Bruce, N. J. Burns, J. A. Gibson, J. M. Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): a randomized controlled trial. Diabetes Care. 2003 Aug;26(8):2250-5.
143. Nielsen JVJ, E. Nilsson, A. K. Lasting improvement of hyperglycaemia and bodyweight: low-carbohydrate diet in type 2 diabetes. A brief report. Ups J Med Sci. 2005;110(2):179-83.
144. Nijpels GB, W. Dekker, J. M. Kostense, P. J. Bouter, L. M. Heine, R. J. A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI). Diabetes Metab Res Rev. 2008 Nov-Dec;24(8):611-6.
145. Nissen SEW, K. Topol, E. J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005 Nov 23;294(20):2581-6.
146. Oldroyd JCU, N. C. White, M. Mathers, J. C. Alberti, K. G. Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Res Clin Pract. 2006 May;72(2):117-27.
147. Page RCH, K. E. Cook, J. T. Turner, R. C. Can life-styles of subjects with impaired glucose tolerance be changed? A feasibility study. Diabet Med. 1992 Jul;9(6):562-6.
148. Pan XL, G. Hu, Y. [Effect of dietary and/or exercise intervention on incidence of diabetes in 530 subjects with impaired glucose tolerance from 1986-1992]. Zhonghua Nei Ke Za Zhi. 1995 Feb;34(2):108-12.
149. Pan XRL, G. W. Hu, Y. H. Wang, J. X. Yang, W. Y. An, Z. X. Hu, Z. X. Lin, J. Xiao, J. Z. Cao, H. B. Liu, P. A. Jiang, X. G. Jiang, Y. Y. Wang, J. P. Zheng, H. Zhang, H. Bennett, P. H. Howard, B. V. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997 Apr;20(4):537-44.
150. Perreault LK, Steven E. Christophi, Costas A. Knowler, William C. Hamman, Richard F. Regression From Pre-Diabetes to Normal Glucose Regulation in the Diabetes Prevention Program. Diabetes Care. 2009 September 2009;32(9):1583-8.
151. Pritchard DAH, J. Taba, F. Nutritional counselling in general practice: a cost effective analysis. J Epidemiol Community Health. 1999 May;53(5):311-6.
152. Ratner RG, R. Haffner, S. Marcovina, S. Orchard, T. Fowler, S. Temprosa, M. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005 Apr;28(4):888-94.
153. Ratzmann KPW, S. Schulz, B. The effect of long-term glibenclamide treatment on glucose tolerance, insulin secretion and serum lipids in subjects with impaired glucose tolerance. Diabete Metab. 1983 May-Jun;9(2):87-93.
154. Ratzmann KPZ, E. Witt, S. Schulz, B. [Effect of a combined diet-training program on the insulin sensitivity of obese persons with normal or disordered glucose tolerance]. Z Gesamte Inn Med. 1982 May 15;37(10):304-8.

155. Ridgeway NAH, D. R. Harvill, L. M. Falin, T. M. Forester, G. M. Gose, O. D. Improved control of type 2 diabetes mellitus: a practical education/behavior modification program in a primary care clinic. South Med J. 1999 Jul;92(7):667-72.
156. Rossner SS, L. Noack, R. Meinders, A. E. Noseda, G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res. 2000 Jan;8(1):49-61.
157. Roumen CC, E. Feskens, E. J. Mensink, M. Saris, W. H. Blaak, E. E. Impact of 3-year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabet Med. 2008 May;25(5):597-605.
158. Rowley KGD, M. Skinner, K. Skinner, M. White, G. A. O'Dea, K. Effectiveness of a community-directed 'healthy lifestyle' program in a remote Australian aboriginal community. Aust N Z J Public Health. 2000 Apr;24(2):136-44.
159. Samaras KH, C. S. Sullivan, D. Kelly, R. P. Campbell, L. V. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. Diabetes Care. 1999 Sep;22(9):1401-7.
160. Sanchez-Reyes LF, G. Yamamoto, J. Martinez-Rivas, L. Campos-Franco, E. Berber, A. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther. 2004 Sep;26(9):1427-35.
161. Sarkadi AR, U. Field test of a group education program for type 2 diabetes: measures and predictors of success on individual and group levels. Patient Educ Couns. 2001 Aug;44(2):129-39.
162. Sartor GS, B. Carlstrom, S. Melander, A. Norden, A. Persson, G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes. 1980 Jan;29(1):41-9.
163. Scheen AJF, N. Hollander, P. Jensen, M. D. Van Gaal, L. F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006 Nov 11;368(9548):1660-72.
164. Scherbaum WAS, A. Mari, A. Nilsson, P. M. Lalanne, G. Jauffret, S. Foley, J. E. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia*. Diabetes Obes Metab. 2008 Aug;10(8):675-82.
165. Sever PSD, B. Poulter, N. R. Wedel, H. Beevers, G. Caulfield, M. Collins, R. Kjeldsen, S. E. Kristinsson, A. McInnes, G. T. Mehlsen, J. Nieminen, M. O'Brien, E. Ostergren, J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004;64 Suppl 2:43-60.
166. Sever PSP, N. R. Dahlof, B. Wedel, H. Collins, R. Beevers, G. Caulfield, M. Kjeldsen, S. E. Kristinsson, A. McInnes, G. T. Mehlsen, J. Nieminen, M. O'Brien, E. Ostergren, J. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005 May;28(5):1151-7.

167. Simmons DF, C. Voyle, J. Fou, F. Feo, S. Gatland, B. A pilot urban church-based programme to reduce risk factors for diabetes among Western Samoans in New Zealand. Diabet Med. 1998 Feb;15(2):136-42.
168. Simmons DV, J. A. Fou, F. Feo, S. Leakehe, L. Tale of two churches: differential impact of a church-based diabetes control programme among Pacific Islands people in New Zealand. Diabet Med. 2004 Feb;21(2):122-8.
169. Sirtori CRC, G. Manzato, E. Mancini, M. Rivellese, A. Paoletti, R. Pazzucconi, F. Pamparana, F. Stragliotto, E. One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations. Atherosclerosis. 1998 Apr;137(2):419-27.
170. Skarfors ETW, T. A. Lithell, H. Selinus, I. Physical training as treatment for type 2 (non-insulin-dependent) diabetes in elderly men. A feasibility study over 2 years. Diabetologia. 1987 Dec;30(12):930-3.
171. Sol BGvdG, Y. van der Bijl, J. J. Goessens, B. M. Visseren, F. L. The role of self-efficacy in vascular risk factor management: a randomized controlled trial. Patient Educ Couns. 2008 May;71(2):191-7.
172. Sone HK, A. Ishibashi, S. Abe, R. Saito, Y. Murase, T. Yamashita, H. Yajima, Y. Ito, H. Ohashi, Y. Akanuma, Y. Yamada, N. Effects of lifestyle modifications on patients with type 2 diabetes: the Japan Diabetes Complications Study (JDCS) study design, baseline analysis and three year-interim report. Horm Metab Res. 2002 Sep;34(9):509-15.
173. Stone DBC, W. E. The prolonged effects of a low cholesterol, high carbohydrate diet upon the serum lipids in diabetic patients. Diabetes. 1963 Mar-Apr;12:127-32.
174. Swinburn BAM, P. A. Ley, S. J. Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care. 2001 Apr;24(4):619-24.
175. Takekoshi HM, K. Suzuki, Y. Atsumi, Y. Kubo, A. Hayashi, K. Horiuchi, A. A ten year follow up study in NIDDM with or without exercise. J Med Assoc Thai. 1987 Mar;70 Suppl 2:149-52.
176. Tapsell LCB, M. J. Teuss, G. Tan, S. Y. Dalton, S. Quick, C. J. Gillen, L. J. Charlton, K. E. Long-term effects of increased dietary polyunsaturated fat from walnuts on metabolic parameters in type II diabetes. Eur J Clin Nutr. 2009 Aug;63(8):1008-15.
177. Tate DFJ, E. H. Wing, R. R. Effects of Internet behavioral counseling on weight loss in adults at risk for type 2 diabetes: a randomized trial. JAMA. 2003 Apr 9;289(14):1833-6.
178. Taylor CBM, N. H. Reilly, K. R. Greenwald, G. Cunning, D. Deeter, A. Abascal, L. Evaluation of a nurse-care management system to improve outcomes in patients with complicated diabetes. Diabetes Care. 2003 Apr;26(4):1058-63.
179. Tenkanen LM, M. Manninen, V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation. 1995 Oct 1;92(7):1779-85.
180. Torgerson JSH, J. Boldrin, M. N. Sjostrom, L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004 Jan;27(1):155-61.

181. Torjesen PAB, K. I. Anderssen, S. A. Hjermann, I. Holme, I. Urdal, P. Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial. Diabetes Care. 1997 Jan;20(1):26-31.
182. Trento MP, P. Borgo, E. Tomalino, M. Bajardi, M. Cavallo, F. Porta, M. A 5-year randomized controlled study of learning, problem solving ability, and quality of life modifications in people with type 2 diabetes managed by group care. Diabetes Care. 2004 Mar;27(3):670-5.
183. Trento MP, P. Tomalino, M. Bajardi, M. Pomero, F. Allione, A. Vaccari, P. Molinatti, G. M. Porta, M. Group visits improve metabolic control in type 2 diabetes: a 2-year follow-up. Diabetes Care. 2001 Jun;24(6):995-1000.
184. Trento MP, P. Bajardi, M. Tomalino, M. Grassi, G. Borgo, E. Donnola, C. Cavallo, F. Bondonio, P. Porta, M. Lifestyle intervention by group care prevents deterioration of Type II diabetes: a 4-year randomized controlled clinical trial. Diabetologia. 2002 Sep;45(9):1231-9.
185. Tuomilehto JL, J. Eriksson, J. G. Valle, T. T. Hamalainen, H. Ilanne-Parikka, P. Keinanen-Kiukaanniemi, S. Laakso, M. Louheranta, A. Rastas, M. Salminen, V. Uusitupa, M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50.
186. Turner RC, C. Holman, R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996 Jan 1;124(1 Pt 2):136-45.
187. Turner RCC, C. A. Frighi, V. Holman, R. R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999 Jun 2;281(21):2005-12.
188. Uusitupa ML, V. Louheranta, A. Salopuro, T. Lindstrom, J. Tuomilehto, J. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes. 2003 Oct;52(10):2532-8.
189. Uusitupa MP, Markku Lindström, Jaana Aunola, Sirkka Ilanne-Parikka, Pirjo Keinänen-Kiukaanniemi, Sirkka Valle, Timo T. Eriksson, Johan G. Tuomilehto, Jaakko for the Finnish Diabetes Prevention Study, Group. Ten-Year Mortality and Cardiovascular Morbidity in the Finnish Diabetes Prevention Study—Secondary Analysis of the Randomized Trial. PLoS ONE. 2009;4(5):e5656.
190. van Sluijs EMvP, M. N. Twisk, J. W. Chin, A. Paw M. J. Calfas, K. J. van Mechelen, W. Effect of a tailored physical activity intervention delivered in general practice settings: results of a randomized controlled trial. Am J Public Health. 2005 Oct;95(10):1825-31.
191. Vanninen EU, M. Lansimies, E. Siitonen, O. Laitinen, J. Effect of metabolic control on autonomic function in obese patients with newly diagnosed type 2 diabetes. Diabet Med. 1993 Jan-Feb;10(1):66-73.
192. Vanninen EU, M. Siitonen, O. Laitinen, J. Lansimies, E. Habitual physical activity, aerobic capacity and metabolic control in patients with newly-diagnosed type 2 (non-insulin-dependent) diabetes mellitus: effect of 1-year diet and exercise intervention. Diabetologia. 1992 Apr;35(4):340-6.

193. Venojarvi MP, R. Hamalainen, H. Marniemi, J. Rastas, M. Rusko, H. Nuutila, P. Hanninen, O. Aunola, S. Role of skeletal muscle-fibre type in regulation of glucose metabolism in middle-aged subjects with impaired glucose tolerance during a long-term exercise and dietary intervention. Diabetes Obes Metab. 2005 Nov;7(6):745-54.
194. Wadden TAW, D. S. Neiberg, R. H. Wing, R. R. Ryan, D. H. Johnson, K. C. Foreyt, J. P. Hill, J. O. Trence, D. L. Vitolins, M. Z. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring). 2009 Apr;17(4):713-22.
195. Watanabe MY, K. Yokotsuka, M. Tango, T. Randomized controlled trial of a new dietary education program to prevent type 2 diabetes in a high-risk group of Japanese male workers. Diabetes Care. 2003 Dec;26(12):3209-14.
196. Wein PB, N. Harris, C. Permezel, M. A trial of simple versus intensified dietary modification for prevention of progression to diabetes mellitus in women with impaired glucose tolerance. Aust N Z J Obstet Gynaecol. 1999 May;39(2):162-6.
197. Weitgasser RL, M. Luger, A. Klingler, A. Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study. Diabetes Res Clin Pract. 2003 Jul;61(1):13-9.
198. Wing RRK, R. Epstein, L. H. Nowalk, M. P. Gooding, W. Becker, D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med. 1987 Oct;147(10):1749-53.
199. Wolever TMG, A. L. Mehling, C. Chiasson, J. L. Connelly, P. W. Josse, R. G. Leiter, L. A. Maheux, P. Rabasa-Lhoret, R. Rodger, N. W. Ryan, E. A. The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. Am J Clin Nutr. 2008 Jan;87(1):114-25.
200. Woollard JB, V. Beilin, L. J. Verheijden, M. Bulsara, M. K. Effects of a general practice-based intervention on diet, body mass index and blood lipids in patients at cardiovascular risk. J Cardiovasc Risk. 2003 Feb;10(1):31-40.
201. Wright ADC, C. A. Macleod, K. M. Holman, R. R. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications. 2006 Nov-Dec;20(6):395-401.
202. Yamanouchi TS, T. Igarashi, K. Ichiyanagi, K. Watanabe, H. Kawasaki, T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med. 2005 Aug;22(8):980-5.
203. Yancy WS, Jr Westman, Eric C. McDuffie, Jennifer R. Grambow, Steven C. Jeffreys, Amy S. Bolton, Jamiyla Chalecki, Allison Oddone, Eugene Z. A Randomized Trial of a Low-Carbohydrate Diet vs Orlistat Plus a Low-Fat Diet for Weight Loss. Arch Intern Med. 2010 January 25, 2010;170(2):136-45.
204. Yates TD, Melanie Gorely, Trish Bull, Fiona Khunti, Kamlesh. Effectiveness of a Pragmatic Education Program Designed to Promote Walking Activity in Individuals With Impaired Glucose Tolerance. Diabetes Care. 2009 August 2009;32(8):1404-10.
205. Yusuf SG, H. Hoogwerf, B. Pogue, J. Bosch, J. Wolffenbuttel, B. H. Zinman, B. Ramipril and the development of diabetes. JAMA. 2001 Oct 17;286(15):1882-5.